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Chapter 1
General Introduction
Adapted from:
Yu-Juei Hsu, Joost G.J. Hoenderop, René J.M. Bindels 
TRP Channels in K idney Disease 
Biochim  Biophys Acta 1772: 928-36, 2007

General Introduction
TRP CHANNELS
The transient receptor potential (TRP) protein superfamily is a diverse group of 
voltage-independent cation-permeable channels expressed in most mammalian cells 
(1-3). Topologically, each TRP protein consists of six putative transmembrane (TM) 
domains, a pore-forming loop between S5 and S6, and intracellular located amino 
(NH2) and carboxyl (COOH) termini (3-5). Based on amino acid homology, TRP 
channels have been divided into seven protein subfamilies (6-8). These have been 
designated as C (Canonical, TRPC1-TRPC7), V (Vanilloid, TRPV1-TRPV6), M 
(Melastatin, TRPM1-TRPM8), A (Ankyrin, TRPA1), P (Polycystin, TRPP1-TRPP3), 
ML (Mucolipin, TRPML1-TRPML3) and N (NOMP, no mechanopotential). Except for 
the TRPN, almost all TRP subfamilies are found in mammals, including human, rat 
and mice. TRPN has to date only been detected in worm, Drosophila, and zebrafish 
(6-8). TRP subunits can assemble as homo- or hetero-tetramers to form cation 
selective channels and most TRP channels are permeable to Ca2+ with the 
permeability ratio relative to Na+ (PCa/PNa), raning from 0 to >100. In general, most of 
them are only poorly selective to Ca2+ with the PCa/PNa, ratio between 0.3 to 10 (7, 8). 
Special cases are TRPM4/5 and TRPV5/6, which are impermeable to Ca2+ (9, 10) and 
highly-Ca2+ selective TRP channels with PCa/PNa >100 (11-13), respectively. These 
unique properties substantiate that TRP channels play a vital role in Ca2+ signaling 
and provide pathways for Ca2+ entry.
Ca2+ is instrumental in many cellular processes, including gene transcription, cell 
proliferation, differentiation and apoptosis (14). Thus, TRP channels potentially 
participate in many important cellular functions by regulation of Ca2+-dependent 
signaling cascades. In addition to influence of Ca2+ influx through plasma 
membrane-expressed TRP channels, recent studies demonstrated that some TRP 
channels subfamilies reside on intracellular membranes: TRPML1 has been shown to
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localize in lysosomes (15, 16), TRPP2 partially in endoplasmic reticulum (ER) 
membranes (17) and some plasmalemmal Ca2+ permeable TRP channels (e.g., 
TRPV1 and TRPM8) in ER and Golgi apparatus (18, 19). Stimulation of these TRP 
channels by special agonists could increase intracellular Ca2+ released from 
intracellular organelles.
The functional roles of TRP channels have been demonstrated in many different 
tissues, such as brain, heart, respiratocry tract, stomach, intestine, bladder, kidney, 
hematologic elements, muscle and skeleton (20). Most TRP channels are activated 
upon binding of intracellular and extracellular messengers, alternation in temperature, 
chemical compounds, mechanical force and osmotic stress, which may participate in 
a wide range of physiological processes such as sensory signaling and regulation of 
systemic osmolality, neuronal excitability, blood circulation and clotting, gut motility, 
airway and bladder hypersensitivity, muscle contraction, and bone mineralization (4, 
20). Due to the pivotal role of Ca2+ as a signal messenger and great functional 
potentials of TRP channels, it is deduced that dysfunction of Ca2+ signaling due to 
abnormality of TRP channels might be involved in the pathogenesis of various 
systemic diseases. However, some TRP channels function as gatekeepers for the 
selective (re)absorption of divalent cations such as Ca2+ and Mg2+. Dysfunction of 
these specific channels will lead to disturbances in body Ca2+ and Mg2+ homeostasis.
TRP CHANNELS IN KIDNEY
The nephron is the functional unit of the kidney and consists of a Malpigian corpuscle, 
with a vascular glomerulus within a matrix formed by mesangial cells and an epithelial 
Bowman’s capsule. The capsule joins a series of tubules starting with the proximal 
tubule (PT), followed by the loop of Henle, the distal convoluted tubule (DCT), the 
connecting tubule (CNT) and ending in the collecting ducts (CD) (21). Recently,
12
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several subfamilies of TRP channels including TRPC, TRPV, TRPM and TRPP have 
been disclosed in different parts of the nephron (Figure 1).
G PT D TL ATL TAL DCT C NT CD
T R P V 4
Figure 1. Distribution of TRP channels along the nephron
Abbreviations: G, glomerulus; PT, proxim al tubule; DTL, descending thin limb; ATL, ascending thin limb; 
TAL, th ick ascending limb; DCT, distal convoluted tubule; CNT, connecting tubule; CD, collecting duct.
A recent study in rat found that TRPC1 is detected in glomeruli and co-localizes with 
aquaporin-1 in PT and descending thin limb (DTL), whereas TRPC3 and TRPC6 are 
predominantly confined to glomeruli and co-expressed with aquaporin-2 in principle 
cells of the CD (22). Among the structure of glomeruli, TRPC1 is exclusively 
expressed in mesangial cells, while TRPC3 and TRPC6 are found in podocytes (22). 
In general, TRPC members are activated subsequent to stimulation of receptors that 
stimulate different isoforms of phospholipase C (PLC). Thus TRPC1, TRPC3 and 
TRPC6 might be involved in PLC-dependent signaling in specific regions of the 
nephron (23).
The distal part of the nephron is a major site responsible for active Ca2+ and Mg2+
13
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reabsorption in the kidney (11, 24). TRPV5, a highly Ca2+-selective channel in the 
TRP family, is the first TRP channel identified in the kidney (12). TRPV5 is abundantly 
expressed in DCT and the connecting tubule (CNT) and has been recognized as the 
gatekeeper of active Ca2+ reabsorption in the kidney (12, 25). TRPV6, a homologous 
highly Ca2+-selective channel, is originally identified in rat duodenum (13). It is also 
expressed in DCT, CNT and cortical and medullary CD (26). Although TRPV6 has 
been implicated as the gatekeeper of intestinal Ca2+ absorption, its role in the kidney 
remains unknown (26). TRPM6, a highly Mg2+-permeable channel, is localized along 
the apical membrane of DCT and has been postulated to be the key channel 
controlling the transcellular Mg2+ reabsorption in the kidney (24). These findings may 
suggest that TRPV5 and TRPM6 function as the crucial players in the process of renal 
reabsorption of divalents (24).
TRPV4 is an osmotically responsive cation channel, which is abundantly expressed in 
the ascending thin limb (ATL), thick ascending limb (TAL), DTL and CNT (27). 
Interestingly, it is absent from nephron segments exhibiting water permeability and 
enhanced aquaporin-2 expression (27). The unique distribution in water-impermeable 
nephron segments and characteristics of TRPV4 suggest that it might participate in 
the renal regulation of water and sodium balance, though its role in the kidney is still 
elusive. TRPP1 and TRPP2 belong to the polycystin TRP subfamily, which exist 
throughout the animal kingdom (3). TRPP2 has been found on plasma membrane 
(PM) and ER (28) and it assembles with TRPP1 to form a multiprotein complex (29), 
which functions as transducer of Ca2+-dependent signaling (30). Importantly, recent 
studies suggest that both proteins are localized in primary cilia of renal epithelial cells 
and might act as mechanosensors (31, 32). TRPP2 has also been implicated in 
several biological processes including cell proliferation, sperm development and 
function, mating behavior and asymmetric gene expression (28).
14
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CA2+ HOMEOSTASIS
Ca2+, the most abundant cation in the body, represents about 2% of total body weight. 
More than 99% is stored in bone and is unavailable for participation in the immediate 
regulation of Ca2+ balance, while the remainder is distributed in the teeth, soft tissue, 
and the extracellular space (33, 34). In mammals, the Ca2+ balance is tightly controlled 
through constant regulation of three physiological processes: intestinal absorption, 
renal reabsorption and exchange of Ca2+ from the bone mass (11). These three 
biological processes are regulated by the combined effects of parathyroid hormone 
(PTH) and 1,25-dihydroxy-vitamin D3 (1,25 (OH)2D3) (11, 35). Given a daily dietary 
Ca2+ intake of 1000 mg, net intestinal absorption amounts to about 200 mg, with the 
remaining 800 mg being excreted in the feces. About 200 mg of Ca2+ will enter and 
leave the bone. In the kidney, approximately 9000 mg of Ca2+ is filtered at the 
glomerulus daily (11, 14). In order to maintain balance, the kidney must excrete 
approximately 200 mg, amounting to less than 2% of the filtered Ca2+ load and the 
remaining 98% of the filtered load must be reabsorbed (36, 37). In the past, our 
understanding of renal Ca2+ handling is mainly based on in vivo micropuncture 
techniques, which is a method to measure the Ca2+ concentration of tubular fluid 
sampling directly from different nephron segments by using micropipettes (38-42). In 
the PT, approximately 65% of the filtered Ca2+ is reabsorbed (36, 43). This transport is 
passive and follows the local Na+ reabsorption. In the DTL and ATL of loop of Henle, 
virtually no Ca2+ is reabsorbed (44, 45). However, the TAL is again permeable to Ca2+, 
and this segment accounts for approximately 20% of the total Ca2+ reabsorption (40, 
41, 45). Several studies showed that reabsorption of Ca2+ in this segment is passive 
through paracellular pathway, driven by the positive lumen potential, which depends 
on the activity of Na-K-2Cl transporter (46-48). In the DCT and CNT, only 5-10% Ca2+ 
reabsorption occurs. This transport process is active, taking place against an
15
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electrochemical gradient (49). Here, hormones such as PTH and 1,25(OH)2D3 
stimulate Ca2+ reabsorption (49, 50). Furthermore, the tight junctions in DCT and CNT 
are relatively impermeable to Ca2+, in line with a predominant role for an active 
transcellular Ca2+ transport pathway. The cortical collecting duct (CCD) accounts for 
maximally 3% of the filtered Ca2+ (42). As net transport occurs against the 
electrochemical gradient for Ca2+, reabsorption of Ca2+ must be active here as well. 
Distribution of Ca2+ reabsorption along the nephron is summarized in Figure 2.
Figure 2. Ca2+ reabsorption along the nephron
The percentage o f the filtered Ca2+ tha t is being reabsorbed by the various nephron segm ents and 
the final urinary excretion o f Ca2+ is indicated. PCT, proximal convoluted tubule; PST, proximal 
straight tubule; TAL, th ick ascending limb o f Henle's loop; DCT, distal convoluted tubule; CNT, 
connecting tubule; CCD, cortical collecting duct.
THE ROLE OF TRPV5 IN RENAL CA2+ HANDLING
The first identification and characterization of epithelial Ca2+ channel TRPV5 by 
Bindels’ group in 1999 unveils the molecular mechanisms underlying the process of 
active renal Ca2+ reabsorption. By using a complementary DNA (cDNA) library
16
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isolated from rabbit primary CNT and CCD, the apical Ca2+ influx channel was shown 
to be involved in transcellular Ca2+ (re)absorption (12). Functional expression cloning 
and injection of the complementary RNA (cRNA) synthesized from this library into 
Xenopus laevis oocytes was carrired out to screen for 45Ca2+ uptake. A pool 
expressing highest 45Ca2+ uptake rates was sequentially subdivided and analyzed 
until a single cDNA was isolated that encoded a novel epithelial Ca2+ channel, named 
ECaC1 (also known as CaT2) and later renamed as the TRPV5 due to its sequence 
and predicted structure which are comparable to TRP superfamily (3, 51). The rabbit 
TRPV5 cDNA contains an open reading frame of 2190 nucleotides that encodes a 
protein of 730 amino acids with a predicted relative molecular weight mass of 83 kDa. 
Hydropathy analysis suggests that TRPV5 contained large and flexible intracellular 
amino- and carboxyl-terminal tails flanking six TM and an additional hydrophobic 
stretch between TM5 and TM6, predicted to be the pore-forming region. The 
hydrophilic amino-terminal tail comprises 327 amino acids and contains six ankyrin 
repeats that are important structural elements for both channel assembly and 
protein-protein interactions (12, 52). The first extracellular loop between TM1 and 
TM2 contains an evolutionary conserved asparagine (N358) crucial for 
complex-glycosylation and in turn for regulating channel activity. Furthermore, the 
pore-residue aspartate-542 (D542) appeared to be crucial for high-affinity Ca2+ 
binding and selectivity (53, 54). The hydrophilic carboxyl-terminal tail comprises 
151-amino acid and harbors potential protein kinase A and C phosphorylation sites, 
which suggests an important role for channel activation (Figure 3) (12, 55).
17
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Figure 3. The proposed topology of the TRPV5 channel
TRPV5 contains six transm em brane (TM )-spanning dom ains and a pore-form ing unit between TM5 
and TM6. S ix ankyrin repeats and one protein kinase C phosphorylation site (indicated by C) present 
in the am ino-term inus. The other protein kinase C phosphorylation site locates in carboxyl-term inus.
In addition, the channel is N-glycosylated at position N358 (num bering of rabbit species) between 
TM1 and TM 2 (from  Hoenderop et al. (55)).
Moreover, when expressed in cultured mammalian cell systems (human embryonic 
kidney 293, HEK 293 cells), as well as in oocytes, TRPV5 is assembled into large 
homotetramers in order to acquire the active conformation state (53). The 
current-voltage relationship of TRPV5 shows strong inward rectification. Detailed 
electrophysiological studies of TRPV5 revealed distinctive features consistent with its 
putative role as apical Ca2+ influx channel that controls transcellular Ca2+ transport 
(12), including a constitutively activated Ca2+ permeability at physiological membrane 
potentials, a high Ca2+ selectivity and Ca2+-dependent feedback regulation of channel 
activity (56, 57). Immunofluorescence staining revealed that TRPV5 is abundantly 
present along the apical membrane in the majority of cells lining the distal part of the
18
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nephron including late part of DCT (DCT2), CNT and cortical CD (58, 59), where it 
co-localizes with associated Ca2+ transport proteins, including calbindin-D28K, 
Na+/Ca2+ exchanger (NCX1), and plasma membrane Ca2+-ATPase (PMCAlb) (59). 
Currently, active Ca2+ reabsorption in the distal nephron is postulated as a three-step 
process: driven by a highly favorable electrochemical driving force Ca2+ enters the cell 
through the apical TRPV5 Ca2+ channel. In the cell, calbindin-D28K binds Ca2+ and 
facilitates its diffusion from the apical towards the basolateral compartment. Finally, 
Ca2+ is transported across the basolateral membrane by the NCX1 and PM CAlb to 
re-enter the bloodstream (Figure 4) (11, 41).
0)
Ca*'
TRPV5 VJ t f
TRPV5
C# f t
Ca!b¡nd¡n-D„
NCX1 
^  ' 3Na-
Ca>*
PMCAlb'
oAT9
Lumen Blood
Figure 4. Transcellular Ca2+ transport across DCT and CNT
Apical Ca2+ influx is m ediated by TRPV5 in renal distal convoluted and connecting tubules. 
Subsequently, Ca2+ diffuses to the basolateral m em brane by Ca2+ binding proteins calb indin-D 28K. 
Extrusion to the bloodstream  takes places via Na+/Ca2+ exchanger (NCX1) and plasma mem brane 
Ca2+-ATPase (PMCA1b).
Recently, the molecular mechanism underlying the paracellular Ca2+ transport in 
kidney has been elucidated. Paracellin-1 (also called claudin-16), localized in the tight
19
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junctions of TAL (60), was identified to be responsible for paracellular divalent cation 
reabsorption. The claudin-16 knockdown mice show reduced divalent cations 
selectivity in TAL resulting in a collapse of the lumen-positive voltage and renal Ca2+ 
and Mg2+ wasting. Accordingly, mutations on paracellin-1 gene in human lead to the 
familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), which 
is characterized by progressive renal Ca2+ and Mg2+ wasting and kidney failure (61).
DISTURBANCE OF CA2+ HOMEOSTASIS IN TRPV5 KNOCKOUT MICE
To study the molecular mechanism in maintaining the extracellular Ca2+ balance, 
several investigators are now applying the powerful tools of transgenic technology to 
help understand how a gene contributes to the Ca2+ balance or may cause a human 
disease.
The generation of TRPV5 knockout (TRPV5-/-) mice by Hoenderop and coworkers, 
following the identification of the epithelial Ca2+ channel TRPV5 (25) comprises the 
recent milestone in a comprehensive understanding of the molecular mechanism of 
active renal Ca2+ reabsorption. TRPV5-/- mice were generated by deletion of exon 13 
that encodes the functional pore region. Micropuncture studies demonstrated that 
Ca2+ reabsorption in DCT and CNT was abolished leading to a striking hypercalciuria 
in these mice. TRPV5-/- mice excreted 6-10 folds more Ca2+ compared to control 
littermate mice. Besides, the knockout mice exhibited prominent reduction of both 
trabecular and cortical bone volume. Despite profound renal Ca2+ leak, 
normocalcemia was maintained in TRPV5-/- mice. In vivo 45Ca2+ absorption assay 
demonstrated intestinal Ca2+ hyperabsorption accompanied by upregulation of 
duodenal Ca2+ transporters TRPV6 and calbindin-D9K and elevated serum 
1,25(OH)2D3 levels in TRPV5-/- mice compared to the controls. These findings 
suggested that hypervitaminosis D-stimulated intestinal Ca2+ absorption compensates
20
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for the renal Ca2+ wasting to preserve Ca2+ balance. Additional gene ablation of 
25-hydroxyvitamin-D3-1a-hydroxylase (1a-OHase) in TRPV5-/- mice further 
substantiated that increased plasma 1,25(OH)2D3 levels constitute a compensatory 
mechanism in an effort to correct the significant renal Ca2+ wasting. The double 
knockout (TRPV5-/-/1a-OHase-/-) mice exhibited undetectable serum 1,25(OH)2D3 
levels, hypocalcemia, downregulation of duodenal Ca2+ transport protein expression, 
hyperparathyrodisim and rickets (62). The increased expression of duodenal Ca2+ 
transporters and the resulting Ca2+ hyperabsorption in TRPV5-/- mice are due to a 
secondary hypervitaminosis D. These effects compensate for the renal Ca2+ leakage 
to maintain normal plasma Ca2+ levels in TRPV5-/- mice. In addition to hypercalciuria, 
TRPV5-/- mice exhibit concomitant hyperphosphaturia, but lack of kidney stone 
formation. Interestingly, these hypercalciuric mice consistently display high urine 
volume and acidic urine with a mean pH value of 5.5, which are well-known inhibitory 
factors for crystallization of Ca2+ salts. Our recent study characterizing the phenotype 
of TRPV5 and proton ATPase (H+-ATPase) double knockout mice demonstrated that 
activation of Ca2+-sensing receptor (CaSR) by increased urinary Ca2+ level leads to 
urinary acidification and polyuria (63). These beneficial adaptations facilitate the 
excretion of large amounts of soluble Ca2+, while preventing renal stone formation in 
TRPV5-/- mice.
REGULATORY MECHANISMS OF TRPV5
The synthesis of TRPV5 subunit occurs at ER-bound ribosomes and subsequently 
undergoes modification (glycosylation, hydroxylation, carboxylation, proteolysis and 
folding) through the ER to the Golgi apparatus (37, 64). These proteins are then 
packed into small vesicles and budded off from the Golgi apparatus. Finally, these 
vesicles are transported through cytosol towards the plasma membrane.
21
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Aforementioned process is complex and mainly involves several steps, including 
transcription, post-transcriptional modification, translation and post-translational 
modification (37, 64), which can be controlled by four categories of regulatory 
mechanisms (Figure 5): (/) transcriptional and translational regulation by calciotropic 
hormones; (//) alteration of channel activity by extracellular and intracellular factors; (///) 
intracellular trafficking and routing regulation to plasma membrane by associated 
proteins; (/v) regulation of channel recycling by Ca2+ and specific hormones.
Figure 5. Regulatory mechanisms of TRPV5
TRPV5 is synthesized in the ER and is subsequently transported to the plasma membrane. Expression 
o f TRPV5 can be contro lled by four distinct regulatory mechanism s: (1) transcriptional and translational 
regulation by calciotropic hormones; (2) alteration o f channel activity by extrace llu lar and in tracellular 
factors; (3) in tracellu lar trafficking and routing regulation to plasma m em brane by associated proteins; (4) 
regulation o fch ann e l recycling by Ca2+ and specific horm ones (adapted and modified from  Hoenderop et 
al. (55)).
22
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(1) Regulation o f TRPV5 transcrip tion  and transla tion
Vitamin D
Vitamin D plays an essential role in Ca2+ homeostasis and bone metabolism (65). In 
humans, the active form of vitamin D, 1,25(OH)2D3 is biosynthesized from its 
precursor 7-dehydrocholesterol through a two-step modification process in the 
presence of sunlight. First step is hydroxylation of vitamin D3 at carbon 25 in the liver. 
The second step is converted 25-hydroxyvitmain D3 (25-(OH)D3) to the active form of 
vitamin D, 1,25(OH)2D3, in the PT by 1a-OHase (65, 66). The biological activities of 
1,25(OH)2D3 are mediated by interacting with vitamin D receptor (VDR) localized in 
the cell nucleus (VDRnuc) to generate genomic response or in caveolae of plasma 
membrane (VDRmem) to generate rapid nongenomic actions (65). Like other steroid 
hormones, 1,25(OH)2D3 acts as a ligand for the VDRnuc and liganded VDRnuc 
undergoes a conformational change to form a complex with a retinoid X receptor 
(RXR). This VDRnuc-R XR  complex binds to DNA elements in the promoter region of 
target genes described as vitamin D response elements (VDREs). Binding to these 
VDREs leads to recruitment of VDR-interacting coregulators into the transcriptional 
machinery, which markedly enhances or suppresses the rate of 
1,25(OH)2D3-responsive gene transcription. On the other hand, binding of 
1,25(OH)2D3 to VDRmem may result in rapid activation of one or more secondary 
messenger signaling, including PLC, protein kinase C (PKC), G protein-coupled 
receptors or phosphatidyl-inositol-3’ kinase (PI3K).
The kidney is a major target organ for 1,25(OH)2D3 and co-expression of VDR with 
TRPV5 in the distal part of the nephron suggested vitamin D may be involved in the 
mechanism of renal Ca2+ reabsorption by regulation of TRPV5 transcription. The initial 
evidence supporting the regulation of TRPV5 by vitamin D was obtained from rats fed 
with vitamin D-depleting diet (67), which were characterized by significant decreased
23
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serum 1,25(OH)2D3 levels, and mRNA and protein expression of TRPV5. Repletion of 
serum 1,25(OH)2D3 resulted in normalization of plasma Ca2+ levels and a significant 
upregulation of TRPV5 to control values. Accordingly, administration of 1,25(OH)2D3 
to mice increased the expression level of TRPV5, TRPV6 and calbindin-D9K in 
duodenum and kidney. The impact of vitamin D on the transcriptional regulation of 
TRPV5 has been further substantiated by targeted deletion of genes encoding 
1a-OHase (68, 69) and VDR (70), which have provided useful mice models for 
inherited human diseases, the vitamin D-dependent rickets type I (VDDR I) and type II 
(VDDR II), respectively. VDDR I is an autosomal recessive disorder caused by 
mutations in the gene encoding 1a-OHase (71). Markedly decreased serum 
1,25(OH)2D3, rickets, growth retardation and secondary hyperparathyroidism are the 
prominent clinical findings. VDDR II is caused by end-organ unresponsiveness of 
active vitamin D due to recessive mutations in the gene encoding the VDR (72). This 
defect leads to an increase in the circulating 1,25(OH)2D3, early onset of severe 
rickets and alopecia. Hoenderop and coworkers demonstrated that renal TRPV5 as 
well as intestinal TRPV6 expression were significantly reduced in the 1a-OHase 
knockout (1a-OHase-/-) mice, compared to wild-type littermates (73). These effects 
were accompanied by decreased calbindin-D28K, calbindin-D9K and NCX1 levels. 
Supplementation of 1,25(OH)2D3 restored expression levels of these Ca2+ 
transporters, resulting in normalization of serum Ca2+ levels. On the other hand, renal 
TRPV5 and duodenal TRPV5 and TRPV6 expression were reduced significantly In 
VDR knockout mice models (74). Together, these data indicate that 1,25(OH)2D3 
exerts its calciotrophic effect by increasing the expression of TRPV5 and thus 
efficiently stimulates renal Ca2+ reabsorption. However, detailed molecular 
mechanisms involved in the genomic or rapid nongenomic regulation of TRPV5 by 
1,25(OH)2D3 has not yet been explored. Interestingly, TRPV5 promoter analysis
24
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showed several putative VDREs located upstream of the start codon suggesting that 
1,25(OH)2D3 might enhance the TRPV5 transciription through the binding of 
VDRnuc-RXR complex to VDREs (75).
Parathyroid hormone (PTH)
PTH is one of the most important regulators of body Ca2+ homeostasis. It is an 
84-amino-acid peptide and synthesized in the chief cells of the parathyroid glands. 
The secretion of PTH from the parathyroid gland is stimulated by fluctuations in blood 
Ca2+ levels sensed by the parathyroid Ca2+-sensing receptor (76). After secretion by 
the parathyroid gland, PTH is cleaved into two fragments. The N-terminal 1-34 
cleavage product is the functional element, which binds to high-affinity PTH receptor 
(PTHR) on the plasma membrane of its target cells to activate a stimulatory G protein 
(GS) coupled to adenylate cyclase and thus to increase intracellular cyclic AMP (cAMP) 
concentration. In the kidney, PTHR mRNA has been detected in DCT2 and CNT, 
which is consistent with the distribution of PTH-stimulating adenylate cyclase. 
Furthermore, PTH has been found to increase Ca2+ reabsorption in this segment 
without affecting transepithelial voltage, suggesting active Ca2+ reabsorption in the 
distal part of the nephron might be regulated by PTH (77). The molecular targets 
involved in PTH-mediated active Ca2+ reabsorption have not been elucidated until the 
discovery of TRPV5. Van Abel et al. explored the molecular mechanism underlying 
PTH-mediated regulation of the Ca2+ transporters in parathyroidectomized rats. 
Parathyroidectomy reduced the expression of TRPV5, calbindin-D28K, and NCX1 in 
kidney. This decline in expression of Ca2+ transporters resulted in decreased active 
Ca2+ reabsorption and the development of hypocalcemia (78). After PTH 
supplementation, the expression of Ca2+ transporters, as well as plasma Ca2+ 
concentration tended to be normalized in these parathyroidectomized rats. Similarly,
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infusion of a calcimimetic compound (NPS R-467) decreased PTH levels, resulted in 
reduced expression of TRPV5, calbindin-D28K, and NCX1, which is consistent with 
diminished Ca2+ reabsorption, and in line with the observed hypocalcemia in mice. In 
addition, incubation with PTH resulted in an elevated expression of the Ca2+ transport 
proteins TRPV5, calbindin-D28K, NCX1, and PMCA1b in primary cultures of rabbit 
CNT cells. Blockade of the apical Ca2+ influx by ruthenium red prevented the 
PTH-induced upregulation of the other Ca2+ transporters further emphasized a 
gatekeeper role of TRPV5.
Calcitonin (CT)
Calcitonin (CT), another important calciotropic hormone, is well-known for its 
antiresorptive character by inhibiting osteoclast-mediated bone resorption. CT is a 32 
amino-acid peptide with a molecular weight of 3.7 kDa synthesized by 
posttranslational processing of a large procalcitonin in the C cells of the thyroid gland 
in mammals (79). Its release is triggered by an increase of the extracellular Ca2+ 
concentration (11) and has been extensively used in treating hypercalcemia, 
osteoporosis and Paget’s disease of bone (79). Although CT has been implicated as a 
calcitropic hormone, patients with a calcitonin-secreting tumor of C cells or after a 
thyroidectomy frequently have normal plasma levels of Ca2+, PTH and 1,25(OH)2D3, 
which questions the physiological importance of CT (80). Recently, calcitonin 
receptors (CTRs) have been identified in two major Ca2+ balance target cells, rat 
osteoclast (81) and porcine kidney epithelial cell (82, 83). Furthermore, CT knockout 
mice exhibited increased bone formation, impaired Ca2+-lowering abilities and 
increased bone resorption in response to exogenous PTH, possibly due to the 
absence of the inhibiting effect of CT on bone resorption (84). These data support a 
crucial role of CT on the skeletal Ca2+ homeostasis, whereas the effects of CT on
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renal and intestinal Ca2+ regulation remain largely unknown.
CT has been observed to decrease renal Ca2+ excretion at physiologic doses (85), 
may be due to concomitant hypocalcemia (86), but there is also evidence supporting a 
direct role of CT on renal Ca2+ reabsorption. CTR belongs to the G-protein superfamily 
and has been demonstrated to couple with both adenylyl cyclase and phospholipase 
C in mammalian cell lines (87). In kidney, CTR is detected in TAL and DCT (88) and its 
distribution corresponds to the reported localization of CT-stimulated adenylyl cyclase 
activity, suggesting that the receptor-mediated actions of CT in renal Ca2+ 
reabsorption utilize cAMP as a second messenger (89). Using isolated perfused 
tubule studies, CT and cAMP analogue have been shown to enhance Ca2+ 
reabsorption in the rabbit distal nephron segments (90). However, the detailed 
molecular mechanism responsible for CT regulated renal Ca2+ handling remains 
unclear. Both CTR and TRPV5 are located primarily in the distal part of the nephron, 
suggesting that CT might affect TRPV5-mediated Ca2+ reabsorption through binding 
to CTR and CTR-associated downstreaming signaling.
Dietary calcium
The average Ca2+ intake has been observed to be in a lower level among Asian 
people compared to the Western population. The mean dietary Ca2+ intake among 
Chinese, Hong Kong and Thailand population are between 350-450 mg/day, which 
reaches only half the recommended value (800 mg/day). Meta-analysis from the 
studies in both premenopausal and postmenopausal women (91) showed that a high 
dietary Ca2+ intake has a positive effect on bone mineral density (BMD) and 
appropriate Ca2+ supplement (~1,000 mg/day) could prevent bone loss in 
premenopausal women (91). Thus adequate Ca2+ supplement is essential for a 
long-lasting positive Ca2+ balance. In addition to the calciotropic hormones, it has
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been shown that dietary Ca2+ content can affect renal Ca2+ transport. However, it is 
difficult to study the solitary effects of dietary Ca2+ without affecting plasma 
1,25(OH)2D3 levels. To investigate the regulatory effects of dietary Ca2+ on Ca2+ 
homeostasis independent of 1,25(OH)2D3 levels, studies were performed in VDR 
knockout (VDR-/-) and 1a-OHase-/- mice fed normal and high-Ca2+ rescue diets (73, 
74). High dietary Ca2+ intake normalized plasma Ca2+, accompanied by restoration of 
the reduced expression levels of renal TRPV5 and intestinal TRPV6 in 1a-OHase-/- 
mice (73). Furthermore, Dardenne et al. showed that supplement with high Ca2+ 
rescue diets in 1a-OHase-/- mice resulted in a partial rescue of the bone phenotype of 
VDDR I (92). In contrast, the Ca2+-enriched rescue diet reduced the expression of 
renal TRPV5 and calbindin-D28K in wild-type littermates by a negative feedback 
mechanism, while these mice exhibited normal serum vitamin D and Ca2+ levels (73, 
74). Similarly, feeding high Ca2+ diet to VDR-/- mice restored the hypocalcemia and 
up-regulated the significantly decreased expression of duodenal TRPV6 mRNA, 
whereas in wild-type mice high dietary Ca2+ content decreased TRPV6 expression 
due to a suppression of serum 1,25(OH)2D3 (74). Thus, these studies showed that 
Ca2+ supplementation can up-regulate TRPV5/6 gene transcription independent of 
circulating 1,25(OH)2D3.
Acidosis and alkalosis
Acid-base homeostasis is known to affect renal Ca2+ handling (11, 93). Chronic 
metabolic acidosis, which can occur as a result of clinical disorders such as renal 
failure, distal renal tubular acidosis, or chronic diarrhea, is associated with increased 
renal Ca2+ excretion (11, 94). Conversely, chronic metabolic alkalosis observed in, for 
example, the milk-alkali syndrome, volume contraction, or treatment of nephrolithiasis 
by bicarbonate supplementation is known to decrease urine Ca2+ excretion (93, 95).
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Recently, the molecular mechanisms that explain the altered renal Ca2+ excretion 
during these disturbances of acid-base balance have been addressed by Bindels and 
coworkers (96). Chronic metabolic acidosis was induced by NH4Cl loading or 
administration of the carbonic anhydrase inhibitor acetazolamide for 6 days. This 
enhanced the calciuresis that was accompanied by decreased renal TRPV5 mRNA 
and protein abundance compared to control mice. In contrast, metabolic acidosis did 
not affect Ca2+ excretion in TRPV5-/- mice, in which active Ca2+ reabsorption is 
effectively abolished. This demonstrates that down-regulation of renal Ca2+ transport 
proteins is responsible for the observed hypercalciuria. Conversely, chronic metabolic 
alkalosis that was induced by NaHCO3 administration for 6 days increased the 
expression of TRPV5 accompanied by diminished urine Ca2+ excretion. However, this 
Ca2+-sparing action persisted in TRPV5-/- mice, suggesting that additional 
mechanisms apart from upregulation of active Ca2+ reabsorption contribute to the 
hypocalciuria. These data suggest that regulation of Ca2+ transport proteins 
importantly contributes to the effects of acid-base status on renal Ca2+ handling.
Estrogen
Estrogen is a sex hormone, derived from ovary and adrenal gland and from peripheral 
conversion in adipose tissue (97). Its major function is to maintain reproduction and 
promote the development of female secondary sex characteristics. Although estrogen 
is usually not considered as a calciotropic hormone traditionally, the idea that 
estrogen plays a role in Ca2+ homeostasis has been widely accepted (98). This 
involvement is clearly illustrated by the fact that estrogen deficiency results in a 
negative Ca2+ balance and osteoporosis among postmenopausal women (99). In 
addition to bone, the small intestine and kidney are two potential targets for estrogen 
action on Ca2+ handling and regulation (100, 101). Van Abel et al. demonstrated that
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estrogen regulates the expression of TRPV5 in kidney in a 1,25(OH)2D3-independent 
manner (100). Estrogen replacement in ovariectomized (OVX) rats resulted in 
significant increased abundance of TRPV5 and associated Ca2+ transport proteins 
(calbindin-D28K, NCX1, and PMCAlb) in kidney (100). 17p-estradiol (E2) enhanced the 
renal TRPV5 mRNA and protein expression in 1a-OHase-/- mice, suggesting a vitamin 
D-independent regulation by estrogen. 17PE2 treatment normalized restored serum 
Ca2+ levels in these hypocalcemic mice suggested a direct role of 17PE2 on renal Ca2+ 
reabsorption via the upregulation of TRPV5. Similarly, 17PE2 treatment resulted in the 
upregulation of duodenal TRPV6 abundance in both OVX rats and 1a-OHase-/- mice. 
On the other hand, Van Cromphaut et al. showed that mRNA expression of TRPV6 
was not altered in estrogen receptor-beta (ERP) knockout mice, but was reduced by 
55% in estrogen receptor-alpha (ERa) knockout mice, suggesting that the estrogen 
effects on duodenal expression of Ca2+ transporter are mediated by ERa (102). 
Together, these data identify estrogen as a novel calciotropic hormone for the renal 
Ca2+ handling and furthure detailed investigations of the molecular mechianism of 
estrogen actions in kidney, intestine and bone are essential for the treatment of 
estrogen-associated Ca2+ disorders.
Androgen
Increased urinary Ca2+ excretion during long-term androgen deficiency has been 
associated with male aging and has long been considered to result mainly from 
increased bone resorption, similar to long-term estrogen deficiency after menopause 
leading to osteoporosis (103). A number of in vitro and in vivo studies suggested that 
these long-term effects of the sex hormones on bone are associated with anabolic 
and anti-resorptive effects through directly and indirectly regulating the proliferation, 
differentiation, mineralization, and gene expression of the bone cells (104). In addition,
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distinct sex differences in the maintenance of the body Ca2+ balance have been 
shown. For instance, it is commonly known that urolithiasis is a male-predominant 
disorder (105). Accordingly, several studies reported that there is greater urinary Ca2+ 
loss in males than in females (106). This suggests that androgen may play an 
opposite role to estrogen in renal Ca2+ reabsorption. Moreover, several lines of 
evidence suggested that androgen could have (in)direct effects on the regulation of 
renal Ca2+ excretion (107, 108). Because the androgen receptor (AR) gene has also 
been found to be expressed in renal epithelial cells (109), these data imply that 
androgen possibly regulates Ca2+ homeostasis via its impact on kidney, next to its 
long-term effect on bone. Furthermore, growing evidence points to sex differences in 
various morphological and functional characteristics of mammalian kidneys (110). 
However, the molecular mechanisms of (active) renal Ca2+ handling by the male sex 
hormone are not known.
(2) Regulation o f TRPV5 activ ity  at plasma membrane
Parathyroid hormone
In addition to its effect on TRPV5 transcription, PTH could significantly elevate the 
influx of 45Ca2+ through regulation of TRPV5 activity (111). The effect of PTH on 
TRPV5 regulation was fully mimicked by PTH(1-31), which specifically activates the 
cAMP-protein kinase A (PKA) pathway, and forskolin, a cAMP-elevating agent. 
Strikingly, both forskolin- and PTH-induced TRPV5 activation was abolished by 
alanine substitution of threonine 709, a potential PKA phosphorylation site in TRPV5. 
Consistently, in vitro phosphorylation of TRPV5 was significantly diminished for this 
T709A mutant. Analyses by cell surface biotinylation and patch clamp showed that 
forskolin did not alter TRPV5 plasma membrane expression, whereas application of 
the PKA catalytic subunit via the patch pipette directly increased TRPV5 channel
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open probability. These data unraveled the molecular mechanism underlying TRPV5 
activation via PKA-dependent phosphorylation of T709, substantiating the 
Ca2+-sparing effect upon PTH release during hypocalcemia.
Intracellular Ca2+
By using patch clamp current recordings combined with Fura-2-based Ca2+ 
measurements in HEK293 cells demonstrated that extracellular Ca2+ ([Ca2+]e) induced 
a large transient inward current and a concomitant rise in intracellular Ca2+ ([Ca2+]i) in 
cells transfected with TRPV5, but had no effects om the cells transfected with the 
Ca2+-impermeable mutant D542A, in which an aspartate in the pore region was 
neutralized (112). Cells dialyzed with 10 mM 1,2- bis (2-aminophenoxy) 
ethane-W,W,W*,W*-tetraacetic acid (BAPTA) displayed large inward currents through 
TRPV5 in response to voltage ramps and increasing [Ca2+]i by dialyzing the cell with 
pipette solutions containing various Ca2+ concentrations, all buffered with 10 mM 
BAPTA, inhibited Ca2+ currents through TRPV5 with an IC50 of 82 nM. These data 
suggested that [Ca2+]i acts as a negative feedback switch regulating TRPV5 activity, 
which is controlled by the concentration of Ca2+ in a micro domain near the inner 
mouth of the channel.
Extracellular and intracellular protons
It has been established that the transcriptional expression of TRPV5 is attenuated by 
chronic metabolic acidosis. In addition to a disturbance of the TRPV5 transcription, 
both extracellular and intracellular proton concentrations inhibit TRPV5 activity. 
Acidification of the apical medium inhibits transcellular Ca2+ transport across primary 
cultures of rabbit CNT and CCD cells, providing a pH-dependent activity of the apical 
Ca2+ influx pathway (113). Similarly, 45Ca2+ uptake in TRPV5-expressing Xenopus
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laevis oocytes is inhibited by acidification of the incubation medium (12, 114). 
Recently, Huang and coworkers proposed a possible mechanism of 
proton-dependent modulation of TRPV5 channel properties. Mutation of the glutamate 
at position 522, preceding the pore region, to glutamine (E522Q) decreased the 
inhibition of the channel by extracellular protons, suggesting that this residue may act 
as the "pH sensor” of TRPV5 (115). Intracellular protons also inhibit TRPV5 activity 
(115). Mutation of lysine-607, surrounding the putative intracellular entrance of the 
pore, to asparagine (K607N) lessened the inhibition of TRPV5 activity by intracellular 
acidification (116). Measurements of the relative permeability of inorganic monovalent 
cations to Na+ indicated that both intra- and extracellular acidification reduces the 
estimated TRPV5 pore diameter, which is possibly due to a rotation of the pore helix.
80K-H
80K-H was originally cloned as a protein kinase C (PKC) substrate of 80 kDa (117). 
Recent studies showed that 80K-H can also act as a receptor for advanced glycation 
end products (RAGE) (118) and interact with PKCzeta and munc18c involved in 
glucose transporter 4 (GLUT4) vesicle transport. 80K-H contains two putative 
EF-hand structures and using glutathione S-transferase (GST) pull-down and 
coimmunoprecipitations assays a physical interaction between 80K-H and TRPV5 in 
Xenopus laevis oocytes was demonstrated (119). Furthermore, both proteins 
co-localized along the apical membrane of DCT and CNT in kidney and exhibited 
similar transcriptional regulation by 1,25(OH)2D3 and dietary Ca2+, indicating that 
regulation of TRPV5 by 80K-H could occur in vivo. The Ca2+-binding properties of 
80K-H are abolished upon inactivation of its two EF-hand structures. Importantly, this 
modification of the EF-hand pair in 80K-H also reduced the TRPV5-mediated Ca2+ 
current and increased the TRPV5 sensitivity to intracellular Ca2+, accelerating the
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feedback inhibition of the channel (119). Therefore, 80K-H may act as a Ca2+ sensor 
to regulate TRPV5 activity at the plasma membrane.
(3) Regulation o f TRPV5 tra ffick ing  and routing
S100A10-annexin 2
S100A10, a 97-amino acid protein member of the S100 superfamily, was identified as 
an associated protein of TRPV5 using the yeast two-hybrid system. It is tightly 
associated with annexin 2, a member of the Ca2+ and phospholipids-binding proteins, 
which is implicated in several biological processes including exocytosis, endocytosis 
and membrane-cytoskeleton interactions (120). A short conserved peptide, VATTV, 
located in the carboxyl-terminal of TRPV5 is crucial for the interaction with S100A10 
(121). Among this motif, the first threonine is the key amino acid for the binding and 
channel function. As this particular threonine was mutated, the activity of TRPV5 was 
abolished accompanied by a disruption in their subcellular localization, suggesting 
that the S100A10-annexin 2 heterotetramer facilitates the trafficking of TRPV5 
towards the plasma membrane. The importance of annexin 2 in this process was 
substantiated by showing that small interfering RNA (siRNA)-based downregulation of 
annexin 2 significantly inhibits TRPV5 currents. The expression of S100A10 was also 
downregulated by this approach, indicating that annexin 2, in conjunction with 
S100A10, is important for TRPV5 activity. However, the association of annexin 2 with 
TRPV5 was only detectable in the presence of S100A10, suggesting that annexin 2 
binds indirectly to the channel and S100A10 operates like a molecular bridge between 
TRPV5 and annexin 2 (121). These findings supported a regulatory role of 
S100A10/annexin 2 controlling TRPV5 trafficking and, therefore, the Ca2+ balance.
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Rab11a
Members of the Rab guanosine triphosphatase (GTPase) family are key regulators of 
membrane traffic (122) and have been implicated in distinct transport steps, such as 
vesicle budding, targeting, and tethering. Rab11a is a small GTPase involved in cargo 
trafficking via recycling endosomes (123) Van de Graaf et al. demonstrated that 
Rab11a co-localized with TRPV5 in Ca2+-transporting epithelial cells of the kidney. 
Furthermore, both molecules are present within vesicular structures below the apical 
plasma membrane (124). Using a combination of GST pull-down and 
coimmunoprecipitation assays confirmed a direct and specific interaction between 
Rab11a and TRPV5, which provides the first evidence of an ion channel directly 
associating with a Rab GTPase. TRPV5 preferentially interacts with Rab11a in its 
GDP-bound conformation (124). Expression of a mutant Rab11a protein, locked in the 
GDP-bound state, results in a marked decrease of TRPV5 at the cell surface, 
indicating a direct role of Rab11a in the trafficking of TRPV5 towards the plasma 
membrane (124). These findings raised the possibility that TRPV5 channels, present 
on the (apical) plasma membrane, are continuously exchanged with TRPV5 channels 
from the intracellular (recycling) endosomes in a Rab11-dependent manner, whereas 
the underlying molecular mechanisms determining the distribution of TRPV5 between 
the plasma membrane and the intracellular pool are currently unknown.
Clathrin and Caveolin
Regulation of the abundance of TRPV5 at the cell surface is critical to the Ca2+ 
homeostasis, whereas little is known about the mechanisms underlying TRPV5 endo- 
and exocytosis. Clathrin, composed of three clathrin heavy chains and three light 
chains intricately braided together, facilitates the formation of small vesicles in the 
cytoplasm (125). Clathrin-mediated endocytosis is one of the major mechanisms
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employed by the cell for the internalization of receptors from the plasma membrane. In 
general terms, this process involves receptors in the plasma membrane binding to a 
clathrin adaptor protein, such as AP2, which induces clathrin polymerization and the 
formation of clathrin-coated pits (125). A recent study by Van de Graaf et al. showed 
that TRPV5 is constitutively internalized in a dynamin- and clathrin-dependent manner. 
Internalized TRPV5 first appears in small vesicular structures and then localizes to 
perinuclear structures with positive Rab11a expression. Disruption of cell surface 
delivery of newly synthesized TRPV5 by brefeldin A does not reduce 
TRPV5-mediated Ca2+ influx in cells, suggesting the presence of a stable intracellular 
pool of the channel capable of recycling back to the surface (126).
Caveolin-1 incorporates with cholesterol and sphingolipids in certain areas of the cell 
surface, leading to the formation of small invaginations named caveolae. Caveolae 
are thought to play a role in important physiological functions such as cell surface 
signaling, endocytosis and intracellular cholesterol transport. Huang et al. showed a 
caveolin-1-mediated internalization of TRPV5, which was inhibited by PKC activator 
1-oleoyl-acetyl-sn-glycerol (OAG) (127). OAG increased TRPV5 current density and 
surface abundance in vitro and the OAG-mediated increase of TRPV5 was prevented 
by preincubation with specific PKC inhibitors. Knockdown of caveolin-1 by siRNA 
prevented the increase of TRPV5 by PKC activation. In addition, mutations of 
serine-299 and/or serine-654 of TRPV5 (consensus residues for phosphorylation by 
PKC) abolished the stimulation by OAG (127). Thus, clathrin and caveolin are two 
novel regulators participating in the process of internalization of TRPV5.
WNK3 and WNK4
WNKs (With-No-Lysine [K]) are a family of serine/threonine protein kinases. Mutations 
in WNK 1 and 4 kinases cause pseudohypoaldosteronism type II (PHA II) and may
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represent a novel signaling pathway regulating blood pressure, and K+ and H+ 
homeostasis (128). PHA II is an autosomal dominant disorder characterized by 
hypertension, hyperkalemia, and metabolic acidosis, with normal glomerular filtration 
rate. Recently, hypercalciuria in combination with decreased bone mineral density has 
been identified as another unique presentation in patients harboring Q565E WNK 4 
mutation (129). Interestingly, both TRPV5 and WNK4 are specifically expressed in the 
distal part of the nephron, suggesting that they may functionally interact. The role of 
WNK4 in the regulation of TRPV5 activity has been addressed by measuring Ca2+ 
uptake in Xenopus  oocytes (130). Co-expression of TRPV5 with WNK4 resulted in a 
twofold increase in TRPV5-mediated Ca2+ uptake, which was due to increased 
surface abundance of TRPV5. The majority of human TRPV5 exogenously expressed 
in the Xenopus oocyte plasma membrane was complexly N-glycosylated and blocking 
complex glycosylation of TRPV5 by syntaxin 6 attenuated the enhancing effect of 
WNK4 on TRPV5 (131). These data suggest that the increased expression of TRPV5 
in plasma membrane was likely due to the enhanced delivery of mature TRPV5 to the 
plasma membrane via the secretory pathway. Similarly, WNK3 also enhanced 
TRPV5-mediated Ca2+ influx in Xenopus oocyte and the kinase domain of WNK3 
alone was sufficient to increase TRPV5-mediated Ca2+ transport (132). The positive 
regulatory effect was abolished by the kinase-inactive D294A mutation, indicating a 
kinase-dependent mechanism. On the other hand, the abundance of the complex 
glycosylated TRPV5 on the plasma membrane was increased by WNK3. However, 
the stimulatory effect of WNK3 on the expression of TRPV5 was abolished by 
microtubule inhibitor colchicine, suggesting that WNK3 may be involved in the 
exocytosis of TRPV5. Together, these results demonstrated that WNK3 and WNK4 
are both positive regulators of the transcellular Ca2+ transport pathway.
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(4) Regulation o f TRPV5 recycling
Tissue kallikrein
The kallikrein-kinin system (KKS) is a complex multi-,enzymatic system and the main 
components include the enzyme kallikrein, the substrate kininogen, effector hormone 
kinins (lysyl-bradykinin and bradykinin, BK) and metabolizing enzymes kininase (133). 
Tissue kallikrein (TK) is a serine protease that is mainly expressed in the DCT, and 
CNT and kinins are converted by partial hydrolysis of kininogen by TK (134). The 
kinins bind to the type 2 BK receptor and then activate PLC by Ga signaling. This 
results in the formation of diacylglycerol (DAG), which in turn activates PKC (135). 
The TK- mediated signal cascades regulate several important physiological functions, 
such as organ blood flow, systemic blood pressure, capillary permeability and 
inflammatory response. In addition, TK has been shown to be involved in the 
regulation of water, sodium and potassium metabolism (136). The role of TK in the 
regulation of Ca2+ balance has not been well studied until the discovery of a marked 
hypercalciuria in TK-deficient mice (137). Gkika and coworkers further explored the 
molecular mechanism of TK involved in renal Ca2+ handling in vitro. Using 
TRPV5-expressing primary cultures of renal Ca2+-transporting epithelial cells, they 
showed that TK activates Ca2+ reabsorption (138). The stimulatory effect of TK was 
mimicked by BK and could be inhibited by application of JE049, a type 2 BK receptor 
blocker. A cell permeable analogue of DAG increased TRPV5 activity and mutation of 
TRPV5 at the putative PKC phosphorylation sites S299 and S654 prevented the 
stimulatory effect of TK, suggesting a PKC-dependent pathway. The cell surface 
biotinylation studies revealed that TK enhances the amount of wild-type TRPV5 
channels, but not of the TRPV5 S299A and S654A mutants, at the plasma membrane 
by delaying its retrieval. Taken together, these data indicate that TK enhances active 
Ca2+ reabsorption through an increased TRPV5 plasma membrane expression via the
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BK-activated PLC/DAG/PKC pathway.
Klotho
The klotho gene, named after the spinner for the thread of life in Greek mythology, 
was identified in 1997 as a gene mutated in the klotho mouse, which displays a 
significant shortened life span with multiple disorders resembling human 
premature-aging syndromes, including hypogonadism, atherosclerosis, premature 
thymic involution, ectopic calcification, impaired bone mineralization, skin atrophy, 
pulmonary emphysema, neurodegeneration, and hearing loss (139). In addition, 
klotho-deficient mice have higher levels of serum phosphorus, calcium, and 
1,25(OH)2D3 than wild-type mice, suggesting that klotho may be critical in Ca2+ 
homeostasis (140). Klotho, a type-I (single-pass) membrane protein, is predominantly 
expressed in kidney, especially in DCT2/CNT (139). The transmembrane klotho forms 
a complex with fibroblast growth factor receptor (FGFR) and functions as a 
co-receptor for fibroblast growth factor 23 (FGF23) and plays a crucial role in the 
regulation of phosphate and vitamin D metabolism in the kidney (141). On the other 
hand, the membrane-anchored proteases ADAM-10 and ADAM-17, belong to a family 
of proteins with a disintegrin-like and metalloproteinase-like domain (ADAM), could 
cleave the transmembrane klotho just above the plasma membrane (142). The entire 
extracellular domain of klotho is then released into blood, urine, and cerebrospinal 
fluid and may function as a humoral factor leading to multiple aging-like phenotypes of 
klotho deficiency mice.
The extracellular domain of klotho is composed of two domains, each having a 
homology to p-glucuronidase of bacteria and plants (139, 143). p-glucuronidase is a 
member of the glycosidase family of enzymes that catalyze breakdown of complex 
carbohydrates and hydrolysis of steroid p-glucuronides by extracellular domain of
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klotho suggested a p-glucuronidase activity (139, 143). Chang et al. demonstrated 
that the presence of extracellular klotho significantly increased the activity of TRPV5 
in cultured rabbit primary CNT cells (144). Moreover, TRPV5-expressing HEK293 
cells also showed a significant rise in channel activity after klotho treatment that was 
concomitant with increased plasma membrane channel abundance and similar 
stimulatory effect was observed by incubation with p-glucuronidase. Importantly, the 
stimulatory effect of klotho or p-glucuronidase was abolished in HEK293 cells 
expressing the TRPV5 glycosylation-deficient mutant TRPV5-N358Q, indicating a 
pivotal role N-glycosylation in TRPV5 activation (144). Recently, Cha et al. suggested 
a sialidase rather than p-glucuronidase activity for klotho, as they observed a 
klotho-mediated removal of terminal sialic acids from the N-glycan in TRPV5 (145). 
This cleavage exposed the underlying galactose-N-acetylglucosamine disaccharides 
in TRPV5, which can directly interact with membrane-bound galectin-1, causing the 
subsequent plasma membrane retention of TRPV5. However, Hoenderop’s group 
found that removal of the entire N-glycan tree by peptide N-glycosidase F (Endo-F) 
resulted in a more pronounced increase in TRPV5 activity compared to that induced 
by klotho treatment, suggesting additional mechanisms besides binding to the 
membrane galectin-1 (146). Additional research focusing on the influence of N-glycan 
metabolism on TRPV5 activity is needed.
TRP CHANNELS AND KIDNEY DISEASES
Growing evidence is supporting the emerging role of TRP channels in renal 
physiology. Thus, TRP channels are implicated in the pathogenesis of a number of 
kidney diseases, and the current knowledge and recent advances concerning the 
correlations between TRP channels and kidney diseases are described briefly here 
and summarized in Table 1.
40
General Introduction
Table 1. TRP channels related to  kidney diseases and m edication
Isoform G ene location  
(hum an)
Distribution in kidney Proposed function in kidney Associated kidney diseases Identified m utations
TRPC1 3q22-24 Mesangial cell, PT, TAL Regulation of mesangial cell 
contractility
Diabetic nephropathy NA
TRPC6 11 q21 -22 Podocyte, principle 
cells of CD
Regulate slit diaphragm 
function and permeability to 
protein
FSGS P112Q, N143S, S270T, 
R895C, E897K, 
K874stop
TRPP1 16p13.3 Cilia of renal epithelial 
cells
Interaction with TRPP2 as 
mechanosensor
ADPKD 56 mutations
TRPP2 4q21-23 Cilia of renal epithelial 
cells
Interaction with TRPP1 as 
mechanosensor
ADPKD 45 mutations
TRPV4 12q24.1 ATL, TAL, DTL, CNT Regulate renal medullary 
tonicity
Na+ and water balance NA
TRPM6 9q22 DCT Renal Mg2+ reabsorption HSH
GS
1769C^ G, 2667+1G ^ A 
2207delG
[3537-1G^A]+[422C^T]
[1280delA]+[3779-91del]
NA
TRPV5 7q35 DCT, CNT Renal Ca2+ reabsorption Adverse effects of diuretics
Adverse effects of 
immunosuppressant agents
Vitamin D analogs associated 
Ca2+ disorders
Uremic calcification
DM associated Ca2+ and Mg2+ 
disorders
Acid-base associated Ca2+ 
and Mg2+ disorders
Idiopathic hypercalciuria
NA
NA
NA
NA
NA
NA
A8V, R154H, A561T
Abbreviations: CD, collecting duct; ATL, ascending thin limb; TAL, th ick  ascending limb, DTL, descending
thin limb; CNT, connecting tubule; DCT, distal convoluted tubule; FSGS, focal segm ental 
glom erulosclerosis; ADPKD, autosom al dom inant polycystic kidney disease; HSH, hypom agnesem ia 
with secondary hypocalcem ia; GS, G ite lm an’s syndrome; DM, diabetes mellitus; del, deletion; NA, not 
available.
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TRPC1 and diabetic nephropathy
TRPC1 is a Ca2+-permeable cation channel in mesangial cell and plays an important 
role in controlling contractile function of the mesangial cell (147). Zucker fatty rat, an 
animal model for human diabetic nephropathy, as well as streptozotocin 
(STZ)-administered rat exhibited downregulation of TRPC1 and the TRPC1 regulator 
hepatic nuclear factor 4a (HNF 4a) (148), Similarly, expression of TRPC1 and HNF 4a 
was reduced in kidney isolated from patients with diabetic nephropathy compared to 
healthy subjects (148). Thus, it is deduced that TRPC1 plays an important role in the 
developemnet of diabetic nephropathy.
TRPC6 and focal segmental glomerulosclerosis
TRPC6 is enriched in the podocyte foot processes and recent work by Winn et al. and 
Reiser et al. reported the identification of six mutations in TRPC6 associated with 
autosomal dominant focal segmental glomerulosclerosis (FSGS) (149, 150). Among 
these six TRPC6 mutants, three of them (P112Q, R895C, E897K) are gain-of-function 
mutations, which result in increased Ca2+ current amplitudes. TRPC6 co-localizes with 
podocin and nephrin and immunoprecipitation studies showed physical interaction 
between TRPC6 and these proteins, indicating that the channel is integrated into the 
signaling complex at the slit diaphragm (149). In addition, Moller et al. demonstrated 
that TRPC6 is functionally connected to the actin cytoskeleton in the podocyte and 
transient overexpression of the channel in mice leads to proteinuria (151). Hence 
TRPC6 mutations might cause proteinuria and play a key role in the pathogenesis of 
FSGS.
TRPP2 and polycystic kidney disease
In kidney, TRPP1 (PKD1) has been identified in the plasma membrane of tubular
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epithelial cells, particularly in DT and CD (152), whereas TRPP2 (PKD2) localizes in 
the plasma membrane and ER, with highest levels in TAL and DCT (153). Polycystic 
kidney disease (PKD), a common genetic disorder which leads to chronic renal failure, 
is characterized by the accumulation of fluid-filled cysts in the kidney, liver, pancreas 
and choroid plexus (154). Autosomal dominant PKD (ADPKD), the most frequent form 
of PKD, has been disclosed to arise from mutations in the PKD1 and PKD2 gene. 
Recent studies showed that PKD1 can activate G proteins and multiple enzymatic 
signaling cascades involved in cyst formation, such as fluid secretion and epithelial 
cell proliferation, polarity and differentiation (155). On the other hand, the interaction 
of PKD2 with the coiled-coil domain of PKD1 inhibits G protein signaling (156). 
Furthermore, Pazour et al. and Yoder et al. found that PKD1 and PKD2 co-localize 
with polaris and cystin in cilia of renal epithelial cells (157, 158) and the PKD1-PKD2 
complex has been proposed as a component of a cilia as mechanosensor of epithelial 
cells (159-161). Furthermore, the expression of PKD2 is increased in orpk mutant 
mice, which have stunted renal cilia and develop PKD (157). Taken together, these 
data suggested that PKD1 and PKD2 might interact with polaris and cystin involved in 
the pathogenesis of PKD secondary to ciliary dysfunction (162). Future studies are 
needed to elucidate how PKD1 and PKD2 alternations influence ciliary function and 
result in cyst formation.
TRPV4 and regulation o f renal medullary tonicity
TRPV4, initially described as OTRPC4 (163), VR-OAC (164), TRP12 (165), and 
VRL-2 (166), is an osmotically-responsive cation channel. In mammals, TRPV4 is 
activated by hypotonic stimuli, resulting in an increase in [Ca2+]i (167). TRPV4 
knockout mice (TRPV4-/-) exhibit dysregulation of vasopressin secretion which is 
explained by its presence in the circumventricular nuclei of the central nervous system
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(CNS) (164, 168, 169). It has, therefore, been suggested that TRPV4 functions as an 
osmoreceptor in the CNS. Interestingly, recent studies demonstrated that TRPV4 is 
highly expressed in mammalian kidney where it is restricted to water-impermeable 
nephron segments, including ATL, TAL and DCT (27). The Na+-K+-2Cl- co-transporter 
(NKCC2), couples the inward movement 1 Na+, 1 K+, 2 Cl- ion in an electroneutral 
process, is mainly responsible for the transcellular reabsorption of NaCl in the TAL, 
which ultimately contributes to the hyperosmotic medulla of the kidney (21). The 
co-expression of NKCC2 and TRPV4 in TAL suggests that they might be functionally 
coupled and involved in the molecular mechanism of renal adaptation to systemic 
osmotic change.
TRPM6 and hypomagnesemia with secondary hypocalcemia
Individuals suffering from hypomagnesemia with secondary hypocalcemia (HSH), an 
autosomal recessive genetic disorder affecting Mg2+ homeostasis, display neurologic 
symptoms including seizures and tetany during infancy (170). Physiological studies of 
HSH patients have shown that there are defects in both intestinal and renal Mg2+ 
(re)absorption (171, 172). Subsequent analysis of the critical region pointed to a gene, 
TRPM6, which was mutated in patients with HSH (170, 171). Bindels and coworkers 
demonstrated that TRPM6 is specifically localized along the apical membrane of the 
renal DCT and the brush-border membrane of the small intestine, epithelia particularly 
associated with active Mg2+ (re)absorption (173). Furthermore, heterologous 
expression of TRPM6 in HEK293 cells, but not TRPM6 mutants identified in patients 
with HSH, induced a Mg2+-permeable cation channel that is tightly regulated by the 
intracellular Mg2+ concentration (173). These findings indicated that TRPM6 
comprises all or part of the apical Mg2+ channel of Mg2+ absorbing epithelia where it 
plays a key role in the pathogenic mechanisms of HSH.
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TRPV5 AND RENAL CA2+ DISORDERS
Numerous clinical disorders and side effects of commonly prescribed medication for 
renal disorders directly result from dysregulation of the body Ca2+ balance and several 
studies recently implicated TRPV5 in the pathogenesis of disturbed Ca2+ homeostasis 
observed in both kidney diseases and from drug treatment therapies.
TRPV5 and immunosuppressant agents
Immunosuppressant drugs, like the calcineurin inhibitors FK506 (tacrolimus) and 
cyclosporine A, along with glucocorticoids such as dexamethasone and prednisolone, 
are prescribed in glomerulonephritis and widely used for renal transplantation. These 
drugs are associated with an increased bone turnover, a negative Ca2+ balance and 
hypercalciuria (174, 175). FK506 treatment in mice could reduce renal TRPV5 mRNA 
and protein expression associated with renal Ca2+ wasting, suggesting that 
down-regulation of Ca2+ channel abundance provides the molecular mechanism for 
FK506-induced hypercalciuria (176). The immunosuppressive action of FK506 
depends on the inhibition of the Ca2+-dependent phosphatase calcineurin in T 
lymphocytes (177, 178). Another calcineurin inhibitor, cyclosporine A, increased 
urinary Ca2+ excretion and decreased calbindin-D28K protein levels (179, 180). This 
suggested that calcineurin inhibition may play a role in the impairment of Ca2+ 
reabsorption. In addition, tacrolimus binds to intracellular immunophilins called 
FK506-binding proteins (FKBPs), which were implicated as ion channel regulators 
(181). Recent studies by Gkika et al. identified FKBP52 as an auxiliary protein of 
TRPV5, inhibiting channel activity. FKBP52 specifically interacted with TRPV5, and 
both proteins co-localize in DCT. On the other hand, gene silencing of FKBP52 or 
administration of the FKBP52 blocker FK-506 alters Ca2+ influx through TRPV5 (182). 
Therefore, binding of FK506 to FKBPs could affect TRPV5 expression explaining the
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hypercalciuric effect of FK506. In contrast to FK506, the glucocorticoid agent 
dexamethasone increased renal TRPV5 expression, suggesting that stimulation of 
corticoid receptors positively affects TRPV5 transcription, counteracting the negative 
Ca2+ balance during treatment with these compounds (176).
TRPV5 and vitamin D analogues
Secondary hyperparathyroidism (SHPT), a common disorder in patients with chronic 
renal failure, develops in response to low plasma levels of Ca2+ and active vitamin D 
metabolites. SHPT requires treatment to minimize the adverse effect of elevated PTH 
on bone and other tissues (183). Vitamin D compounds have been widely used in the 
treatment of this disorder and several different analogues are available for clinical 
practice (184). The 1a-hydroxyvitamin D2 (1a(OH)D2) is a vitamin D prodrug, less 
calcemic than 1,25 (OH)2D3 in animal studies, which must be metabolized to become 
active (183), resulting in altered pharmacokinetics relative to active vitamin D 
compounds. 1a,24-dihydroxyvitamin D2 (1,24(OH)2D2) is an active metabolite of 
1a(OH)D2 with greatly reduced calcemic activity relative to 1,25(OH)2D3 (185, 186). 
The 1a-OHase knockout mice were used to study the activity of vitamin D compounds, 
namely 1,25(OH)2D3, 1a(OH)D2, and 1,24(OH)2D2, on serum Ca2+ levels and the 
expression of Ca2+ transport genes. All three compounds were able to increase serum 
Ca2+ levels, although at different time-scales, reflecting their individual 
pharmacokinetics, thereby increasing serum 1,25(OH)2D3 levels. Interestingly, TRPV5 
and TRPV6 mRNA levels in duodenum increased in parallel with serum levels of Ca2+. 
Effects of vitamin D compounds on Ca2+ regulatory genes in kidney were more 
diverse, of which 1,24(OH)2D2 did not up-regulate TRPV5 (187). However, use of 
compounds such as 1,25(OH)2D3 has frequently been accompanied by the undesired 
side effects of hypercalcemia and hyperphosphatemia through intestinal
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hyperabsorption, which increase the risk of soft tissue and vascular calcification (188). 
To avoid these side effects, new vitamin D analogues have been developed with the 
aim of suppressing PTH secretion with minimal calcemic action (189, 190). In this 
respect, Nijenhuis et al. reported a novel vitamin analogue ZK191784 displaying 
tissue-specific effects when administered in vivo or in vitro (190). ZK191784 
enhanced renal TRPV5 expression and exerted an agonist effect on Ca2+ handling in 
kidney. However, ZK191784 did not stimulate intestinal Ca2+ absorption. This 
compound acts as an intestine-specific 1,25(OH)2D3 antagonist by down-regulation of 
TRPV6 expression in duodenum. The tissue-specific 1,25(OH)2D3 effect of this new 
generation of vitamin D analogues might be of great benefit in the treatment of SHPT.
TRPV5 and uremic calcification
Chronic renal failure (CRF) is characterized by hyperphosphatemia, hypocalcemia 
and SHPT (191). Dysregulation of phosphate (Pi), Ca2+ and PTH leads to catastrophic 
complications in patients with CRF. Maintenance of Ca2+ and Pi balance is pivotal to 
prevent progression of renal failure, development of SHPT, generation of uremic bone 
diseases and cardiovascular sequelae (192, 193). Until now, it remains a challenge to 
manage Pi and Ca2+ abnormalities in uremic patients. Recently, a newly discovered 
gene, klotho, predominantly expressed in kidney, has been found to be involved in the 
development of human aging (139). The klotho mutant mice show reduced life span, 
decreased activity, infertility, osteoporosis, atrophy of skin, abnormal Ca2+ and 1,25 
(OH)2D3 metabolism, hyperphosphatemia and vascular calcification (139). 
Interestingly, some characteristics of CRF patients resemble the phenotypes of klotho 
knockout mice and diminished klotho production has been found in uremic patients 
(194). Furthermore, Chang et al. found that klotho possesses glucuronidase activity 
and co-localizes with TRPV5 in DCT (144). Klotho can hydrolyze extracellular sugar
47
Chapter 1
residues on TRPV5, which contributes to the entrapment of TRPV5 in the plasma 
membrane and, thereby, increases Ca2+ reabsorption (144). Another study by 
Segawa et al. demonstrated that hyperphosphatemia in klotho-/- mice is due to 
dysregulation of expression and trafficking of the renal type Na/Pi IIa/IIc transporters 
rather than to intestinal Na/Pi IIb uptake (195). Taken together, klotho regulates 
TRPV5 and Na/Pi transporters, two major transport proteins responsible for Ca2+ and 
Pi handling in the kidney, respectively. Thus, it is tempting to speculate that klotho is 
involved in the pathogenesis of Ca2+ and Pi abnormalities in CRF by influencing the 
expression of TRPV5 and Na/Pi.
TRPV5, TRPM6 and diabetes mellitus
Renal Ca2+ and Mg2+ wasting are two common complications of uncontrolled diabetes 
mellitus (DM) (196). After glomerular filtration, Ca2+ and Mg2+ are reabsorbed 
substantially in the proximal tubule and subsequently in TAL and DCT (24). Although 
only a small part of these divalents are reabsorbed in DCT, recent studies 
demonstrated that TRPV5 and TRPM6 controle the final urinary Ca2+ and Mg2+ 
concentrations in this latter segment, respectively (24, 62). Increasing evidence 
supported the gatekeeper role of these two TRP channels in renal active Ca2+ and 
Mg2+ handling in DCT. However, the underlying mechanisms contributing to 
diabetes-associated hypercalciuria and hypermagnesiuria remain unclear. Increased 
filtration load of these divalent cations, and tubular reabsorption defects in TAL or 
DCT have been proposed to be responsible for renal Ca2+ and Mg2+ loss (197, 198). 
Recently, Lee et al. measured the expression of TRPV5 and TRPM6 in STZ-induced 
diabetic rats (199). In their study, diabetic rats displayed a significant increase in their 
fractional excretion of Ca2+ and Mg2+, accompanied by an increased mRNA 
abundance, rather than anticipated down-regulation, of TRPV5 and TRPM6 in kidney.
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In addition, insulin administration normalized the hyperglycemia-associated 
hypercalciuria and hypermagnesiuria and abolished the up-regulation of renal TRPV5 
and TRPM6. These findings suggest that the increased TRPV5 and TRPM6 
abundance in STZ-induced diabetic rats is due to a compensatory adaptation to an 
increased load of Ca2+ and Mg2+ secondary to hyperglycemia.
LINKS BETWEEN RENAL NA+ AND CA2+ HANDLING
It is well known that urinary Na+ and Ca2+ handling are related (200, 201). Oral or 
parenteral administration of Na+ raises urinary Ca2+ excretion in experimental animals 
(201-203) and in humans (204). There is also a frequently observed correlation 
between urinary Na+ and Ca2+ excretion in 24-h urine samples of healthy subjects and 
of patients with kidney stones. In addition, an increase of dietary Na+ is associated 
with increased urinary Ca2+ excretion in men and women of all ages (200, 205). A 
previous study showed that a 100 mmol/day increase in dietary Na+ led to increased 
Ca2+ excretion of about 1 mmol/day (200). These two cations have similar 
reabsorption sites in the renal tubule, and this may explain the close association of 
Na+ and Ca2+ clearance (58, 206, 207). In the PT, 65% of filtered Na+ is reabsorbed, 
and the key step in this process is the Na+-K+-ATPase pump, which is located in the 
basolateral membrane. This pump maintains an intracellular negative potential by 
actively transporting Na+ out of the cell, and creates a favorable electrochemical 
gradient that promotes passive Na+ entry into the cell. In the PT, reabsorption of Na+ is 
partially linked to specific solute cotransporters, including Na+-glucose (SGLT-2), 
Na+-amino acid, Na+-Pi, and Na+-lactate carrier proteins in the apical membrane. Na+ 
entry also occurs by antiport with H+ (Na+/H+ exchanger NHE3). H+ secretion into the 
lumen results in NaHCO3 reabsorption by a Na+/HCO3- cotransporter (NBC1) in the 
basolateral membrane. In this segment, the majority of Ca2+ is reabsorbed passively
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by solvent drag that results from Na+ and water reabsorption. Approximately 25% of 
filtered Na+ is actively reabsorbed in the TAL by the Na+-K+-2Cl- cotransorter (NKCC2), 
which uses the driving force created by the Na+-K+-ATPase pump. NKCC2, which 
couples the movement of 1 Na+, 1 K+ and 2 Cl-, is the target for a major class of 
diuretics known as "loop diuretics” , including furosemide and bumetanide. The 
reabsorption of Na+ and subsequent recycling of K+ into the lumen via the apical 
ATP-sensitive inward-rectifying K+ channel (ROMK) leads to a positive luminal charge, 
and this plays a major role in driving the paracellular reabsorption of Ca2+. In the DCT, 
5% of filtered Na+ is actively reabsorbed through the Na+-Cl- cotransorter (NCC), 
which is located in the apical membrane. The energy for this process is also indirectly 
provided by the basolateral Na+-K+-ATPase pump. This transport is unresponsive to 
loop diuretics, but is impaired by thiazide-type diuretics. The DCT is the major site of 
transcellular Ca2+ reabsorption, in which Ca2+ enters the cell through the apical 
epithelial Ca2+ channel TRPV5. Although TRPV5 and NCC are both expressed in the 
DCT, reabsorption of Ca2+ can be dissociated from Na+ in this segment. In the CCD, 
the remaining 4-5% of filtered Na+ enters the cell via a specific Na+-selective ion 
channel (ENaC), which is primarily located in the apical membrane of principal cells. 
This channel is inhibited by amiloride, a K+-sparing diuretic. Current evidence 
suggests that Ca2+ is actively reabsorbed independently of Na+ transport in this 
segment, but the protein responsible for active Ca2+ reabsorption remains unknown. 
Although Na+ and Ca2+ have the same reabsorption sites in the TAL and DCT, 
inhibition of Na+ reabsorption by appropriate diuretics in these two segments has 
distinct effects on urinary Ca2+ excretion (208, 209). Micropuncture studies showed 
that administration of furosemide inhibited the activity of NKCC2, resulting in an 
increase in fractional excretion of Na+ (FENa+) and Ca2+ (FECa2+). Conversely, when 
NCC activity was impaired by thiazide, FENa+ increased by threefold but there was no
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significant effect on FECa2+ (209). These interesting findings have stimulated research 
into the molecular interactions of renal Na+ and Ca2+ handling.
TRPV5, NKCC2 AND BATTER’S SYNDROME
Reabsorption of Na+ and Ca2+ is closely linked in TAL where NKCC2 plays an 
important role in regulation of renal Na+ and Ca2+ handling (207). Inhibition of NKCC2 
by furosemide reduces the lumen-positive transepithelial voltage and consequently 
diminishes paracellular transport of Ca2+, which promotes urinary Ca2+ excretion in 
proportion to Na+ excretion (207). Patients with Batter’s syndrome caused by NKCC2 
mutations manifest hypokalemia, metabolic alkalosis and hypercalciuria similar to 
those seen in patients given furosemide (210). Although the NKCC2 has been 
established as the main target responsible for furosemide related hypercalciuria, the 
effect of furosemide on Ca2+ transport molecules in the distal part of the nephron has 
not yet been much explored. Lee et al. recently investigated the acute and chronic 
effects of furosemide on renal Ca2+ excretion and expression of Ca2+ transport 
molecules in the distal part of the nephron by treating wild-type mice with a single 
dose of furosemide and twice-daily furosemide injections for 3 days, respectively 
(211). In acute experiments, furosemide enhanced urinary Ca2+ excretion associated 
with increased expression of TRPV5, TRPV6 and calbindin-D28K, which were 
measured 4 hours after one single dose of furosemide. Chronic administration of 
furosemide induced a 3- to 4-fold increase in urinary Ca2+ excretion and upregulation 
of TRPV5, TRPV6, calbindin-D28K and calbindin-D9K with or without salt supplement. 
Furosmide increased the abundance of Ca2+ transport molecule in the distal part of 
the nephron may serve as a compensatory adaptation, which represents a solute-load 
dependent effect in response to increased Ca2+ delivery from TAL causing by 
inhibition of NKCC2.
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TRPV5, THIAZIDE DIURETICS AND GITELMAN’S SYNDROME
TRPV5 and thiazide diuretics
Thiazide diuretics are among the most commonly prescribed drugs employed in the 
treatment of arterial hypertension. These diuretics enhance renal Na+ excretion 
through inhibition of NCC present in the apical membrane of DCT cells (212). Chronic 
thiazide administration induces hypocalciuria in human (213) and animal studies (214) 
suggesting that hypocalciuria may result from direct stimulation of transcellular Ca2+ 
reabsoprtion (214) and, in particular, apical Ca2+ entry through TRPV5 (215, 216). 
Alternatively, hypocalciuria was proposed to result from enhancement of passive 
paracellular Ca2+ reabsorption in proximal tubules secondary to extracellular volume 
contraction, distinct from any direct effect on transcellular Ca2+ transport (217, 218). 
Thiazide-induced hypocalciuria occurs in spite of reduced renal expression of Ca2+ 
transport proteins in rat (219). In addition, ECV contraction mimics the hypocalciuria, 
and volume repletion completely reverses thiazide-induced hypocalciuria in these rats 
(219). Micropuncture experiments disclosed that the reabsorption of Na+ and, 
importantly, Ca2+ in the PT is increased during chronic hydrochlorothiazide (HCTZ) 
treatment, whereas Ca2+ reabsorption in DCT/CNT appeared unaffected (220). 
Chronic HCTZ administration induced hypocalciuria in TRPV5-/- mice, in which active 
Ca2+ reabsorption is abolished. HCTZ did not affect renal expression of the proteins 
involved in active Ca2+ transport, including TRPV5 mRNA and protein expression in 
wild-type mice (220). Lee et al. confirmed that thiazide treatment in mice does not 
affect renal TRPV5 expression, except when thiazide treatment is combined with salt 
repletion (221). However, salt repletion alone stimulated TRPV5 mRNA expression to 
a similar extent, suggesting that this effect is not thiazide-specific (221). Together 
these studies conclusively demonstrated that thiazide does not directly affect TRPV5 
expression and transcellular Ca2+ reabsorption, but increased passive Ca2+
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reabsorption in the PT explaining the Ca2+-sparing effect of thiazides.
TRPV5 and Gitelman’s syndrome
Gitelman’s syndrome (GS) is an autosomal recessive renal tubular disorder 
characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, and 
hypocalciuria (222). At the molecular level, GS is caused by inactivating mutations in 
the SLC12A3 gene encoding the NCC in the luminal membrane of DCT (223). Thus, 
the electrolyte disturbances in GS resemble those observed during long-term 
administration of thiazide diuretics. Loffing et al. demonstrated that renal TRPV5 
expression is unaffected in NCC knockout mice, an animal model for GS (224, 58). In 
accordance, micropuncture experiments in these mice showed that active Ca2+ 
reabsorption is unaltered in DCT/CNT and indicated increased fractional absorption of 
both Na+ and Ca2+ upstream of DCT (58). However, NCC knockout mice developed 
hypocalciuria and hypomagnesemia, but not hypokalemic alkalosis. This latter 
observations is not consistent with GS in human (224).
To date, more than 100 distinct NCC mutations, including missense, nonsense, 
insertion and deletion, have been identified in patients with GS (225). The majority of 
patients are compound heterozygotes with two different mutations on the two alleles 
for NCC (226). It has been reported that 7 % of GS patients carry three or more 
different NCC mutations in one patient (227). Multiple independent mutant alleles 
have also been found within families with GS (227). However, only some of these 
published NCC mutations have been proven to be functional defects. Bindels’ group 
demonstrated several NCC mutations with functional defects by determining 
metolazone-sensitive Na+ uptake, subcellular localization and glycosidase-sensitive 
glycosylation of human NCC (hNCC) in Xenopus laevis oocytes expressing mutant 
hNCC (228, 229). They classified these mutations into three distinct categories,
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including defective protein processing, defective protein insertion and defective 
intrinsic activity. These functional analyses of mutations in hNCC provide detailed 
insight into the underlying pathogenic mechanisms of GS.
The reported prevalence of heterogeneous NCC mutations seems to be higher in 
Oriental than in Western countries. In the Swedish and Italian population, the 
prevalence of heterozygous mutations based on phenotypic expression is 
approximately 1 % (230). In a recent study performed in Taiwan, the overall incidence 
of positive heterogeneous mutations for 12 NCC mutations in 100 unrelated healthy 
Chinese subjects was approximately 3 % (231). Most of these NCC mutations were 
recurrent and were relatively different from those reported in Western countries 
Patients with GS usually present the clinical symptoms during childhood or 
adolescence. In addition to hypocalciuria, they are in general characterized by low 
blood pressure due to renal salt wasting (232, 233). In a large Amish kindred with GS, 
patients with homozygous NCC mutations actually had impaired renal Na+ 
reabsorption and a significantly lower blood pressure than their non-affected relatives. 
Children, but not adults, with heterozygous NCC mutations had also significantly 
lower blood pressure and higher 24 hour urine Na+ excretion than the non-affected 
controls (232). Given these findings, heterozygous NCC mutations should not be rare 
in general populations. Therefore, elucidating the prevalence of heterozygous NCC 
mutations will help to estimate the incidence of GS and will aid in understanding the 
physiologic effects of heterozygous NCC. Nevertheless, there is still a lack of large 
epidemiologic studies that have examined correlations between heterozygous NCC 
mutations and blood pressure in children.
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AIM OF THIS THESIS
Ca2+ is critical in many physiological functions and its balance is maintained by the 
concerted actions of the kidney, intestine, and bone. In the kidney, TRPV5 
co-localizes with intracellular binding proteins, calbindin-D28K and calbindin-D9K and 
with the basolateral transporters, NCX1 and PMCA1b, which together constitute the 
fundamental machinery for active Ca2+ reabsorption in the distal part of the nephron. 
The characterization of TRPV5-/- and calbindin-D28K-/- mice has greatly improved our 
knowledge of the molecular mechanisms of active renal Ca2+ reabsorption. In clinical 
practice, numerous kidney diseases and the side effects of commonly prescribed 
medications are associated with hypo- or hypercalcemia. TRPV5 appears to 
contribute to the pathogenesis of Ca2+ disturbance, so a balance of the expression 
and activity of TRPV5 is important for the maintenance of extracellular Ca2+ levels 
within the physiological range. The aim of this thesis was to investigate the 
relationship of active renal Ca2+ transporters and to assess the hormonal regulation 
and molecular mechanisms involved in electrolyte reabsorption in the distal part of the 
nephron.
In Chapter 2, we report on the effect of calbindin-D28K deficiency on active Ca2+ 
reabsorption in the presence or absence of TRPV5 by use of single and double 
knockout mice (calbindin-D28K-/-, TRPV5-/- and TRPV5-/-/calbindin-D28K-/-). We 
characterized these mice by measuring the expression of Ca2+ transport protein 
mRNA and protein. CT is extensively used to treat hypercalcemia, but its effect on 
Ca2+ transport in the DCT is unclear. In Chapter 3, we report on the potential 
contribution of TRPV5 to overall renal Ca2+ regulation in response to CT by use of 
TRPV5+/+ and TRPV5-/- mice. In Chapter 4, we studied the effect of androgens on 
active Ca2+ reabsorption by the expression of the Ca2+ transport proteins TRPV5 and 
calbindin-D28K in castrated mice, in an effort to elucidate the effects of sex hormones
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on renal Ca2+ handling. In Chapter 5, the allele frequency of hot spots heterozygous 
for NCC mutations in 500 Chinese children was characterized, to estimate the 
prevalence of GS and its association with blood pressure. Finally, Chapters 6 and 7 
provide a general discussion and summary of the studies performed in this thesis.
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Functional characterization of TRPV5/calbindin-D28K double knockout mice
ABSTRACT
The epithelial Ca2+ channel TRPV5 facilitates apical Ca2+ entry during active Ca2+ 
reabsorption in the distal convoluted tubule. In this process cytosolic Ca2+ remains at 
low non-toxic concentrations since the Ca2+ influx is rapidly buffered by calbindin-D28K. 
Subsequently, Ca2+ bound to calbindin-D28K is shuttled towards the basolateral Ca2+ 
extrusion systems. To address the in vivo role of TRPV5 and calbindin-D28K in the 
maintenance of the Ca2+ balance, single and double knockout mice of TRPV5 and 
calbindin-D28K (TRPV5-/-, calbindin-D28K-/- and TRPV5'/'/calbindin-D28K'/') were enrolled 
and characterized. These mice strains were fed two Ca2+ diets (0.02 % and 2 % w/w) 
to investigate the influence of dietary Ca2+ content on the Ca2+ balance. Urine 
analysis indicated that TRPV5'/'/calbindin-D28K'/' mice exhibit on both diets 
hypercalciuria compared with wild-type mice. Ca2+ excretion in TRPV5-/-/calbindin- 
D28K-/- mice was not significantly different from TRPV5-/- mice, whereas calbindin- 
D28K-/- mice did not show hypercalciuria. The similarity between TRPV5-/-/calbindin- 
D28K-/- and TRPV5-/- mice was further supported by an equivalent increase in renal 
calbindin-D9K expression and in intestinal Ca2+ hyperabsorption due to up-regulation 
of calbindin-D9K and TRPV6 expression in the duodenum. Elevated serum 
parathyroid hormone and 1,25-dihydroxyvitamin D3 levels accompanied the 
enhanced expression of the Ca2+ transporters. Intestinal Ca2+ absorption and 
expression of calbindin-D9K and TRPV6, as well as serum parameters of the 
calbindin-D28K-/- mice did not differ from wild-type mice. These results underline the 
gatekeeper function of TRPV5 being the rate-limiting step in active Ca2+ reabsorption, 
unlike calbindin-D28K, which is possibly compensated by calbindin-D9K.
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INTRODUCTION
Ca2+ homeostasis is of crucial importance for many physiological functions including 
neuronal excitability, muscle contraction, blood clotting and bone mineralization. 
Therefore, the Ca2+ balance is tightly controlled through constant regulation of three 
physiological processes: intestinal absorption, renal reabsorption and exchange of 
Ca2+ from the bone mass (1). Both in intestine and kidney Ca2+ enters the interstitium 
by passive paracellular as well as active (re)absorption (2,3). Active Ca2+ 
(re)absorption is critical in this process, since it constitutes the primary target for 
regulation by calciotropic hormones, including 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
and parathyroid hormone (PTH), enabling the organism to regulate the extracellular 
Ca2+ concentration on the body’s demand (4).
Active absorption of dietary Ca2+ occurs primarily in the proximal small intestine, 
whereas renal active Ca2+ reabsorption is restricted to the distal convoluted tubule 
(DCT) and the connecting tubule (CNT) (5,6). Ca2+ absorption occurs also in bone, 
where it is crucial for bone formation to achieve adequate bone quality and strength, 
as well as for osteoclastic bone resorption (7). At the cellular level, active Ca2+ 
(re)absorption implies entry of Ca2+ across the luminal membrane through the 
epithelial Ca2+ channels, followed by intracellular buffering, facilitated diffusion by 
Ca2+-binding proteins and finally extrusion across the basolateral membrane by a 
Na+/Ca2+ exchanger and/or a plasma membrane Ca2+ pump. Ca2+ influx occurs 
through two highly Ca2+-selective members of the transient receptor potential (TRP) 
cation channel family, TRPV5 and TRPV6, which constitute the gatekeepers of active 
Ca2+ (re)absorption in kidney and intestine, respectively (8,9). Indeed, ablation of 
TRPV5 (TRPV5-/-) in mice impairs renal Ca2+ reabsorption resulting in robust 
hypercalciuria (10). As a consequence, TRPV5-/- mice develop compensatory dietary 
Ca2+ hyperabsorption in the intestine. Furthermore, the structure of the bones in
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these mice is significantly disturbed showing reduced trabecular and cortical bone 
thickness (11).
Following influx through TRPV5 and TRPV6 Ca2+ binds to cytosolic proteins in order 
to diffuse towards the basolateral surface of the epithelial cell. Two Ca2+-binding 
proteins, i.e. calbindin-D28K and calbindin-D9K, are regarded as key components of 
Ca2+ (re)absorption (4). In mammals calbindin-D28K is primarily expressed in kidney, 
whereas calbindin-D9K is abundantly present in small intestine. Only in mouse kidney 
both calbindin-D28K and calbindin-D9K are expressed in the distal part of the nephron 
(12). The physiological importance of calbindin-D28K in renal Ca2+-transporting 
epithelia is underlined by the consistent co-expression with TRPV5 and their co­
regulation by calciotropic hormones including PTH, 1,25(OH)2D3 and also dietary 
Ca2+ (13,14).
The aim of the present study was to investigate whether calbindin-D28K deficiency is 
critical for active reabsorption in the presence or absence of TRPV5. To this end, 
single and double knockout mice of calbindin-D28K and TRPV5 (calbindin-D28K-/-, 
TRPV5-/- and TRPV5-/-/calbindin-D28K-/-) were generated. These mice were 
functionally characterized including measurements of expression of the Ca2+ 
transporter proteins at mRNA and protein level.
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MATERIALS AND METHODS 
Animal experiments
TRPV5-/- mice were generated as described previously (10). Calbindin-D28K"/" mice 
were kindly provided by Dr. Michael Meyer (Physiologisches Institut, Ludwig 
Maximilians Universität München, Munich, Germany) (15). Crossbreeding of TRPV5-/- 
/calbindin-D28K+/+ with TRPV5+/+/calbindin-D28K-/- mice resulted in offspring 
heterozygous for both TRPV5 and calbindin-D28K (TRPV5+/-/calbindin-D28K+/-). This 
heterozygous offspring displayed the wild-type phenotype and was subsequently 
intercrossed to obtain TRPV5-/-/calbindin-D28K-/- mice. Genotypes were determined by 
polymerase chain reaction (PCR) analysis using specific primers for Trpv5 (gene for 
TRPV5) as described previously (10,16) and for Calbl (gene for calbindin-D28K): two 
sense primers 5’-TGCAGCGGCTAGTTTGAGAGTG-3’ to detect the wild-type allele 
and 5’-TGACTAGGGGAGGAGTAGAAG-3’ to detect the null allele in combination 
with a common anti-sense primer 5’-GCAAGTAACTAATGGCATCG-3’. At the age of 
4 weeks mice were fed ad libitum two diets containing either 0.02 % or 2 % (w/w) 
Ca2+ for 5 weeks and subsequently placed in metabolic cages (Techniplast, Buggiate, 
Italy), which enabled 24-hour collection of urine. At the end of the experiment, blood 
samples were taken and the mice were sacrificed. Subsequently, kidney and 
duodenum tissue were sampled. Urine and serum Ca2+ concentrations were 
analyzed using a colorimetric assay kit (Roche, Mannheim, Germany). Serum PTH 
was measured using an immunoradiometric assay (Immutopics Inc., San Clemente, 
CA, USA). Serum Vitamin D levels were determined by an [I125]1,25(OH)2D3 RIA 
assay (IDS Inc., Fountain Hills, AZ, USA). The animal ethics board of the Radboud 
University Nijmegen approved all animal experimental procedures.
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Real-time quantitative PCR analysis
Renal and duodenal mRNA expression levels of calbindin-D28K, calbindin-D9K, TRPV5 
and TRPV6 were quantified by real-time quantitative PCR as described previously 
(17), using the ABI Prism 7700 Sequence Detection System (PE Biosystems, 
Rotkreuz, Switzerland). The expression level of the housekeeping gene 
hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used as an internal 
control to normalize differences in RNA extractions and reverse transcription 
efficiencies.
Immunoblotting
Total kidney and duodenum lysates of all mice groups were prepared as described 
previously (17). Briefly, protein concentrations of the homogenates were determined 
by the Bio-Rad protein assay (Bio-Rad, München, Germany) and 10 ^g of each 
sample was loaded on 12 % or 16.5 % (wt/v) sodium dodecyl sulfate-polyacrylamide 
electrophoresis (SDS-PAGE) gels and blotted to PDVF-nitrocellulose membranes 
(Immobilon-P, Millipore Corporation, Bedford, MA). Blots were incubated with a rabbit 
anti-calbindin-D28K polyclonal antibody (1:10,000, Sigma, St Louis, MO, USA), a 
rabbit anti-calbindin-D9K polyclonal antibody (1:5,000, Swant, Bellinzona, Switzerland) 
or a rabbit ß-actin polyclonal antibody (1:20,000, Sigma) at 4°C for 16 hours. 
Subsequently, blots were incubated with a goat anti-rabbit peroxidase-labeled 
secondary antibody (1:10,000, Sigma). Immunoreactive protein was detected by the 
chemiluminescence method (Pierce, Rockford, IL, USA). The immunopositive protein 
bands were scanned and the pixel density was determined by using the Molecular 
Analyst Software of BioRad Laboratories (Hercules, CA, USA).
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In vivo 45Ca2+ absorption assay
Ca2+ absorption was assessed by measuring serum 45Ca2+ at early time points after 
oral gavage as described previously (10). Briefly, mice were fasted 16 hours 
(overnight) before the test and a 45Ca2+ solution was administrated by oral gavage. 
Blood samples were obtained at indicated time intervals and serum (10 ^l) was 
analyzed by liquid scintillation counting. Differences in serum Ca2+ concentration 
were calculated from the 45Ca2+ content in the samples and the specific activity of the 
administrated 45Ca2+.
Statistical analyses
Values are expressed as means ± SEM. Statistical significance (P<0.05) between 
groups was determined by one-way ANOVA. In case of significance the Tukey- 
Kramer multiple comparisons test was applied. All analyses were performed using 
the Statview Statistical Package Software (Power PC, version 4.51, Berkeley, CA).
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RESULTS 
Serum parameters
Wild-type, TRPV5-/-, calbindin-D28K-/- and TRPV5-/-/calbindin-D28K-/- mice of 4 weeks 
old were fed a diet containing 0.02 % or 2 % (w/w) Ca2+ for 5 weeks. All mice strains 
were fertile and had similar average litter sizes (Table 1). Furthermore, serum 
analysis showed that TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice on 0.02 % (w/w) 
Ca2+ diet exhibit increased PTH and 1,25(OH)2D3 levels compared with wild-type 
mice. In contrast, serum PTH and 1,25(OH)2D3 levels in calbindin-D28K-/- mice were 
not significantly different from wild-type mice. The increased PTH and 1,25(OH)2D3 
levels were normalized in TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice fed the high 
Ca2+ diet. Serum Ca2+ levels were not significantly altered between the mice 
genotypes, regardless of the dietary treatment (Table 1).
Table 1
Characteristics of TRPV5 and calbindin-D28K single and double knockout mice
wild-type TRPV5-/- calbindin-D28K-/" TRPV5-/-/calbindin-D28K-/-
Ca2+ diet (w/w) 0.02 % 2 % 0.02 % 2 % 0.02 % 2 % 0.02 % 2 %
body weight (g) 25.6 ± 1.4 26.1 ± 1.4 25.5 ± 1.7 25.5 ± 1.4 23.2 ± 1.7 22.3 ± 1.9 23.6 ± 0.9 24.7 ± 1.4
Serum Ca2+ (mM) 2.0 ± 0.1 2.0 ± 0.1 2.0 ± 0.2 2.1 ± 0.1 2.0 ± 0 1.9 ± 0 2.0 ± 0.1 2.2 ± 0.1
PTH (pg/ml) 25.3 ± 4.5 6.4 ± 1.9 182.1 ± 51.0a 2.6 ± 0.9b 47.9 ± 22.5 6.5 ± 2.8 114.6 ± 30.4a 2.4 ± 1.2b
1,25(OH)2Ds (pmol/l) 561 ± 94 139 ± 26 1302±207a 283 ± 74b 595 ± 86 155 ± 33 2190 ± 192ac 659 ± 160b
aP<0.05 versus wild-type mice on the same diet; bP<0.05 versus the same mice group on 0.02 % (w/w) 
Ca2+ diet; cP<0.05 versus TRPV5'/' mice on 0.02 % (w/w) Ca2+ diet.
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mRNA expression of epithelial Ca2+ transporters
To evaluate the regulation of mRNA expression levels of the Ca2+ transporters in 
kidney and duodenum, quantitative real-time PCR assays were applied. In kidney, 
calbindin-D9K mRNA expression levels were increased in TRPV5-/- and TRPV5-/- 
/calbindin-D28K-/- mice fed the 0.02 % (w/w) Ca2+ diet (closed bars) compared with 
wild-type mice. Furthermore, renal calbindin-D9K expression was similar in calbindin- 
D28K-/- compared to wild-type mice. Exposure of the mice to the high Ca2+ diet (open 
bars) resulted in down-regulation of renal calbindin-D9K mRNA in TRPV5-/- and 
TRPV5-/-/calbindin-D28K-/- mice (Figure 1A). On the other hand, dietary Ca2+ content 
did not affect renal expression of calbindin-D28K mRNA which was significantly 
reduced in TRPV5-/- compared with wild-type mice (Figure 1B). In duodenum, 
TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice fed the 0.02 % (w/w) Ca2+ diet (closed 
bars) demonstrated an up-regulation of calbindin-D9 K and TRPV6 mRNA expression 
in comparison to wild-type mice. On the same Ca2+ diet, duodenal calbindin-D9K and 
TRPV6 expression remained unchanged in calbindin-D28K-/- compared to wild-type 
mice (closed bars). The high Ca2+ diet (open bars) reduced intestinal calbindin-D9K 
and TRPV6 mRNA expression in all mice strains (Figure 2A, B).
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Figure 1. Renal mRNA expression of Ca transporters. Expression of calbindin-D9K (A) 
and calbindin-D28K (B) mRNA in kidney of wild-type, TRPV5-/-, calbindin-D28K-/- and TRPV5-/- 
/calbindin-D28K-/- mice (n=10), was analyzed by quantitative real-time PCR analysis. Mice 
were fed with a 0.02 % (w/w) (closed bars) or 2 % (w/w) (open bars) Ca2+ diet. Values are 
calculated as a ratio of HPRT expression in relative percentages compared with the wild­
type mice on 0.02 % (w/w) Ca2+ diet. Data are presented as means ± SEM. *P<0.05 versus 
wild-type on the same diet. #P<0.05 versus the same group on 0.02 % (w/w) Ca2+ diet.
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Figure 2. Duodenal mRNA expression of Ca transporters. Expression of calbindin-D9K 
(A) and TRPV6 (B) mRNA in duodenum of wild-type, TRPV5'/_, calbindin-D28K/" and TRPV5- 
/'/calbindin-D28K"/" mice (n=10), was assessed by quantitative real-time PCR analysis. Mice 
were fed with a 0.02 % (w/w) (closed bars) or 2 % (w/w) (open bars) Ca2+ diet. Values are 
calculated as a ratio of HPRT expression in relative percentages compared with the wild­
type mice on 0.02 % (w/w) Ca2+ diet. Data are presented as means ± SEM. *P<0.05 versus 
wild-type on the same diet. #P<0.05 versus the same group on 0.02 % (w/w) Ca2+ diet.
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Protein expression of epithelial Ca2+ transporters
To validate whether the changes in renal and duodenal mRNA levels of the Ca2+ 
transporters resulted in altered protein expression, the abundance of the Ca2+ 
transporters was semi-quantified by immunoblot analysis. In kidney, calbindin-D9K 
protein expression was increased in TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice fed 
the 0.02 % (w/w) Ca2+ diet compared with wild-type mice (closed bars). On the same 
diet, calbindin-D28K-/- mice expressed wild-type levels of calbindin-D9K protein in 
kidney (closed bars). However, an increase in dietary Ca2+ content from 0.02 % to 2 
% (w/w) resulted in down-regulation of renal calbindin-D9K in wild-type, TRPV5-/- and 
TRPV5-/-/calbindin-D28K-/- mice (open bars, Figure 3A, B). Furthermore, renal 
calbindin-D28K protein abundance was significantly decreased in TRPV5-/- mice in 
accordance with the down-regulated mRNA levels. Variations in dietary Ca2+ did not 
affect renal calbindin-D28K protein expression in both wild-type and TRPV5-/- mice 
(Figure 3C, D). In duodenum, calbindin-D9K protein expression was increased in 
TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice compared with wild-type and calbindin- 
D28K-/- mice in line with measured mRNA expression levels. Finally, dietary Ca2+ 
restriction resulted in a significant increase of duodenal calbindin-D9K protein in 
TRPV5-/- and TRPV5-/-/calbindin-D28K-/- mice, which was consistent with the calbindin- 
D9K mRNA expression data (Figure 4A, B).
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C
D
Figure 3. Renal prote in  expression  o f ca lb ind in -D 28K and ca lb ind in -D 9K. Immunoblot of 
total kidney homogenates from wild-type, TRPV5'/_, calbindin-D28K"/" and TRPV5'/'/calbindin- 
D28k"/" mice (n=6) on a 0.02 % (w/w) and a 2 % (w/w) Ca2+ diet probed with anti-calbindin- 
D9K antibody (A) or anti-calbindin-D28K antibody (C). The intensities of the calbindin-DgK (B) 
and the calbindin-D28K (D) immunopositive bands were quantified by densitometry and 
presented as a ratio to p-actin expression in relative percentages compared with wild-type 
mice fed with a 0.02 % (w/w) diet. Mice were fed with a 0.02 % (w/w) (closed bars) or 2 % 
(w/w) (open bars) (w/w) Ca2+ diet. Data are presented as means ± SEM. *P<0.05 versus 
wild-type on the same diet. #P<0.05 versus the same group on 0.02 % (w/w) Ca2+ diet.
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Figure 4. Duodenal prote in expression o f ca lb ind in -D 9K. Immunoblot analysis of 
duodenum homogenates from wild-type, TRPV5'/_, calbindin-D28K/" and TRPV5'/'/calbindin- 
D28k-/" mice (n=6) on a 0.02 % (w/w) and a 2 % (w/w) Ca2+ diet probed with anti- calbindin- 
DgK antibody (A). The intensity of the calbindin-DgK immunopositive bands was quantified by 
densitometry and presented as a ratio to p-actin expression in relative percentages 
compared with wild-type mice fed with a 0.02 % (w/w) diet (B). Mice were fed with a 0.02 % 
(w/w) (closed bars) or 2 % (w/w) (open bars) Ca2+ diet. Data are presented as means ± 
SEM. *P<0.05 versus wild-type on the same diet. #P<0.05 versus the same group on 0.02 % 
(w/w) Ca2+ diet.
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Functional analysis of Ca2+ (re)absorption
The various mice strains were functionally characterized by measuring their urinary 
Ca2+ excretion and intestinal Ca2+ absorption. On both Ca2+ diets, urinary Ca2+ 
excretion was increased in TRPV5-/- and TRPV5'/'/calbindin-D28K'/' mice compared 
with wild-type mice. On the other hand, Ca2+ excretion was not significantly different 
in calbindin-D28K'/' compared to wild-type mice. Dietary Ca2+ restriction did not affect 
the amount of Ca2+ excreted in the urine (Figure 5A). Subsequently, intestinal Ca2+ 
absorption was investigated by measuring serum 45Ca2+ at early time points after oral 
gavage. On the 0.02 % (w/w) Ca2+ diet the time curves of 45Ca2+ absorption did not 
differ between the four mouse strains (Figure 5B). On the 2 % (w/w) Ca2+ diet 
intestinal 45Ca2+ absorption was significantly reduced in all groups compared with 
mice exposed to the low Ca2+ diet. However, the amount of 45Ca2+ absorption 
remained significantly higher in TRPV5-/- and TRPV5'/7calbindin-D28K'/' mice 
compared with wild-type and calbindin-D28K-/- mice (Figure 5C).
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Figure 5. Functiona l characterization o f s ing le  and doub le  
knockou t m ice fo r TRPV5 and ca lb ind in -D 28K. 24-hour urinary Ca2+ 
excretion in wild-type, TRPV5'/_, calbindin-D28K/" and TRPV5'/7calbindin- 
D28k-/" mice (n=10) fed with a 0.02 % (closed bars) or 2 % (open bars) 
(w/w) Ca2+ diet (A). Changes in serum Ca2+ (A|iM) within 10 minutes 
after 45Ca2+ administration by oral gavage in wild-type (closed 
diamond), TRPV5'/_ (open square), calbindin-D28K/" (closed triangle) and 
TRPV5'/7calbindin-D28K'/' (open circle) mice (n=6) fed with a 0.02 % (B) 
or 2 % (C) (w/w) Ca2+ diet. Data are presented as means ± SEM. 
*P<0.05 versus wild-type on the same diet.
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DISCUSSION
The present study demonstrates that TRPV5 may constitute a more critical 
component of active Ca2+ reabsorption in kidney than calbindin-D28K. This conclusion 
is based on the following experimental data. First, TRPV5-/-/calbindin-D28K-/- and 
TRPV5-/- mice showed a comparable hypercalciuria and compensatory Ca2+ 
hyperabsorption in comparison to wild-type mice. Second, the expression of 
calbindin-D9K in kidney as well as calbindin-D9K and TRPV6 in duodenum increased 
equally in TRPV5-/-/calbindin-D28K-/- and TRPV5-/- mice compared with wild-type mice. 
Third, up-regulation of TRPV6 and calbindin-D9K in TRPV5-/-/calbindin-D28K-/- and 
TRPV5-/- mice was accompanied by an analogous increase in serum PTH and 
1,25(OH)2D3 levels. Fourth, urinary Ca2+ excretion, intestinal Ca2+ absorption, 
expression levels of the epithelial Ca2+ transporters and serum parameters in 
calbindin-D28K-/- mice were not different from wild-type mice. Fifth, dietary Ca2+ 
restriction did not influence the Ca2+ excretion in the evaluated mice strains, while it 
enhanced intestinal Ca2+ absorption in TRPV5-/-/calbindin-D28K-/- and TRPV5-/- mice. 
The observed hyperabsorption is in line with the up-regulation of duodenal calbindin- 
D9K and TRPV6 expression.
Calbindin-D28K contains six high affinity binding sites for Ca2+ and is predominantly 
present in kidney, intestine (birds only), pancreas, placenta, bone and brain (4,12). In 
these tissues, calbindin-D28K is widely regarded as a key component in cellular Ca2+ 
handling by acting as a cytosolic Ca2+ buffer to protect cells against large fluctuations 
in the intracellular Ca2+ concentration (18), as well as a shuttle facilitating Ca2+ 
diffusion from the luminal to the basolateral surface (4). In mouse kidney, calbindin- 
D28K strikingly co-localizes with TRPV5, which constitutes the apical Ca2+ entry 
mechanism in DCT and CNT (4,19). Taking into account that calbindin-D28K 
expression is regulated by calciotropic hormones in a similar way to TRPV5 (4,20),
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both proteins could be functionally linked in the process of active Ca2+ reabsorption. 
Indeed, TRPV5-/- mice displayed a profound renal Ca2+ wasting combined with 
significant reduction of renal calbindin-D28K expression levels. This suggested that the 
impaired TRPV5-mediated Ca2+ influx suppresses the expression of calbindin-D28K. 
Our previous experiments in primary cultures of rabbit CNT and CCD cells 
demonstrated that blockage of TRPV5-mediated Ca2+ influx by the channel inhibitor 
ruthenium red down-regulates calbindin-D28K expression, indicating that regulation of 
the latter protein is highly dependent on the magnitude of the Ca2+ influx through 
TRPV5 (14). Arnold and Heintz showed that Ca2+ is important for gene transcription. 
A Ca2+-responsive element was identified in the promoter sequence of calbindin-D28K 
that partly underlies the Purkinje cell-specific expression of calbindin-D28K (21). 
However, it is not known whether this element is active in kidney or whether 
additional intracellular signaling molecules are involved. Together, these findings 
underline the TRPV5-coordinated expression of calbindin-D28K and imply that TRPV5 
constitutes the rate-limiting step of active Ca2+ reabsorption in kidney.
In contrast to TRPV5-/- mice that displayed a significant hypercalciuria, calbindin- 
D28K-/- mice exhibit normal Ca2+ excretion values. In line with our data are two 
previous studies showing that genetic ablation of calbindin-D28K does not modulate 
Ca2+ excretion in mice fed a regular rodent chow diet containing 1% (22) or 0.02 % 
(w/w) Ca2+ (23,24). In contrast, Sooy et al. and Lee et al. fed calbindin-D28K-/- mice a 
defined diet containing 1% (w/w) Ca2+ showing a two to three-fold increase in urinary 
Ca2+ excretion compared with wild-type controls (23,24). In addition, compared with 
vitamin D receptor (VDR) knockout mice, mice lacking both VDR and calbindin-D28K 
fed a regular chow diet have significantly higher urinary Ca2+ excretion (1.7 fold), 
more severe hyperparathyroidism and rachitic skeletal phenotype (22). Ca2+ excretion 
in TRPV5-/- mice, however, was ten-fold higher than in wild-type mice and, thus, more
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severe compared with calbindin-D28K-/- mice or mice lacking both the VDR and 
calbindin-D28K. Furthermore, we showed that the renal Ca2+ leak in TRPV5-/- mice is 
not increased in the TRPV5-/-/calbindin-D28K-/- mice. These findings suggest that 
TRPV5 acts as the gatekeeper in the process of Ca2+ reabsorption in the DCT and 
CNT.
Although previous studies demonstrated increased Ca2+ excretion in calbindin-D28K-/- 
mice, our data indicate no significant differences in serum Ca2+, PTH, and 
1,25(OH)2D3 levels in calbindin-D28K-/- mice compared to wild-type mice (24). A 
compensatory intestinal Ca2+ hyperabsorption or increased high bone turnover could 
occur in these knockout mice. In contrast, we found similar intestinal 45Ca2+ 
absorption rates, as well as intestinal TRPV6 and calbindin-D9K expression in 
calbindin-D28K-/- and wild-type mice. Previous studies by Sooy et al. (24) and Zheng et 
al. (22) are in line with our data on intestinal calbindin-D9K expression. Zheng and co­
workers demonstrated a modest decrease in bone mineral density in calbindin-D28K-/- 
mice (22). In addition, detailed structural analysis of teeth and bones showed that 
mineralization was unaffected in calbindin-D28K-/- mice (24). Consequently, neither a 
disturbed Ca2+ absorption nor an abnormal bone phenotype can account for the 
excess of urinary Ca2+ observed in their calbindin-D28K-/- mice. Theoretically, ablation 
of calbindin-D28K should seriously impair the Ca2+ buffering capacity of the TRPV5- 
expressing tubules, which in turn should inhibit the activity of TRPV5. However, the 
lack of a general hypercalciuria in calbindin-D28K-/- mice suggests that calbindin-D28K 
deficiency might be compensated by other renal Ca2+-binding proteins. Interestingly, 
the specific co-expression of calbindin-D9K and calbindin-D28K in mice DCT cells hints 
to a comparable function of calbindin-D9K in Ca2+ reabsorption (13). In the VDR-/- 
mice there is a 90% decrease in the level of renal calbindin-D9k compared with wild­
type mice (22). Thus in mice lacking both VDR and calbindin-D28k the increased
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urinary Ca2+ excretion may reflect the loss of compensation by calbindin-D9K (22). 
However, we cannot exclude the possibility that other molecular mechanisms could 
compensate for the deficiency of calbindin-D28K or that downstream reabsorptive 
segments balance an impaired Ca2+ transport capacity of DCT lacking calbindin-D28K. 
In the present study, we observed that the expression of renal and duodenal Ca2+ 
transporters is regulated by the dietary Ca2+ content. However, it is difficult to study 
the direct effects of dietary Ca2+, without affecting serum PTH and 1,25(OH)2D3 levels. 
Indeed, dietary Ca2+ restriction was accompanied by a compensatory increase in 
serum PTH and 1,25(OH)2D3 levels. In VDR-/- mice, renal calbindin-D9K expression 
was significantly reduced without an obvious response to dietary Ca2+ alteration 
(25,26). Studies in other mice models showed that renal and intestinal calbindin-D9K 
abundance correlate positively with the serum 1,25(OH)2D3 levels (17). Thus, a direct 
regulatory role of vitamin D in the overall calbindin-D9 K expression is evident. 
Conversely, intestinal calbindin-D9K and plasma membrane calcium ATPase (PMCA) 
expression was suppressed by alterations of dietary Ca2+ content in VDR-/- mice (27). 
Interestingly, we demonstrated previously that a reduction in the expression of renal 
Ca2+ transport proteins can be normalized by a high Ca2+ diet in 1a-OHase knockout 
mice which lack circulating 1,25(OH)2D3 (13). All together, these findings suggest that 
the abundance of Ca2+ transport proteins can be controlled by vitamin D-dependent 
and -independent means.
In conclusion, TRPV5 and calbindin-D28K are functionally coupled and play an 
important role in renal Ca2+ handling where TRPV5 constitutes the rate-limiting step 
of active Ca2+ reabsorption in DCT and CNT. In contrast to TRPV5-/- mice, calbindin- 
D28K-/- mice display normal serum parameters, intestinal Ca2+ absorption and renal 
Ca2+ excretion. Ablation of calbindin-D28K in TRPV5-/- mice does not aggravate the
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TRPV5-/- phenotype indicating that the role of calbindin-D28K can possibly be 
compensated by calbindin-D9K
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Calcitonin stimulates Ca2+ transport
ABSTRACT
Calcitonin (CT) is known to affect renal Ca2+ handling. However, it remains unclear 
how CT affects Ca2+ transport in the distal convolutions. The aim of this study was to 
investigate the contribution of the renal epithelial Ca2+ channel, TRPV5, to renal Ca2+ 
handling in response to CT. C57BL/6 mice received a single bolus injection of CT, 
which significantly reduced the urinary Ca2+ excretion. In addition, urinary Na+ and K+ 
excretion also decreased after CT administration. No apparent changes in renal 
expression of TRPV5, calbindin-D28K (CaBP28K) or TRPV6 could be detected 
between CT- and vehicle-treated mice. To evaluate whether TRPV5 activity is needed 
for the CT-induced increase in Ca2+ reabsorption, mice with genetic ablation of TRPV5 
(TRPV5'/_), were employed. TRPV5-/" mice as well as their wild type (TRPV5+;+) 
controls, received three bolus injections of CT over a 40 hr study period. Overnight (16 
hr) as well as the subsequent 24 hr urine was collected. Overnight urinary Ca2+ 
excretion was reduced in both TRPV5-/" and TRPV5+/+ mice after a bolus injection of 
CT. The subsequent 24 hr urinary excretion of Ca2+ which was collected after the third 
bolus injection, showed no effect of CT on renal Ca2+ handling in either mice group. 
Accordingly, CT did not alter the intrarenal protein abundance of TRPV5 and 
CaBP28K after three bolus injections of CT. In conclusion, CT augments the renal 
reabsorptive capacity for Ca2+. This increase is likely to occur independently of 
TRPV5.
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INTRODUCTION
Disturbances in the systemic Ca2+ concentration often result in instability of the 
neurological and cardiac systems (e.g. hypercalcemia causes fatigue, nausea, and 
abnormal heart rhythms (1). Thus, maintenance of serum the Ca2+ concentration 
plays an important role in stabilizing these physiological processes. Several hormones 
have been known to affect the systemic Ca2+ concentration. Calcitonin (CT) is a 32 
amino-acid peptide synthesized by posttranslational processing in the C cells of the 
thyroid gland in mammals (2). CT acts primarily by inhibiting osteoclast-mediated 
bone resorption and is secreted in response to increases in systemic Ca2+ 
concentration (2). Historically, CT has been extensively used in treating 
hypercalcemia, osteoporosis and Paget’s disease (2). Throughout the kidney and 
elsewhere, CT acts primarily by activating the adenylate cyclase pathway (3, 4).
In the kidney, vectorial NaCl transport within the thick ascending limb (TAL) drives 
paracellular transport of Ca2+. Administration of CT to rats increases the renal 
reabsorption of Ca2+, which is in part achieved by increasing the reabsorption of Ca2+ 
in the TAL. Here application of CT also increases vectorial NaCl transport (5-7). Active 
transcellular Ca2+ transport is restricted to the distal convolutions. Here, luminal Ca2+ 
enters across the apical membrane via the epithelial Ca2+ channel, transient receptor 
potential vanilloid 5 (TRPV5) (8, 9). Studies in rabbit suggest that CT exerts its effect 
on Ca2+ reabsorption only in the distal convoluted tubule (DCT), while no stimulation 
occurs in the connecting tubule (CNT) (10). In addition, CT fails to stimulate cyclic 
adenosine monophosphate (cAMP) accumulation in the CNT of rabbits (11). Our 
group has also been unable to show stimulatory effects of CT on cAMP production in 
rabbit primary CNT cultures (12). In the rabbit, TRPV5 localizes primarily to the CNT 
where CT does not affect Ca2+ reabsorption. However, in mouse, TRPV5 is highly 
expressed in apical membrane domains of particularly the late distal convoluted
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tubule (DCT2), with a gradual decrease along CNT and initial collecting duct (iCD) (13, 
14), suggesting that TRPV5-mediated Ca2+ uptake predominates in the DCT2 
segment. Similarly, in rat, immunohistochemical data suggests that TRPV5 
expression appears in the DCT2 and is further observed in the CNT (15). The 
intrarenal distribution of TRPV5 in human is currently not known.
In comparison to rabbit, the boundaries defining the DCT/CNT/iCD regions in human, 
rat, and mouse are morphologically less well defined, with cell types from different 
segments intermingled. In the kidney of rats, the "bright” portion of the DCT retains 
responsiveness to CT, resulting in increased cAMP production (4). CT binding sites 
have been identified in the rat kidney, including the TAL and DCT (16). Detailed 
micropuncture studies performed by Elalouf et al. investigated the effects of CT on 
distal tubule electrolyte transport in rats deprived of vasopressin, parathyroid hormone 
(PTH), and glucagon. Here they demonstrated that NaCl, as well as Ca2+ transport 
was increased by CT infusion (17). Other cAMP-elevating hormones such as PTH 
affect TRPV5-mediated Ca2+ transport. Thus, PTH supplementation to 
parathyroidectomized rats increases the expression of TRPV5, independent of serum 
1,25-dihydroxyvitamin D3 levels, suggesting that perhaps intracellular elevations in 
cAMP affect the abundance of TRPV5 (18). In addition, cAMP generation has been 
shown to increase TRPV5 single channel activity via a protein kinase alpha 
(PKA)-dependent mechanism (19). However, it is unclear whether there is a functional 
overlap between PTH and CT in the DCT2 regions of rats and mice and whether the 
CT-induced increase in cAMP could lead to a similar activation in the DCT2 segment 
as PTH.
In order to better understand the molecular actions of CT on overall renal Ca2+ 
balance and to delineate the potential effects of CT on TRPV5-dependent Ca2+ 
reabsorption, several experimental series were performed in wild-type and
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TRPV5-deficient mice. Due to the rapid action of CT we investigated the short-term 
effects by of CT on the renal Ca2+ excretion.
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MATERIALS AND METHODS 
Experimental protocol 1
Male C57BL/6 mice (12 weeks of age) were housed in a light and 
temperature-controlled room with ad libitum access to deionized drinking water and 
standard chow (0.28 % (wt/wt) NaCl, 1.00 % (wt/wt) Ca, 0.22 % (wt/wt) Mg; LabDiet, 
USA). Mice were injected subcutaneously with a single dose of salmon CT (20 U/100g 
bodyweight, Norvartis Pharmaceuticals, Taiwan, n=6) or vehicle (n=6) and placed in 
metabolic cages. After 16 hrs, overnight urine was collected and the animals were 
sacrificed under halothane anesthesia. Blood was obtained via orbital puncture before 
cervical dislocation. The kidneys were dissected out and snap frozen for RNA 
extraction. The animal ethics boards of the National Defense Medical Center (Taipei, 
Taiwan) approved all animal experimental procedures.
Experimental protocol 2
TRPV5-/- mice were generated by targeted ablation of the TRPV5 gene as described 
previously (20). After acclimatization, TRPV5+/+ and TRPV5-/- mice received salmon 
CT (20 U/100g bodyweight, n=6) or vehicle (n=6) in three subcutaneous bolus 
injections spaced over 40 hrs. During this period the mice were housed in metabolic 
cages. Overnight (16hr) urine was collected during the period between the first and 
second dose of CT. Subsequently, 24h urine was collected during the remainder of the 
study, where the mice received the last two injections. At the end of the experiment, 
animals were killed under halothane anesthesia, blood was removed and tissue 
samples were harvested for immunohistochemistry and Western blotting. The animal 
ethics board of the Radboud University Nijmegen approved the animal experimental 
procedures.
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Urine and serum analyses
Urine and serum concentrations of Ca2+ were analyzed using a colorimetric assay kit 
(Roche, Mannheim, Germany). Urine and serum concentrations of Na+ and K+ were 
determined using an automated analyzer (AU 5000 chemistry analyzer, Olympus, 
Tokyo, Japan).
RNA extraction and semi-quantitative PCR
Total RNA was extracted from kidney using Trizol Total RNA Isolation Reagent (Sigma, 
St Louis, MO, USA) as described previously (21). The obtained total RNA was 
subjected to DNase treatment to prevent genomic DNA contamination. Thereafter, 1.5 
^g of total RNA was reverse transcribed by Moloney-murine leukemia virus-reverse 
transcriptase (Promega, Madison, WI, USA). The cDNA was used to determine 
intrarenal mRNA expression levels of TRPV5, calbindin-D28K (CaBP28K) and 
TRPV6 by quantitative real-time PCR, using the ABI Prism 7700 Sequence Detection 
System (PE Biosystems, Rotkreuz, Switzerland). The expression level of the 
housekeeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT) was 
used as an internal control to normalize differences in RNA extractions and reverse 
transcription efficiencies. The primers and fluorescent probes used are as previously 
described (MDBIO, Taipei, Taiwan) (21, 22)
Immunohistochemistry
Kidney tissue was immersion fixed in 1 % (wt/vol) periodate-lysine-paraformaldehyde 
for 2 hours at room temperature, and subsequently incubated overnight at 4oC in 
phosphate-buffered saline (PBS) containing 15% (wt/vol) sucrose. The kidneys were 
snap frozen in liquid nitrogen and 7 ^m sections cut on a cryostat microtome (Microm 
HM 550, MICROM International GmbH, Germany). For immunohistochemical
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detection of TRPV5, kidney sections were stained with a guinea pig anti-TRPV5 
antibody (1:50) (8) or mouse anti-CaBP28K antibody (1:1,000; Sigma). To visualize 
TRPV5 and CaBP28K, sections were stained with goat anti-guinea pig Alexa 
488-conjugated anti-IgG (1:300; Sigma) and goat anti-mouse Alexa 488-conjugated 
anti-IgG (1:300; Sigma), respectively. TRPV5 protein expression was semi-quantified 
by taking 5 digital images of each kidney section on with a Zeiss Axioskop microscope 
(Carl Zeiss, Inc., Thornwood, NY, USA) and calculating the integrated optical density 
using Image-Pro Plus version 3.0 software (Media Cybernetics, Silver Spring, MD).
Immunoblotting
Total mouse kidney lysates were prepared as described previously (23). The protein 
concentration of the homogenates was determined with the Bio-Rad protein assay 
(Bio-Rad, München, Germany). Samples were submitted to 12% (wt/vol) SDS-PAGE 
and blotted to polyvinyldifluoride-nitrocellulose membranes (Immobilon-P, Millipore 
Corp., Bedford, MA). Blots were incubated overnight with a rabbit anti-CaBP28K 
polyclonal antibody (1:5,000; Sigma) at 4°C. Subsequently, blots were incubated with 
a goat anti-rabbit peroxidase-labeled secondary antibody (1 hr; 1:10,000; Sigma, St. 
Louis, MO). Immunoreactive protein was detected by the chemiluminescence method 
(Pierce, Rockford, IL). Immunopositive bands were scanned using an imaging 
densitometer (Bio-Rad Gs-690) to determine pixel density (Molecular Analyst 
Software; BioRad Laboratories, Hercules, CA).
Statistical analyses
Values are expressed as mean ± SEM. Statistical significance (p<0.05) in 
experimental protocol 1 was determined using the student’s t-test. In experimental 
group 2, significance was determined by a one-way ANOVA. In case of significance
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the Tukey-Kramer multiple comparisons test was applied. The analyses were 
performed using the Statview Statistical Package Software (Power PC, version 4.51, 
Berkeley, CA).
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RESULTS
CT increases renal Ca2+ reabsorption in C57BL/6 mice
To assess the acute effects of CT, overnight urine was collected following a bolus 
injection of the hormone (20U/100g bodyweight) or vehicle, respectively. The effect of 
overnight CT exposure on renal and systemic Ca2+ handling is depicted in Figure 1. 
Administration of CT resulted in a significant decrease in the urinary excretion of Ca2+ 
(p<0.034). Serum Ca2+ concentrations were slightly reduced after overnight CT 
administration (p<0.027). Urinary excretion of Na+ and K+ showed a significant 
decrease after CT injection (Table 1). In addition, the urinary Na+/K+ ratio remained 
unchanged excluding an effect on the collecting duct. These data are consistent with 
a primary effect of CT on electrolyte transport in the TAL and DCT (5-7, 17).
A B
Figure 1. Renal Ca2+ excretion (A) and serum Ca2+ concentration (B) after a bolus 
injection CT. Data is presented as mean ± SEM. Asterisks indicates statistical 
significance (p<0.05).
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Table 1. Serum concentrations and urinary excretion of Na+ and K+ after a bolus 
injection CT
Urine Serum
Diuresis (ml) Na+ (|jmol) K+ (|jmol) Na+/K+ ratio Na+ (mM) K+ (mM)
Control 1.21 ± 0.11 268 ± 32 639 ± 30 0.42 ± 0.03 150 ± 0.4 5.34 ± 0.11
CT 0.98 ± 0.18 132 ± 16* 305 ± 50* 0.44 ± 0.02 152 ± 0.5 5.30 ± 0.03
*p<0.05 versus controls; CT, calcitonin.
Data is presented as mean ± SEM. Asterisks indicates statistical significance (p<0.05)
CT does not change the renal mRNA expression of TRPV5, CaBP28K and 
TRPV6
To evaluate whether the increased Ca2+ reabsorption could in part be due to 
transcriptional changes in Ca2+ transport proteins located in the distal convolutions, 
quantitative real-time PCR was used to estimate TRPV5, CaBP28K and TRPV6 
abundance. As can be seen in Figure 2, no changes were observed in the renal 
mRNA expression of either transcript. Although CT did not modulate the changes of 
TRPV5, it does not exclude the potential involvement of TRPV5. Therefore, we 
investigated the effect of CT in TRPV5+/+ and TRPV5-/- mice after 1 and 3 injections of 
CT.
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A B C
F igure 2. Sem i-quantita tive  mRNA expression  o f TRPV5 and CaBP28K after ove rn igh t bolus 
in jection  o f CT. Representative histograms of mRNA expression of TRPV5 (A), CaBP28K (B) and 
TRPV6 (C) in kidney. Data are presented as mean ± SEM.
CT stimulates Ca2+ reabsorption in TRPV5/' mice
Administration of CT to TRPV5+/+ and TRPV5-/- mice resulted in a decreased overnight 
urinary Ca2+ excretion in both groups. However, after repeated administration of CT, 
the urinary Ca2+ excretion returned to normal in both TRPV5+/+ and TRPV5-/- mice, as 
compared to their corresponding vehicle-injected controls (Figure 3). Serum Ca2+ 
concentrations were measured after 40 hrs in this experimental series, but no 
difference was observed after CT administration in either strain (Figure 3). This is in 
line with the observed rapid effect of CT on serum Ca2+ concentrations.
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A B
Figure 3. Renal Ca excretion after 1 and 3 
bo lus in jections spaced ove r 40 hrs in 
TRPV5+/+ and TRPV5-/- mice. 16 hrs urinary Ca2+ 
excretion after a single bolus injection of CT (A) 
and the consecutive 24 hrs of urinary Ca2+ 
excretion after 3 injections (B). Serum Ca2+ 
concentrations after 3 CT bolus injections spaced 
over 40 hrs (C). Data is presented as mean ± 
SEM. * p<0.05 versus TRPV5+/+ controls. # p<0.05 
versus TRPV5'/_ controls.
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Renal protein expression of Ca2+ transporters remains unaltered after 3 CT 
injections
Kidneys retrieved from TRPV5+/+ and TRPV5-/- mice by the end of the experiment 
were used to assess the effects of CT on renal Ca2+ transporter expression. TRPV5 
and CaBP28K protein abundance was semi-quantified by immunohistochemistry 
(Figure 4) and immunoblotting (Figure 5), respectively. Computerized analysis of 
immunohistochemical images did not reveal any changes in TRPV5 protein 
expression after CT administration in TRPV5+/+ mice compared to their vehicle- 
injected control TRPV5+/+ mice (Figure 4). This is in line with the observation that CT 
affects renal Ca2+ transport independent of TRPV5. In addition, the renal CaBP28K 
protein expression remained unchanged after CT administration in TRPV5-/- mice 
(Figure 4 and 5). The CaBP28K protein expression of TRPV5-/- mice was significantly 
reduced compared to TRPV5+/+ mice (20) (Figure 4 and 5).
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TRPV5+/+ B TRPV5+/+ TRPV5'
F igure 4. Im m unoh istochem ica l s ta in ing  o f renal Ca2+ transpo rte rs  after 3 bo lus in jec tions  in 
TRPV5+/+ and TRPV5-/- mice. Representative images of immunohistochemical staining of TRPV5 (A) 
and CaBP28K (B) in kidney cortex. Semiquantification of renal TRPV5 (C) and CaBP28K (D) protein 
abundance was performed by computerized analysis of immunohistochemical images. Data were 
calculated as integrated optical density (IOD; arbitrary units) and depicted as percentage of TRPV5+/+ 
controls. Data is presented as mean ± SEM. * p<0.05 versus TRPV5+/+ vehicle-injected controls. N=6 
animals per group.
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A
B
Figure 5. Effects o f CT on renal 
CaBP28K protein expression in 
TRPV5+/+ and TRPV5-/- mice.
Immunoblots of protein samples 
(10|jg each) from homogenates of 
kidney tissue were labeled with 
antibodies against CaBP28K (A). 
Expression of CaBP28K protein 
was quantified by
computer-assisted densitometry 
analysis and presented as the 
ratio to p-actin expression levels in 
relative percentages (B). Data are 
presented as mean ± SEM. 
Asterisks indicates statistical 
significance (p<0.05) versus 
TRPV5+/+ controls. N=6 animals 
per group.
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DISCUSSION
A bolus injection of CT significantly reduced the urinary excretion of Ca2+ in wildtype 
mice. This decrease was associated with a reduction in the urinary Na+ and K+ 
excretion, leaving the urinary Na+/K+ ratio unchanged. These data are consistent with 
the previously reported effects of CT on stimulating TAL and DCT transport of NaCl 
and K+ (6, 7, 17, 24). Earlier studies in the TAL of mice and rats have demonstrated 
that CT activates NaCl transport only in the cortical TAL (6, 24). This segment of the 
TAL is also thought to drive paracellular Ca2+ reabsorption in these species. Although 
never delineated in detail, CT is likely to activate a cAMP cascade leading to 
increased NKCC2 -mediated transport, perhaps via increased membrane trafficking 
and potentially phosphorylation (5, 6, 25). Currently, it remains unknown which 
transporter CT stimulates in the DCT (17). One option may be the thiazide-sensitive 
NaCl cotransporter that resides there. Further studies are needed to evaluate this 
hypothesis.
A significant, albeit small, change in serum Ca2+ concentrations was observed after 
overnight CT administration. Earlier reports showing that infusion of CT, depending on 
dose, acutely reduces serum Ca2+ concentrations, that frequently reverts to normal 
range within one day (26). In line with this, no change was observed in systemic Ca2+ 
concentrations after 3 injections of CT spaced over 40 hrs. One may suggest that the 
reduced excretion of Ca2+ in the presence of CT occurs to compensate for the acute 
surge in systemic Ca2+ concentrations normally associated with CT administration. 
However, in thyroparathyroidectomized (TPTX) rats, Ca2+ infusion prior to CT 
treatment was given in order to avoid hypocalcemia in the animals. In these TPTX rats, 
CT was still able to reduce the fractional excretion of Ca2+ despite normocalcemia (27). 
This is consistent with a direct effect of CT on the kidney. The effect of CT on urinary 
Ca2+ excretion is also absent after repeated administration of CT to either TRPV5+/+ or
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TRPV5-/- mice. Reduced surface expression of CT receptors and decreased mRNA 
expression has been shown to explain such escape phenomena in other cell types 
(28). This may also explain why patients with a CT-secreting tumor frequently have 
normal systemic concentrations of Ca2+ (29).
The present study was initiated to investigate the potential effect of CT on 
TRPV5-mediated Ca2+ reabsorption. Injections of CT for 16 or 40 hrs did not change 
the renal abundance of TRPV5. In addition, TRPV5+/+ and TRPV5-/- mice responded in 
a similar manner to CT administration. Given the data obtained in these experimental 
models, it is likely that the effect of CT on renal Ca2+ transport occurs independently of 
TRPV5. Although CT does not affect TRPV5-mediated Ca2+ reabsorption, it is clear 
from this study that CT strongly stimulates renal Ca2+ reabsorption. This is likely to 
occur primarily through changes in Ca2+ transport within the TAL. It should be stated 
that although the effects of CT on renal Ca2+ transport are present in TRPV5+/+ as well 
as in TRPV5-/- mice, and that TRPV5 expression is unaltered after CT administration, 
does not fully exclude an effect upon TRPV5. Although unlikely, a lack of stimulation 
of CT on TRPV5 in TRPV5-/- mice, may be masked due to the pronounced effect of CT 
in the TAL. TRPV6 is a highly selective Ca2+ channel which has been localized to 
apical membrane domains in kidney (30). As TRPV6 may play a role in apical Ca2+ 
entry of tubules in the distal part of the nephron, mRNA abundance of the channel 
was determined after an overnight bolus injection of CT. Administration of CT did not 
change the expression level of renal TRPV6. These data indicate that the effect of CT 
on renal Ca2+ transport occurs independently of TRPV6.
In the rat, CT has been shown to increase NaCl as well as Ca2+ transport in the DCT 
(17), thus vectorial transfer of Ca2+ does occur to a greater extent in the presence of 
CT. The present study suggests that these effects occur largely independent of 
TRPV5. In addition, microperfusion experiments in rabbits show that CT stimulates
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Ca2+ transport in the early DCT, where TRPV5 is not expressed (10). This raises the 
question, how does Ca2+ transport occurs in the early DCT and does it contribute 
significantly to overall renal Ca2+ handling? Further studies are needed to determine 
the potential effect of CT on electrolyte transporters in these segments.
In conclusion, overnight CT administration increases renal Ca2+ reabsorption in mice. 
This effect occurs independently of TRPV5 as no change can be detected in TRPV5 
and CaBP28K expression and similar responses to CT is observed in TRPV5+/+ and 
TRPV5-/- mice.
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Testosterone attenuates renal TRPV5 expression
ABSTRACT
Sex differences in renal handling of Ca2+ have previously been reported. However, the 
overall contribution of androgens to these sex differences remains uncertain. The aim 
of this study was to determine whether testosterone affects active renal Ca2+ 
reabsorption by regulating the Ca2+ transport proteins Transient Receptor Potential 
Vanilloid-subtype 5 (TRPV5) and calbindin-D28K. Male mice, compared to females, 
had a higher urinary Ca2+ excretion accompanied by reduced renal expression of Ca2+ 
transporters. In addition, androgen deficient bilaterally orchidectomized (ORX) mice 
excreted less Ca2+ in their urine than sham-operated controls. ORX-induced 
hypocalciuria was normalized after testosterone replacement. Consistently, androgen 
deficiency resulted in augmentation of both renal mRNA and protein abundance of 
TRPV5 and calbindin-D28K, which in turn was suppressed by testosterone treatment. 
Importantly, no significant differences in serum estrogen, parathyroid hormone or 
1,25-dihydroxyvitamin D3 levels were observed between control, ORX and 
testosterone-supplemented ORX mice. Moreover, androgens directly affect renal Ca2+ 
reabsorption, as primary cells of rabbit connecting tubules/cortical collecting ducts 
incubated with the selective non-aromatizable androgen dihydrotestosterone showed 
a reduced transcellular Ca2+ transport. In conclusion, this study demonstrates that sex 
differences in renal Ca2+ handling are in part mediated by the inhibitory actions of 
androgens on TRPV5-mediated active renal Ca2+ transport.
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INTRODUCTION
Several studies have reported sex differences in the urinary Ca2+ excretion, showing a 
greater urinary Ca2+ loss in males than in females (1, 2). In addition, estrogens have 
been shown to increase the renal reabsorption of Ca2+, which is in good agreement 
with the observed gender differences (3). Presently, it remains unclear whether 
androgens play an opposing role to estrogens in modulating renal Ca2+ reabsorption. 
The androgen receptor (AR) is expressed in renal epithelial cells (4), and a growing 
body of evidence points to sex differences in various functional characteristics of 
mammalian kidneys; for example, a higher glomerular filtration rate in the male rat 
kidney (possibly due to higher renal plasma flow and lower vascular resistance) 
(reviewed in (5)). However, the role of androgens in regulating renal Ca2+ handling 
remains poorly characterized.
In the kidney, Ca2+ re-enters the blood by passive paracellular as well as active 
transcellular reabsorption. The active Ca2+ reabsorptive component is restricted to the 
distal convoluted tubules (DCT) and the connecting tubules (CNT) (6-9). Here, Ca2+ 
enters the epithelial cell via the highly Ca2+-selective ion channel Transient Receptor 
Potential Vanilloid-subtype 5 (TRPV5). Subsequently, Ca2+ is bound to calbindin-D28K 
that transports Ca2+ from the apical to the basolateral side where the 
Na+/Ca2+-exchanger (NCX1) and the plasma membrane ATPase (PMCA1b) extrude 
Ca2+ into the peritubular lumen (6).
Active Ca2+ reabsorption is critical in determining the final urinary Ca2+ excretion, and 
has been demonstrated to be regulated by calciotropic hormones, including 
parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (6, 10, 11). 
Estrogens have also been shown to affect the active regulation of the (renal) Ca2+ 
balance, although sex hormones are usually not considered as calciotropic factors (6, 
12).
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The present study aims to determine whether androgens affect active Ca2+ 
reabsorption by regulating the expression of the Ca2+ transport proteins TRPV5 and 
calbindin-D28K, in an effort to elucidate the sex differences in renal Ca2+ handling. 
Because androgen and androgen deficiency also affect bone mineralization via a 
long-term process (13), we evaluated the short-term effects of androgen on the 
expression of the renal Ca2+ transporters at the mRNA and protein level in 
orchidectomized (ORX) mice and ORX mice receiving testosterone replacement. In 
addition, to exclude possible secondary effects of androgens on other hormonal 
systems or bone turnover, non-aromatizable dihydrotestosterone (DHT) was applied 
to an isolated cell system of primary renal DCT/CNT cells in which transepithelial Ca2+ 
transport was measured.
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METHODS 
Animal experiments
Experiment A: male (n = 15) and female (n =15) C57BL6 mice, 12 weeks of age, were 
housed in a light and temperature-controlled room with ad libitum access to deionized 
drinking water and standard chow (0.28 % (wt/wt) NaCl, 1.00 % (wt/wt) Ca, 0.22 % 
(wt/wt) Mg; LabDiet, USA). After acclimatization, mice were housed in couples in 
metabolic cages and 24 h urine was collected. After urine sampling, animals were 
sacrificed and blood and kidney samples were taken.
Experiment B: male C57BL6 mice (n = 36), 12 weeks of age, were housed and fed as 
described for experiment A. After acclimatization, the mice were randomly allocated to 
either a sham or bilateral ORX operation under (1.5 %) halothane anesthesia and 
divided into three groups (n = 12 in each group): (i) sham-operated mice serving as 
control animals; (ii) ORX mice treated with vehicle; (iii) ORX mice treated with 
Sustanon 250 (ORX+T) subcutaneously (250 mg/kg/week; Sustanon 250 is a 
long-acting mixture of testosterone ester (14)) (Organon Laboratories Ltd, Cambridge, 
UK). The operation was performed under halothane anesthesia. After 2 weeks, these 
mice were housed in couples in metabolic cages and 24 h urine was collected. 
Thereafter, animals were sacrificed and blood and kidney samples were taken.
The animal ethics boards of the National Defense Medical Center (Taipei, Taiwan) 
approved all animal experimental procedures.
Urine and serum analyses
Urine and serum concentrations of Cr and Ca2+ were determined using an automated 
analyzer (AU 5000 chemistry analyzer, Olympus, Tokyo, Japan). Serum 1,25(OH)2D3 
levels were determined by an [I125]1,25(OH)2D3 RIA assay (DiaSorin, Stillwater, MN, 
USA). Serum PTH concentrations were determined by IMMULITE PTH assay
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(Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA). Both serum 
testosterone and estrogen concentrations were measured using chemiluminescence 
immunoassays (Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA).
Determinination of intestinal Ca2+ absorption.
Male and female wildtype mice (7-8 weeks of age) breed off a C57Bl/6 strain, were 
used as previously described (15). Radioactive 45Ca2+ was given by oral gavage, after 
an overnight fast. Intestinal absorption was determined by repeatedly measuring 
serum 45Ca2+ content as previously described in detail (15). Briefly, the solution used to 
measure Ca2+ absorption contained 0.1 mM CaCl2, 125 mM NaCl, 17 mM Tris, and 1.8 
g/l fructose and well as with 20 .^Ci 45CaCl2/ml. blood samples were obtained at 1, 2, 3, 
4, and 7 min after oral gavage. Serum 45Ca2+ content was determined by liquid 
scintillation counting. Changes in serum Ca2+ concentration was calculated from the 
45Ca2+ content of the serum samples and the specific activity of the administrated
45Ca2+.
Expression of renal Ca2+ transporters
To determine mRNA expression levels, total RNA was extracted from kidney using 
Trizol Total RNA Isolation Reagent (Sigma, St Louis, MO, USA). The obtained total 
RNA was subjected to DNase treatment to prevent genomic DNA contamination. 
Thereafter, 1.5 ^g of total RNA was reverse transcribed by Moloney-murine leukemia 
virus-reverse transcriptase (Promega, Madison, WI, USA), as described previously (3). 
The obtained cDNA was used to determine TRPV5, calbindin-D28K, NCX1, and 
PCMA1b mRNA levels in kidney cortex by real-time quantitative RT PCR, using the 
ABI Prism 7700 Sequence Detection System (PE Biosystems, Rotkreuz, Switzerland). 
The expression level of the housekeeping gene hypoxanthine-guanine
129
Chapter 4
phosphoribosyl transferase (HPRT) was used as an internal control to normalize 
differences in RNA extractions and reverse transcription efficiencies. The primers and 
fluorescent probes used are as previously described (MDBIO, Taipei, Taiwan) (3, 16). 
For protein expression quantification, total kidney lysates of the mice were prepared 
and analyzed as described previously (17). Briefly, proteins in kidney lysates were 
separated using SDS-PAGE and subsequent electro-transferred to polyvinylidene 
fluoride membranes (Immobilon-P, Millipore Corporation, Bedford, MA). Blots were 
incubated with rabbit anti-calbindin-D28K (Sigma, St Louis, MO, USA) or rabbit p-actin 
(Sigma) polyclonal antibodies. Subsequently, the blots were incubated with a goat 
anti-rabbit peroxidase-labeled secondary antibody (Sigma). Immunoreactive protein 
was detected by the enhanced chemiluminescence method (Pierce, Rockford, IL, 
USA). Protein expression of the immunopositive bands was quantified by the use of 
pixel density scanning and computed calculation using the Molecular Analyst software 
of BioRad Laboratories (Hercules, CA, USA).
Immunohistochemical labeling of renal Ca2+ transporters
Kidneys were immersion-fixed in 1 % (wt/v) periodate-lysine-paraformaldehyde 
fixative for 2 h at room temperature, and incubated overnight at 4 °C in 
phosphate-buffered saline containing 15 % (wt/v) sucrose. Subsequently, 7 ^m 
sections were cut from liquid nitrogen frozen kidney tissue samples for 
immunohistochemistry as described previously (18). For detection of TRPV5 protein 
abundance, kidney sections were stained with a guinea pig anti-TRPV5 antibody, as 
described (18), and a mouse anti-calbindin-D28K antibody (Sigma). TRPV5 and 
calbindin-D28K were visualized by staining those sections with goat anti-guinea pig and 
goat anti-mouse Alexa 488-conjugated anti-IgGs (Sigma), respectively. Next, to 
semi-quantify the TRPV5 protein expression, 5 digital images of each kidney section
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were taken with a Zeiss Axioskop microscope (Carl Zeiss, Inc., Thornwood, NY, USA) 
and the integrated optical density (IOD) was measured by computer analysis with the 
Image-Pro Plus version 3.0 software (Media Cybernetics, Silver Spring, MD).
Double staining using anti-TRPV5 and a rabbit anti-AR antibody (N-20, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) was performed using the TSA™ Plus 
Fluorescein amplification system (Perkin Elmer, Groningen, The Netherlands) for 
TRPV5 and a goat anti-rabbit IgG conjugated to Alexa 594 for visualization of the AR. 
Confocal pictures were acquired with an Olympus FV1000 laser scanning microscope 
(Center Valley, PA, USA). Differential interference contrast (DIC) was superimposed 
on the fluorescence images.
Primary cultures of rabbit CNT/cortical collecting ducts (CCD) and 
determination of transepithelial Ca2+ transport
Rabbit kidney CNT and CCD cells were immunodissected from the kidney cortex of 
New Zealand White rabbits (5 weeks of age) with antibody R2G9 and set in primary 
culture on permeable filter supports (0.33 cm2; Corning-Costar, Cambridge, MA, USA), 
as previously described in detail (19). The culture medium was a 1:1 mixture of 
Dulbecco’s modified Eagle’s medium and Ham’s F12 (Gibco, Paisley, UK) 
supplemented with 5 % decomplemented fetal calf serum, 10 jg/m l ciproxin, 10 |jl/ml 
nonessential amino acids (Gibco), 5 jg/m l insulin, 5 jg/m l transferrin, 50 nM 
hydrocortisone, 70 ng/ml prostaglandin E1 , 50 nM Na2 SeO3 , 5 pM triiodothyronine, 
and 5 jM  indomethacin equilibrated with 5 % CO2-95 % air at 37 °C. Before 
incubation with DHT, the transepithelial resistance (R) was measured to assure the 
integrity of the cells. In all filters used, the R was greater than 400 Q x cm2.
Five days after seeding, cells were incubated for 24 h with 10 nM 
(5a,17p)-17-Hydroxy-androstan-3-one (dihydrotestosterone (DHT); Sigma), or vehicle
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(ethanol absolute), at the apical and basolateral compartments. Transport assays 
were performed on confluent monolayers the following day as described previously 
(19, 20). Briefly, Confluent monolayers were washed twice and pre-incubated in 
physiological salt solution (140 mM NaCl, 2 mM KCl, 1 mM K2HPO4, 1 mM MgCl2, 1 
mM CaCl2, 5 mM glucose, 5 mM L-alanine, 5 jM  indometacin, and 10 mM 
HEPES-Tris (pH 7.4)) for 15 min at 37°C. The monolayers were subsequently 
incubated in physiological salt solution for another 90 min to measure transepithelial 
Ca2+ transport. DHT was added to both the apical and basolateral compartments. At 
the end of the experimental period, the apical medium was removed and assayed for 
total Ca2+ concentrations, using a colorimetric assay kit (Boehringer). Under these 
experimental conditions, net apical-to-basolateral Ca2+ transport is linear for at least 3 
h. Ca2+ transport was calculated into nmol/h/cm2.
Statistical analyses
Values are expressed as means ± S.E.M. Statistical significance (p < 0.05) between 
groups was determined by an unpaired Student’s t-test (for comparisons between two 
individual groups), or by one-way analysis of variance (for multiple comparisons). All 
analyses were performed using the Statview Statistical Package Software (Power PC, 
version 4.51, Berkeley, CA, USA).
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RESULTS
Sex differences for urinary Ca2+ excretion and renal expression of Ca2+ 
transporters
To investigate whether sex differences affect renal Ca2+ handling, 24 h urinary Ca2+ 
excretion and Ca2+/Cr ratios were determined in age-matched male and female mice. 
Body weight (26.7 ± 0.8 in male vs. 25.4 ± 1.8 g in female) and diuresis (1.3 ± 0.5 in 
male vs. 1.1 ± 0.3 ml/24 h in female) was not significantly different between both 
sexes. Male mice, in comparison to females, demonstrated a significant higher 24 h 
urinary Ca2+ excretion (4.1 ± 0.3 vs. 3.3 ± 0.2 ^mol/day) and Ca2+/Cr ratio (0.23 ± 0.03 
vs. 0.18 ± 0.02) (Figure 1). In addition, male and female mice consumed similar 
amounts of food ((3.3 ± 0.02 g vs. 3.2 ± 0.03 g) and hence ingested comparable 
amounts of Ca2+ (33.0 ± 0.2 vs. 32.4 ± 0.3). In an unrelated experimental series, 
intestinal radioactive Ca2+ uptake was determined in male and female mice. Intestinal 
Ca2+ absorption was determined by an in vivo absorption assay, measuring serum 
levels of radioactive 45Ca2+ at several time points after oral gavage. The intestinal 
absorption of Ca2+ was similar in the male and females (Figure 1S).
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Figure 1. Mice sex differences in urinary Ca2+ excretion. (A) 24 h urine Ca2+ excretion and 
Ca2+/Cr ratio were determined in both female and male mice. Data are presented as means ± 
S.E.M. Cr, creatinine. * p < 0.05 male vs. female mice. n = 8 samples per group. (B) Intestinal 
45Ca2+ absorption into serum of male (♦ ) and female (■ ) mice after oral gavage. n = 5 animals per 
group
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These functional differences were paralleled by a significant decline in the renal 
mRNA expression of TRPV5, calbindin-D28K, N CX and PCMA1b (Figure 2A,B). For 
calbindin-D28K abundance, this was confirmed by immunoblotting (Figure 2C); 
densitometrical analysis of the immunoblots showed significantly less calbindin-D28K 
protein expression in male than in female mice (Figure 2D). Similarly, computerized 
analysis of immunohistochemical images revealed a significant decrease in TR PV5  
and calbindin-D28K abundance in male mice as compared to female mice (Figure 3).
A
B
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Figure 2. Mice sex differences in the expression of renal Ca2+ transporters. (A) renal mRNA 
expression of TRPV5 and calbindin-D28K were determined by real-time quantitative RT-PCR analysis, 
expressed as the ratio of HPRT, and depicted as percentage of female mice. (B) Similarly, mRNA 
expression of PMCA1b and NCX1 was determined in kidney RNA isolates from male and female mice. 
mRNA expression was corrected for endogenous HPRT (C) Immunoblots of protein samples (10 |jg each) 
from homogenates of kidney tissues were labeled with antibodies against calbindin-D28K or p-actin (D) 
Expression of calbindin-D28K protein was quantified by computer-assisted densitometry analysis and 
presented as the ratio to p-actin expression levels, in relative percentages compared with female mice. 
Data are presented as means ± S.E.M. * p < 0.05 male vs. female mice. n = 6 samples per group
136
Testosterone attenuates renal TRPV5 expression
Figure 3. Mice sex differences between protein expression of Ca transporters in kidney. (A)
Representative images of immunohistochemical staining of TRPV5 and calbindin-D28K in male and female kidney 
cortex. (B) Semi-quantification of renal TRPV5 and calbindin-D28K protein abundance was performed by 
computerized analysis of immunohistochemical images. Data were calculated as IOD (arbitrary units) and 
depicted as percentage of female mice. Data are presented as means ± S.E.M. * p < 0.05 male vs. female mice. n 
= 8 samples per group.
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Localization of the androgen receptor in mouse kidney
Binding of the steroid hormone to the androgen receptor (AR) may regulate the 
expression of renal Ca2+ transporters. To investigate whether the AR is localized in 
TRPV5-expressing cells, immunohistochemical labeling of TRPV5 and the AR was 
performed using mouse kidney sections. As depicted in Figure 4, TRPV5 and the AR 
are co-expressed in renal epithelial cells.
TRPV5 AR DIC
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Figure 4. Characterization of AR localization in kidney. Confocal laser microscopy of 
double-labeled mouse kidney sections using guinea pig anti-TRPV5 (TRPV5, upper left panel) 
and rabbit anti-AR antibodies (AR, upper middle panel). Differential interference contrast (DIC, 
upper right panel) and overlay (lower panel) are also presented.
Effects of ORX and testosterone treatment on serum and urine parameters
To specifically address the effects of androgens on renal Ca2+ handling, urine 
(fractional) Ca2+ excretion was measured in sham-operated and ORX mice, and in 
ORX mice supplemented with testosterone (ORX+T). Importantly, the body weight of 
mice between sham-operated, ORX and ORX+T groups was not different (27.1 ± 0.7,
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26.1 ± 0.9, and 26.9 ± 0.9 g, respectively). ORX significantly decreased urinary 
excretion of Ca2+ (4.4 ± 0.3 (sham-operated) vs. 2.3 ± 0.2 (ORX) ^mol/day) and the 
Ca2+/creatinine (Cr) ratio (0.28 ± 0.05 (sham-operated) vs. 0.16 ± 0.03 (ORX)) (Figure 
5). A change in renal transport was apparent, as the fractional Ca2+ excretion was 
significantly reduced (0.94 ± 0.12 (sham-operated) vs. 0.49 ± 0.04 (ORX) %). 
Testosterone supplementation of ORX mice restored renal Ca2+ excretion (4.3 ± 0.3 
^mol/day) and the Ca2+/Cr ratio (0.25 ± 0.03) to values comparable with the 
sham-operated mice. Table 1 summarizes the effects of ORX and testosterone 
replacement therapy on systemic Ca2+ handling, calciotropic hormones, and sex 
hormones. Serum testosterone levels were reduced effectively in untreated ORX mice, 
whereas supplementation with Sustanon 250 resulted in significantly higher serum 
testosterone levels. Importantly, serum PTH, 1,25(OH)2D3, and estrogen levels were 
not significantly different in ORX mice as compared to sham-operated and ORX+T 
mice.
Figure 5. Differences in urinary Ca excretion of Sham-operated, ORX and ORX+T 
mice. 24 h urine Ca2+ excretion and Ca2+/Cr ratio were determined in Sham-operated, 
ORX and ORX+T mice. Data are presented as means ± S.E.M. Cr, creatinine. * p < 0.05 
male vs. female mice. n = 8 samples per group.
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Table 1. Serum biochemistry of sham-operated and ORX mice with or w ithout 
testosterone replacement
Sham ORX ORX+T
Ca2+ (mmol/l) 2.8 ± 0.1 2.6 ± 0.1 2.5 ± 0.1
Testosterone (ng/dl) 499 ± 129 59 ± 11 a 1005± 291 ab
Estrogen (pg/ml) 63 ± 16 36 ± 12 50 ± 10
PTH (pg/ml) 23.9 ± 6.5 20.7 ± 5.5 25.4 ± 7.4
1,25(OH)2D3 (pmol/ml) 156 ± 19 130 ± 11 143 ± 17
Sham, sham-operated mice; ORX, orchidectomized mice; ORX+T, orchidectomized mice treated with 
Sustanon 250 subcutaneously (250 mg/kg/week) for 2 weeks; PTH, parathyroid hormone; 1,25(OH)2D3, 
1,25-dihydroxyvitamin D3. a p < 0.05 vs. sham-operated mice; b p < 0.05 vs. ORX mice. n = 8 samples per 
parameter.
Effects of ORX and testosterone treatment on the expression of renal Ca2+ 
transporters
To address the molecular mechanism responsible for the effect of testosterone on 
renal C a2+ handling, the expression of TR PV5 and calbindin-D28K genes were 
examined using real-time quantitative reverse transcriptase (RT) PCR, 
immunoblotting and immunohistochemistry. O R X  mice demonstrated a 3.2-fold 
increase in TR PV5 and a 2.0-fold increase in calbindin-D28K mRNA expression as 
compared to sham-operated mice (Figure 6A). Conversely, administration of 
testosterone to O R X  mice (O RX+T) resulted in a significant decrease of TR PV5 and 
calbindin-D28K mRNA expression (Figure 6A, dashed bars). Similarly, NCX1 was 
increased in the O R X  group, while both NCX1 and P M C A lb  were decreased in the 
O R X+T group (Figure 6S). As determined by semi-quantitative immunoblotting, 
protein abundance of calbindin-D28K was increased in O R X  mice compared to 
sham-operated mice (Figure 6C, D). In accordance, calbindin-D28K protein abundance 
in O R X+T mice was comparable to the sham-operated controls (Figure 6C,D). In line
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with the above, semi-quantification of protein expression, the immunohistochemical 
labeling experiments revealed a significant up-regulation of TRPV5 (2.7-fold) and 
calbindin-D28K (1.5-fold) signal in ORX mice when compared to sham-operated mice 
(Figure 7). Furthermore, treatment of ORX mice with testosterone led to a significant 
decline in TRPV5 and calbindin-D28K signals (Figure 7).
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C
Figure 6. Effects of ORX and testosterone treatment on renal mRNA expression of Ca2+ 
transporters. (A) Renal mRNA expression of TRPV5 and calbindin-D28K in sham-operated, ORX and 
ORX+T mice were analyzed by quantitative real-time RT-PCR analysis, expressed as the ratio of 
HPRT and depicted as percentage of sham-operated mice. (B) Expression of PM C Alb and NCX1 in 
the kidney of sham, ORX, and ORX+T mice (C) Immunoblots of protein samples (10 |jg each) from 
homogenates of kidney tissue of sham-operated, ORX and ORX+T mice were labeled with antibodies 
against calbindin-D28K or p-actin. (D) Expression of calbindin-D28K protein was quantified by 
computer-assisted densitometry analysis and presented as the ratio to p-actin expression levels, in 
relative percentages compared with sham-operated mice. Data are presented as means ± S.E.M. 
Sham, sham-operated mice; ORX, orchidectomized mice; ORX+T, orchidectomized mice treated with 
Sustanon 250 subcutaneously (250 mg/kg/week) for 2 weeks. * p < 0.05 vs. sham-operated mice. # p < 
0.05 vs. ORX mice. n = 8 samples per group.
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Figure 7. Immunohistochemical staining of renal Ca2+ transporters in sham-operated, ORX 
and ORX+T mice. (A) Representative images of immunohistochemical staining of TRPV5 and 
calbindin-D28K in kidney cortex of sham-operated, ORX and ORX+T mice. (B) Semi-quantification of 
renal TRPV5 and calbindin-D28K protein abundance was performed by computerized analysis of 
immunohistochemical images. Data were calculated as IOD (arbitrary units), depicted as 
percentage of sham-operated mice, and presented as means ± S.E.M. Sham, sham-operated mice; 
ORX, orchidectomized mice, ORX+T, orchidectomized mice treated with Sustanon 250 
subcutaneously (250 mg/kg/week) for 2 weeks. * p < 0.05 vs. sham-operated mice. # p < 0.05 vs. 
ORX mice. n = 8 samples per group.
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Effect of DHT on transcellular Ca2+ transport in rabbit kidney CNT and CCD 
primary cell cultures
The effect of androgen on renal Ca2+ handling in the ORX mice may be facilitated by 
the possible interference of other organs (e.g. bone) or hormones (calciotropic, 
estrogen). Therefore, the effect of androgen on TRPV5-mediated Ca2+ transport was 
studied in an isolated renal cell system. Primary cultures of rabbit CNT/CCD cells 
were grown to confluence on permeable supports. The cells were treated with DHT or 
vehicle, and the rate of transepithelial Ca2+ transport was determined. Application of 
10 nM DHT to the polarized confluent cell monolayers for 24 h significantly inhibited 
the net apical-to-basolateral transport of Ca2+ (p<0.02) (Figure 8).
vehicle- DHT  
treated 10 nM
Figure 8. Effect of DHT on net apical to 
basolateral Ca2+ transport in primary cultures 
of rabbit CNT/CCD cells. Transepithelial Ca2+ 
transport across confluent monolayers was 
measured in the absence or presence of 10 nM 
DHT. At the end of the 90 minutes incubation 
period apical medium was collected to determine 
the amount of Ca2+ transport across the 
monolayer. Transepithelial Ca2+ transport is 
expressed as percentage of vehicle-treated cells 
(set to 100 %) ± S.E.M. Data from 2 independent 
experiments (n = 6) was combined. * p < 0.001.
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DISCUSSION
The present study is to our knowledge the first to delineate the effect of androgens on 
renal handling of Ca2+ and TRPV5-mediated active Ca2+ transport. We find that 
testosterone contributes significantly to the sex differences observed in renal Ca2+ 
handling. This conclusion is based on the following observations: First, male mice 
have a greater urinary Ca2+ excretion compared to females, a feature accompanied by 
a reduced renal expression of Ca2+ transport proteins. Second, androgen-deficient 
ORX mice show a significant decline in the urinary excretion of Ca2+, which 
normalizes after testosterone replacement. Similar data was obtained when 
evaluating the fractional excretion of Ca2+, suggesting that the testosterone-induced 
increase of urinary Ca2+ excretion is due to inhibition of tubular Ca2+ reabsorption. 
Forth, the mRNA and protein abundance of renal Ca2+ transporters was up-regulated 
in ORX mice, while the expression of renal Ca2+ transporters was suppressed by 
resupplying these mice with testosterone. Fifth, the serum 1,25(OH)2D3, PTH, and 
estrogen levels did not differ between the sham-operated, ORX and ORX+T mice, 
suggesting that androgens may primarily affect the transcription of the renal Ca2+ 
transporters, rather than having an indirect effect via calciotropic hormones or 
estrogen. Also, inhibition of transcellular Ca2+ transport after DHT treatment was 
observed in isolated rabbit kidney CNT/CCD primary cell cultures.
Fe(male) sex hormones regulating Ca2+ transport
Our observation that male mice show a greater urinary Ca2+ excretion than females is 
in agreement with previous clinical studies evaluating sex differences in humans (1, 2). 
In addition, orchidectomy induced hypocalciuria in male mice, thus resembling a 
female-like phenotype. Moreover, testosterone supplementation of ORX mice caused 
a normalization of their urinary Ca2+ excretion, accompanying a decreased expression
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of renal C a2+ transport proteins such as TRPV5, NCX, PMCA1b, and calbindin-D28K. 
Previous studies evaluating the effect of estrogen on renal C a2+ handling, 
demonstrated that the hormone exerts a direct effect on renal C a2+ reabsorption via 
up-regulation of these C a2+ transport proteins (3). Thus, both testosterone and 
estrogen have opposing regulatory properties in terms of renal expression of C a2+ 
transporters. Similar sex differences have been found for the regulation of the 
thiazide-sensitive sodium-chloride cotransporter (NCC) that is expressed in the DCT. 
Chen et al. (21) demonstrated that the density of NCC (quantified by binding 
[3H]metolazone to NCC) was two-fold higher in female than in male rats. Furthermore, 
O R X  resulted in an up to 84 % increase in metolazone binding sites in males, 
whereas ovariectomy decreased the density by maximally 31 % in females (21).
Role of calciotropic hormones in androgen regulation?
In the present study no difference in the serum 1,25(O H )2D3 and PTH concentrations 
were detected between sham-operated, ORX, and O R X+T mice, suggesting that the 
up-regulation of TR PV5 in O R X  mice is not mediated by these calciotropic hormones. 
Conversely, androgens have previously been suggested to affect C a2+ homeostasis 
by altering the regulation of calciotropic hormones. Some discrepancy has been 
reported in the literature; in a study by Nyomba et al. (22), the serum concentration of 
1,25(O H )2D3 was shown to decrease after O R X  in male rats, while testosterone 
replacement therapy restored serum 1,25(O H)2D3 to normal levels. In agreement with 
our data, a study by Hope et al. (23), reported that O R X  performed in male rats could 
not be associated with any changes in active 1,25(O H)2D3 levels. Possible 
explanations for these discrepancies are currently unclear and may not exclude a 
contribution of 1,25(O H)2D3 to overall Ca2+ handling by androgens.
146
Testosterone attenuates renal TRPV5 expression
Here, we showed that the AR is present in TRPV5-expressing cells, which is in line 
with earlier results demonstrating the presence of the AR in the distal part of the 
nephron (24). It is presently unclear whether the activated AR is directly or indirectly 
involved in decreasing the expression of the investigated Ca2+ transporters and hence 
a higher urinary Ca2+ excretion. We investigated this directly by expressing a 5 kb 
fragment (-5,000 to +1) of the mouse TRPV5 promoter coupled to the luciferase gene 
in androgen-responsive human prostate adenocarcinoma (LnCAP) cells (data not 
shown). However in these cells, we were not able to observe any effect of DHT on 
luciferase activity. Currently, it remains unclear how large the promoter fragment 
should be to adequately drive TRPV5 transcription in response to androgens. In 
addition, transcriptional regulators that could be necessary for the androgen-mediated 
inhibition may be absent in this cell system. The exact mechanism whereby 
testosterone alters TRPV5 expression remains to be clarified.
Short vs. long term effects of androgens on Ca2+ homeostasis
In this study, we aimed to evaluate the primary effect of androgens on renal Ca2+ 
handling. The inhibitory effect of testosterone on renal Ca2+ reabsorption seems at 
variance with the increased Ca2+ excretion found in elderly men with androgen 
deficiency, which is thought to be associated with male osteoporosis during aging 
(25-27). However, the short-term renal effects of androgen deficiency presented here 
should be separated from the long-term consequences of andropause in terms of 
bone remodeling. This issue was appropriately addressed in a study of Mauras et al. 
(13). They studied young men who were made hypogonadal for different time periods 
by injection of a gonadotropin-releasing hormone agonist. The contribution of Ca2+ 
released from bone to urine losses was shown to remain unchanged for 4 weeks, but,
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thereafter, significantly increased upon 10 weeks after induction of hypogonadism. In 
our experiments, we studied the effects of androgen deficiency in mice within the time 
frame of 2 weeks, to avoid the possible interference of Ca2+ released from bone. We 
could clearly delineate a change in intrarenal Ca2+ transport. Furthermore, we 
substantiated our in vivo results by experiments in isolated rabbit kidney CNT/CCD 
primary cell cultures. These cells express endogenous TRPV5 and calbindin-D28K, 
and are a consistent model to investigate active transepithelial Ca2+ transport ex vivo 
(11). Here, we found that incubation with the non-aromatizable androgen DHT (10 nM, 
which is in line with a physiological concentration of testosterone) for 24 h resulted in 
a marked inhibition of apical-to-basolateral Ca2+ transport. This finding further 
supports the inhibitory role of androgen on the regulation of renal active Ca2+ 
reabsorption in vivo.
In conclusion, this study provides evidence that androgens contribute to sex 
differences observed in renal Ca2+ handling via inhibiting the expression of renal Ca2+ 
transport proteins. Furthermore, this effect is independent of calciotropic hormones or 
estrogen.
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Prevalence of heterozygous NCC Mutations in Chinese Children
ABSTRACT
Gitelman’s syndrome (GS) caused by homozygous or compound heterozygous 
mutations in the thiazide-sensitive sodium chloride cotransporter (NCC) usually 
manifests in children and is associated with low blood pressure. However, the 
prevalence of heterozygous NCC mutations and their association with low blood 
pressure in children has not been studied. Five hundred unrelated children from The 
Taipei Children Heart Study were enrolled. Genomic DNA was isolated from 
peripheral blood and the SLC12A3 gene was amplified by polymerase chain 
reaction (PCR). The 15 NCC mutations previously identified in Chinese patients with 
GS were evaluated using restriction fragment length polymorphism (RFLP) analysis. 
Blood pressure, biochemistry, and urine pH were measured. The allelic frequency of 
heterozygous NCC mutations and their association with low blood pressure was also 
investigated. RFLP analysis for the 15 NCC mutations revealed heterozygous T60M 
in 1, T163M in 1, S283Y in 4, R642C in 2, W844X in 2, R928C in 9 and 
R959frameshift in 10 children. The overall incidence of positive heterozygous NCC 
mutations was approximately 2.9%. There were no significant differences in systolic 
and diastolic blood pressure, biochemical profiles, and urine pH between children 
with heterozygous NCC mutations (n=29) and non-affected controls (n=471) except 
a slightly higher fasting plasma glucose concentration in NCC-heterozygous children 
(91 ± 2.3 vs 88 ± 0.4 mg/dL, p<0.05). Within the various NCC mutations, children 
also had comparable blood pressure. A relatively high prevalence of heterozygous 
NCC mutations in Chinese children suggests that patients with GS are not rare in 
this population. Heterozygous NCC mutations are not associated with lower blood 
pressure in Chinese children.
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INTRODUCTION
Gitelman’s syndrome (GS) (OMIM 263800) is an autosomal recessive salt-losing
tubulopathy characterized by hypokalemic alkalosis with hypomagnesemia and
hypocalciuria (1,2). Due to laboratory similarity to chronic thiazide administration,
GS was long considered to be a functional defect of the thiazide-sensitive NaCl
co-transporter (NCC) in the distal convoluted tubules (DCT) (3,4). Using a candidate
gene approach, Simon et al first identified inactivating mutations in the SLC12A3
gene encoding NCC from families of GS patients in 1996 (3). To date, more than 100
distinct NCC mutations have been identified in patients with GS (5,6). The majority
of patients are compound heterozygotes with two different mutations on the two
alleles for NCC (3,7). Furthermore, it has been reported that 7% of GS patients
carried three or more different NCC mutations (8). Multiple independent mutant
alleles have also been found within families with GS (8,9). From these findings,
heterozygous NCC mutations should not be rare. Understanding the prevalence of
heterozygous NCC mutations in a population will help estimate the incidence of GS
as well as study the physiologic effects of heterozygous NCC.
Patients with GS usually present the clinical symptoms during childhood or
adolescence and are associated with low blood pressure due to renal salt wasting
(10,11). In a large Amish kindred with GS, patients with homozygous NCC actually
had impaired renal sodium (Na+) reabsorption and a significantly lower blood
pressure than their non-affected relatives. Children, but not adults, with
heterozygous NCC mutations had also significantly lower blood pressure and higher
24 hour urine Na+ excretion than the non-affected controls (10). However, there is
still a lack of large epidemiologic studies in children that support a definitive
correlation between heterozygous NCC mutations and blood pressure. To date, we
have identified 15 NCC mutations including 11 missense, 2 nonsense, 1 insertion
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and 1 deletion mutations in Chinese patients with GS (12,13). Most of these NCC 
mutations were recurrent and relatively different from those reported in Western 
countries (Table 1) (14). These 15 NCC mutations were selected as candidates for 
heterozygous NCC mutations. Therefore, the aims of this study are to investigate 
the allele frequency of these 15 heterozygous NCC mutations in 500 Chinese 
children, estimate the prevalence of GS, and assess its association with blood 
pressure.
METHODS
Subjects
This study is a part of the Taipei Children Heart Study, an epidemiologic cohort 
designed to evaluate CVD risk factors among schoolchildren in Taipei in 1995. The 
sampling methods and results have been clearly described elsewhere (15). The 
genotype of NCC mutations was determined in 500 children with mean age of 13.3 
years (range 12 to 16 years). The study protocol was approved by the Ethics 
Committee on Human Studies at Tri-Service General Hospital, National Defense 
Medical Center, in Taiwan, R.O.C. Informed consent was obtained from all study 
parents and children.
Blood pressure and biochemical profiles
Blood pressure was measured after a 10-minute rest period in a sitting position.
Systolic and diastolic blood pressure was the mean of two measurements by
well-trained doctors using mercury sphygmomanometers. Twelve-hour fasting blood
samples were obtained and biochemical values including creatinine, blood urea
nitrogen, lipid profiles, liver profiles and uric acid were determined by automated
methods (AU 5000 chemistry analyzer; Olympus, Tokyo, Japan). First
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morning-voided urine after overnight fast was collected and urine pH was measured 
with a pH electrode.
Genomic DNA isolation and polymerase chain reactions (PCR)
Genomic DNA was isolated from peripheral blood for PCR amplification of individual 
exons of the SLC12A3 (National Center for Biotechnology Information (NCBI) 
number NM-000339).
Restriction fragment length polymorphism analysis (RFLP)
Fifteen NCC mutations including 12 previously-reported and 3 newly-identified 
mutations in Chinese patients with GS were selected (Figure 1) (12,13). 
PCR-amplified DNA fragments were digested with 15 different restriction enzymes 
(Table 1), and electrophoresis was carried out on 2% agarose gel. The detection of 
NCC mutations by RFLP was confirmed by direct sequencing.
N426K
T163M IVS7-1G>A+971 InsACCGAAAATTTT I
N H 2 COOH R928C
Figure 1. Schematic diagram of 15 NCC mutations in Chinese GS patients. The NCC is
represented as 12 transmembrane domain protein with cytoplasmic amino and carboxyl termini. The 
sites of mutations in exons are denoted by arrows.
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Allele frequency of mutated NCC
RFLP analysis was used to count the occurrence of the 15 above-mentioned 
mutations (let a=the number of occurrences of the first mutation in the sample 
population, b=occurrences of the second mutation, etc). The overall incidence of 
positive heterozygous mutations was calculated as (a+b+c+d+e+...)/(500x2).
Statistical analysis
The data are expressed as mean ± SEM. The Student’s unpaired f-test was used to 
compare the differences in clinical and biochemistry characteristics between the 
combined children with all heterozygous NCC mutations and those with wild type 
NCC. Analysis of co-variance (ANCOVA) was used to compare the differences of 
continuous variables among the seven different NCC subgroups after adjustment for 
age and sex. The Bonferroni multiple comparisons procedure was used in multiple 
pair-wise comparisons between the subgroups. The Kruskal-Wallis test was used 
when the variables among these groups were not normally distributed. Differences 
were considered significant when the p value was less than 0.05.
RESULTS
Allele frequency of NCC mutations
Among the 500 children, RFLP analysis for the 15 NCC mutations revealed
heterozygous T60M in 1, T163M in 1, S283Y in 4, R642C in 2, W844X in 2, R928C
in 9, and R959frameshift in 10 (Table 1). Among these NCC mutated alleles, the
R928C and R959frameshift alleles were the most common in this population of
Chinese children. The H90Y, L215P, IVS7-1G>A+971InsACCGAAAATTTT, N426K,
N442K, T649M, S710stop, and R871H mutations were not detected at all. The
frequency of the T60M, T163M, S283Y, R642C, W844X, R928C and R959frameshift
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alleles were 0.1, 0.1, 0.4, 0.2, 0.2, 0.9 and 1.0 %, respectively. The overall incidence 
of positive heterozygous NCC mutations was approximately 2.9%.
Table 1
NCC mutations, enzyme restriction and allele frequency in Chinese children
Nucleotide mutation Consequence Restriction Allele frequency
C185T T60M Puv I 1/500x2 (0.1 %)
C274T H90Y Rsa I 0/500x2 (0 %)
T650C L215P AluI 0/500x2 (0 %)
C494T T163M BceA I 1/500x2 (0.1 %)
C854A S283Y Rsa I 4/500x2 (0.4 %)
971 InsACCGAAAAl 1 1 1 ADIFV322-326NRKFF Tsp509 I 0/500x2 (0 %)
C1284G N426K Hpy8 I 0/500x2 (0 %)
C1332G N442K Rsa I 0/500x2 (0 %)
C1930T R642C Hpa II 2/500x2 (0.2 %)
C1952T T649M Nla III 0/500x2 (0 %)
C2135A S710stop Hpy188I 0/500x2 (0 %)
G2538A W844stop Hinf I 2/500x2 (0.2 %)
G2618A R871H Nla III 0/500x2 (0 %)
C2788T R928C Tsp GW I 9/500x2 (0.9 %)
2881-2delAG R959frameshift Hin f  I 10/500x2 (1.0 %)
*denotes mutations also reported in Western countries. **The consequence of
IVS7-1G>A+971 InsACCGAAAATTTT mutation has been proven to be skipping of exon 7 and 8 
(reference 14)
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Blood pressure and biochemistry in NCC-heterozygous children 
As shown in Table 2, blood pressure (systolic blood pressure 114 ± 2.9 vs 116 ± 0.7 
and diastolic blood pressure 67 ± 1.7 vs 68 ± 0.9 mmHg) in children with 
heterozygous NCC mutations (n=29) were comparable to those of non-affected 
controls (n=471). Notably, we found that NCC-heterozygous children had a small, 
but significantly higher fasting plasma glucose concentration when compared to 
non-affected controls after adjusting for age, sex and body-mass index (BMI). 
However, there was no significant difference in plasma creatinine, blood urea 
nitrogen, lipid profiles, liver profiles, and uric acid between non-affected and 
NCC-heterozygous children. Urine pH was also comparable between non-affected 
and NCC-heterozygous children (urine pH 5.7 ± 0.03 vs 5.7 ± 0.14).
Blood pressure and biochemistry in different NCC-heterozygous children 
The clinical and biochemical parameters of children who carried the seven observed 
NCC-heterozygous mutations are shown in Table 3. There was no significant 
difference in the measurement of blood pressure among these seven subgroups. 
Although the mean systolic blood pressure of children heterozygous for 
R959frameshift was lower than children with other NCC- heterozygotes, this 
difference did not reach statistical significance after adjusting for age and gender. In 
addition, both the systolic and diastolic blood pressure of children heterozygous for 
R959frameshift were comparable with age- and gender-matched non-affected 
controls.
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Table 2
Blood pressure and biochemistry in NCC-heterozygous children
Wild type (n= 471) Heterozygous (n= 29)
Gender (M: F) 220:251 11: 18
Age (y/o) 13.5 i  0.04 13.5 i  0.1
BW (kg) 52.4 i  0.5 53.5 i  3.0
BMI (kg/m2) 22.0 i  0.2 22.0 i  0.9
SBP (mmHg) 116 i  0.7 114 i  2.9
DBP (mmHg) 68 i  0.5 67 i  1.9
Hgb (g/dL) 14.3 i  0.1 14.2 i  0.2
Glu (mg/dL) 88 i  0.4 91 i  2.3‘
UA (mg/dL) 6.2 i  0.1 6.7 i  0.3
TG (mg/dL) 72 i  1.5 68 i  5.5
TC (mg/dL) 165 i  1.3 170 i  4.9
ALT (IU/L) 15 i  0.4 18 i  2.4
BUN (mg/dL) 10.3 i  0.1 10.2 i  0.2
Cr (mg/dL) 0.7 i  0.01 0.7 i  0.02
U pH 5.7 i  0.03 5.7 i  0.14
Data expressed as mean ± SEM. * denotes p < 0.05 when wild vs heterozygous children 
Abbreviations: BW, body weight; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; Hgb, hemoglobin; Glu, glucose; UA, uric acid; TG, triglyceride; TC, total cholesterol; 
ALT, Alanine aminotransferase; BUN, urea nitrogen; Cr, creatinine; U pH, urine pH.
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Table 3
Blood pressure and biochemistry in different NCC-heterozygous children
Heterozygous (29)
R959framshift (10) R928C (9) S283Y (4) R642C (2) W844X(2) T60M(1 ) T163M(1)
Gender (M: F) 4:6 4:5 3:1 0:2 1:1 0:1 0:1
Age (y/o) 13.2 i  0.8 14.0 i  0.7 13.3 i  0.5 12.5 i  0.7 14 i  1.4 13 14
BW (kg) 52.8 i  22.4 56.6 i  15.3 43.7 i  8.5 48.3 i  8.9 58.9 i  6 34.7 60.5
BMI (kg/m2) 20.5 i  6.9 20.7 i  3.7 17.7 i  2.1 21 i  4.1 20.8 i  3.8 14.3 23.6
SBP (mmHg) 103 i  9.9 118 i  15.7 121 i  17.9 112 i  21 131.5 i  9.2 97 109
DBP (mmHg) 62 i  6.7 70 i  7.4 68.5 i  21.8 63 i  14.1 73.5 i  0.7 66 61
Hgb (g/dL) 13.9 i  0.9 14.5 i  1.9 13.7 i  0.5 14.1 i  1.3 14.5 i  2.1 15 13.5
Glu (mg/dL) 90 i  18.8 88 i  6.1 100 i  9.5 93.5 i  12 101 i  7.1 89 83
UA (mg/dL) 6.9 i  1.4 7.1 i  1.9 6.4 i  1.5 7.5 i  3.3 5.7 i  0.2 5 6.2
TG (mg/dL) 52 i  25 76 i  31 68 i  31 86 i  54 79 i  40 92 72
TC (mg/dL) 151 i  19 178 i  22 166 i  32 202 i  35 137 i  18 199 183
ALT (IU/L) 21.4 i  27.1 15.1 i  4.4 13 i  4.2 50.5 i  58.7 16 i  4.2 10 13
BUN (mg/dL) 10.3 i  1.7 10.1 i  2.2 9.65 i  3 10.2 i  1.2 9.5 i  0.2 12.2 11.2
Cr (mg/dL) 0.7 i  0.07 0.7 i  0.12 0.65 i  0.05 0.6 i  0.14 0.65 i  0.21 0.6 0.7
U pH 5.6 i  0.9 5.7 i  0.6 6 i  1.1 5.36 i  0.4 5.75 i  1.1 6 6
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DISCUSSION
In this study, we examined the prevalence of heterozygous NCC mutations and their 
association with blood pressure in 500 Chinese children. We found the allelic 
frequency of heterozygous NCC mutations was higher than expected, approximately 
2.9%. Overall, NCC-heterozygous children did not have a significantly lower blood 
pressure but a significantly higher fasting plasma glucose level than non-affected 
controls.
There are few studies that address the prevalence of heterozygous NCC mutations
in a large general population (13,16-18). In the Western countries, the prevalence of
heterozygous mutations has been estimated at approximately 1% in the Swedish
and Italian populations based on phenotypic expression. However, carrier
prevalence of the 15 NCC mutations proven or inferred to be functional from the
screen of entire coding exons in 3125 unrelated subjects of Framingham Heart
Study was approximately 0.5% (19). In the Far East, the overall frequency of 9
heterozygous NCC mutations as detected by the TaqMan system was 2.0% in 1852
Japanese subjects (16,20). Using RFLP, our previous study showed that
heterozygous carrier for 12 previously-identified NCC mutations in 100 unrelated
healthy Chinese adults was approximately 3% (13). In this study, the allele
frequency of 15 heterozygous NCC mutations in 500 Chinese children was also
approximately 2.9%. A recent study in China also found a 3% prevalence of
heterozygous NCC mutations from direct sequencing screening for 10 NCC
mutations in 50 unrelated healthy subjects (21). The discrepancy of prevalence of
heterozygous carriers between Western and Asian countries may be related to
screening methods with the entire NCC gene or selected NCC for analysis and
pathogenicity of selected NCC mutations. If the pre-selected 15 NCC mutations in
our study were all pathogenic, the expected prevalence of patients with autosomal
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recessive GS should be at least 2.1 per 10,000 children (2.9/100 * 2.9/100 * 1/4). 
Our results suggest that GS should not be rare in the Chinese population and is 
more common than in Western countries. Because most patients with GS may have 
nonspecific symptoms such as weakness, fatigue, cramps, nocturia, thirst, and salt 
carving during early childhood and a significant impact on quality of life (2, 5, 22), an 
early diagnosis of GS is often difficult but needed. Screening of recurrent "hot spot” 
NCC mutations in children and any suspected patients might provide further genetic 
counseling for heterozygous carriers and achieve earlier diagnosis of GS.
NCC is a member of the cation/Cl- cotransporter gene family. The NCC mutations in 
GS are located throughout the entire coding sequence of the NCC protein (5, 12, 13, 
23). Most of the reported NCC mutations reside in the carboxyl terminus, which has 
been demonstrated to be involved in the intracellular trafficking of NCC to the apical 
membrane (13,24-26). In the present study, four out of the seven (57%) 
heterozygous NCC mutations are located within the cytoplasmic carboxyl terminus 
and we found that R928C (0.9%) and R959frameshift (1.0%) were the two most 
common heterozygous NCC mutations among Chinese children. As expected, 
frameshift of NCC from R959 causes protein dysfunction and should be pathogenic 
(9). R928C is also proposed to be pathogenic because R928 is conserved among 
various species and the substitution of arginine (R) to cysteine (C) which introduces 
a sulfur-containing side chain or removes a cationic amino acid might result in a 
functional defect of NCC. In addition, R928C has not been reported as a 
polymorphism in other ethnic groups. Nevertheless, in vitro functional expression 
study of R928C is needed to confirm the pathogenicity of this mutant by measuring 
tracer 22Na+ uptake in oocytes or mammalian cells.
NCC activity in the DCT has been implicated in the regulation of blood pressure. In
contrast to enhanced NaCl reabsorption in the DCT, as in pseudohypoaldosteronism
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type II due to WNK1/4 mutations with secondary hypervolemia and hypertension 
(27), diminished renal NaCl reabsorption due to NCC mutations in GS cause renal 
salt wasting and relative hypovolemia leading to low to normal blood pressure
(10,11). It was proposed that heterozygous NCC carriers may also have impaired 
renal salt reabsorption and increased susceptibility to diuretic. A previous study in a 
large Amish family of GS demonstrated that heterozygous children, but not adults, 
had significantly lower blood pressure accompanied by a higher urinary Na+ 
excretion than their non-affected relatives (10). Why this phenomenon was only 
seen in children remains elusive. However, another intra-familial study in Sweden 
found that NCC-heterozygous subjects had significantly lower blood pressure but 
did not have a significantly higher urinary Na+ excretion than control (11). A new  
study from Lifton group shows that inactivating NCC carrier is associated with a 
significant blood pressure reduction and a reduced risk of hypertension in the 
Western population (19). Conversely, NCC-heterozygous children in our study and 
NCC-heterozygous adults in a Japanese study did not have similar relative 
hypotension (28). Perhaps racial differences, genetic background, and variable salt 
intake in these studies may account for this discrepancy.
The nature and position of the NCC mutations may be a determining factor in the 
severity of GS. Among different NCC mutations in this study, the children carrying 
R959frameshift, T60M , and T163M  mutations seemed to exhibit relatively lower 
blood pressure, compared with other NCC-heterozygotes. However, this difference 
did not reach statistical significance after adjusting for age and gender. The number 
of different specific NCC mutations was very limited. Clarification of whether blood 
pressure could be related to specific heterozygous NCC mutations needs a larger 
cohort to validate.
W e found NCC-heterozygous children had a slightly higher fasting plasma glucose
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concentration than non-affected controls. This finding was in line with the Swedish 
study on relatives of GS families, which also showed a significantly higher fasting 
glucose concentration in NCC-heterozygous relatives (11). Although glucose 
metabolism and insulin resistance in GS patients remain under investigation, 
glucose intolerance has been shown in patients treated with thiazide diuretics. 
Diuretic-related hypokalemia and activation in renin-angiotensin-aldosterone have 
been suggested in the pathogenesis of impaired glucose tolerance in 
thiazide-treated patients (29-31). However, normal serum potassium concentration 
and the lack of correlation between plasma glucose, renin and aldosterone levels in 
NCC-heterozygous relatives in the Swedish study argue against the 
previously-proposed mechanism. Because NCC is not reported to be expressed in 
insulin-secreting pancreas and insulin-sensitive tissue such as skeletal muscle, liver 
and adipose, the role of heterozygous NCC mutations in glucose metabolism merits 
further investigation.
There are some limitations to this study. First, it is well known that some dietary
factors, such as reduced salt intake and increased potassium intake can effectively
lower blood pressure levels (32). All the children in this study pursued a usual diet
without any restriction of salt or potassium. Second, we did not measure the urine
Na+ or other electrolytes excretion rate to evaluate the correlation with blood
pressure. However, Fava et al. have demonstrated a lack of correlation between
blood pressure and urine Na+ excretion in NCC-heterozygous and non-affected
subjects (11). Third, the number of children carrying different individual
heterozygous NCC mutation is relatively small. It is difficult to discriminate the
effects of different specific heterozygous NCC mutants on blood pressure. Fourth,
we only sequenced the fragments of NCC mutations detected by RFLP rather than
entire SLC12A3 gene. Finally, this study was an observational cross-section in
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design. The effects of heterozygous NCC on the blood pressure and glucose 
metabolism require a large scale longitudinal study as well as further bench work in 
vitro and in vivo.
In conclusion, we have found that a relatively high prevalence of heterozygous NCC  
mutations in children suggests that GS patients are not rare in the Chinese 
population. NCC-heterozygous children did not have significantly reduced blood 
pressure but significantly higher fasting plasma glucose concentration. The effects 
of heterozygous NCC mutations on the cardiovascular system and glucose 
metabolism warrants further investigation.
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General Discussion

General discussion
INTRODUCTION
The calcium ion (Ca2+) is essential for the normal function of all living cells. Numerous 
hereditary and clinical disorders directly or indirectly result from dysregulation of the 
body Ca2+ balance (1, 2). In human, 99% of total body Ca2+ resides in the skeleton, 
and 1% is distributed in the soft tissues and extracellular fluids (1, 2). The concerted 
action of intestinal Ca2+ absorption, bone (de)mineralization and renal Ca2+ excretion 
maintain a normal Ca2+ balance (3). In kidney, Ca2+ can re-enter the circulation by 
paracellular (passive) as well as transcellular (active) Ca2+ reabsorption. Passive Ca2+ 
reabsorption takes place in PCT and TAL, which is driven by convective flow and the 
local electrical gradient, respectively (4). Active Ca2+ reabsorption comprises a 
sequence of processes restricted to the DCT and the CNT and hormonal regulation 
mainly occurs in this segment (3, 5). At the cellular level, transcellular reabsorption is 
mediated by Ca2+ entry across the apical membrane through the specialized epithelial 
Ca2+ channels, TRPV5 and TRPV6, intracellular buffering of Ca2+ and facilitated 
diffusion of Ca2+ bound to Ca2+-binding proteins (calbindin-D28K and calbindin-D9K) and 
finally Ca2+ extrusion across the basolateral membrane by a Na+/Ca2+ exchanger 
(NCX1) and a plasma membrane Ca2+-ATPase (PMCA1b) (3, 6). TRPV5 has been 
first identified by our group in 1999 and this apical Ca2+ influx channel was shown to 
be involved in transcellular Ca2+ (re)absorption by functional analysis (7). 
Subsequently, the generation of TRPV5 (8) and calbindin-D28K (9) knockout mice 
greatly improves our knowledge about the molecular mechanisms of active renal Ca2+ 
reabsorption and provides an useful model to dissect the relationship between TRPV5 
and calbindin-D28K. Our and other laboratories have demonstrated that transepithelial 
Ca2+ transport is stimulated by the classic calciotropic hormones, PTH and 
1,25(OH)2D3, via an upregulation of mRNAs encoding TRPV5, calbindins and NCX1. 
Although estrogen is not usually recognized as a calciotropic hormone, our recent
175
Chapter 6
study provided evidences that estrogen positively regulates the expression of TRPV5 
in a 1,25(OH)2D3-independent pathway (10), inferring that this sex hormone might 
play a role in the regulation of the channel. Moreover, extensive studies have shown 
that TRPV5 is critically involved in acquired renal Ca2+ disorders, such as 
immunosuppressant agents or vitamin D analogues-associated Ca2+ dysregulation 
and inherited diseases, such as vitamin D-dependent rickets (VDDR) and Gitelman’s 
syndrome (GS). The central role of TRPV5 in active Ca2+ reabsorption makes it a 
potential pharmaceutical target for the treatment of clinical Ca2+ disorders. Therefore, 
understanding the interrelationship between TRPV5 and other renal Ca2+ transporters 
and the modulation of TRPV5 by classical and novel calciotropic hormones is 
fundamental for the development of therapeutic modality targeting on 
TRPV5-mediated Ca2+ reabsorption.
This thesis aimed to investigate the in vivo role of TRPV5 and calbindin-D28K in the 
maintenance of the Ca2+ balance by studying TRPV5/calbindin-D28K double knockout 
mice (Chapter 2), the transcriptional regulation of TRPV5 by calcitonin (CT) (Chapter 
3) and androgen (Chapter 4) and the prevalence of heterozygous NCC mutations and 
their association with low blood pressure in Chinese children (Chapter 5). This 
chapter discusses the research findings presented in this thesis, which significantly 
contributed to our understanding of the molecular pathways involved in transcellular 
Ca2+ reabsorption and the unique role of TRPV5 in this process.
IS CALBINDIN-D28k A KEY PLAYER IN RENAL CA2+ HANDLING?
Active Ca2+ transport in the kidney and duodenum is carried out in three steps: Ca2+ 
entry through epithelial Ca2+ channels (TRPV5 and/or TRPV6), buffering and/or 
transport by calbindin-D28k and -D9k, and extrusion through the NCX1 and PMCA1b. 
To study the molecular mechanism in maintaining the extracellular Ca2+ balance,
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several investigators are now applying the powerful tools of transgenic mice 
technology to better understand how gene expression contributes to the Ca2+ balance 
or may cause a human disease.
There are two major subclasses of vitamin D-dependent Ca2+-binding proteins, 
calbindin-D28K and calbindin-D9K. Calbindin-D28K, the main Ca2+-binding protein in DCT 
and CNT, facilitates Ca2+ diffusion and lowers the intracellular Ca2+ concentration to 
avoid mitochondrial dysfunction leading to ATP depletion and cell death secondary to 
intracellular Ca2+ accumulation (9, 11). Although several studies suggested a crucial 
role for calbindin-D28k in the process of active renal Ca2+ reabsorption, calbindin-D28K 
knockout (calbindin-D28K-/-) mice exhibit a normal Ca2+ balance or mild hypercalciuria 
depending on the Ca2+ diet (12, 13). Calbindin-D9K is a cytosolic Ca2+-binding protein 
that is expressed in a variety of tissues, such as uterus, placenta, intestine, pituitary 
gland and bone. In mouse kidney, calbindin-D9K colocalized with parvalbumin, a 
divalent cation buffering protein that contains a pair of functional EF-hand motifs, 
exclusively expressed in the DCT where it is thought to facilitate Ca2+ reabsorption. 
Similar to calbindin-D28K-/- mice, calbindin-D9k knockout (calbindin-D9K-/-) mice are 
indistinguishable from wild-type mice either in phenotype or by serum Ca2+ level (14, 
15). The phenotypes of calbindin-D9k and calbindin-D28k single knockout mice argue 
against their biological importance in active Ca2+ processing and compensatory action 
of other Ca2+ transport proteins might explain why normal Ca2+ balance in these two 
kinds of knockout mice. To explore the importance of these Ca2+ transporters, double 
knockout mice lacking TRPV5/calbindin-D28K and calbindin-D28K/calbindin-D9K were 
generated (16-18). We investigated whether calbindin-D28K deficiency is critical for 
active Ca2+ reabsorption in the presence or absence of TRPV5 (17). Interestingly, 
TRPV5-/-/calbindin-D28K-/- mice displayed prominent Ca2+ abnormalities similar to the 
TRPV5-/- mice such as hypercalciuria and increased Ca2+ absorption. These findings
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suggest that TRPV5, but not calbindin-D28K, is the critical component in renal active 
Ca2+ reabsorption. In addition, dietary Ca2+ restriction results in a significant 
upregulation of renal calbindin-D9k, accompanied by elevated serum 1,25(OH)2D3 
levels in TRPV5-/-/calbindin-D28K-/- and TRPV5-/- mice, suggesting that calbindin-D9K 
could possibly compensate calbindin-D28K in a vitamin D-dependent manner. The 
compensatory role of calbindin-D9K for calbindin-D28K has been further elucidated by 
the characterizations of calbindin-D28K and calbindin-D9K double knockout 
(calbindin-D28K-/7calbindin-D9K-/-) mice (18). On a normal Ca2+ diet, 
calbindin-D28K-/-/calbindin-D9K-/- mice did not exhibit any changes in phenotype or the 
renal mRNA expression of TRPV5, TRPV6, NCX1 and PMCA1b as compared to 
wild-type or calbindin-D28K-/- mice. On Ca2+-deficient dietary conditions, the phenotype 
and the renal mRNA expression of TRPV5, TRPV6 and calbindin-D9K in 
calbindin-D28K-/- mice were similar to the wild-type mice, whereas in 
calbindin-D28K-/-/calbindin-D9K-/- mice, serum Ca2+ levels and bone length were 
decreased. The renal expression of TRPV6 mRNA was significantly reduced in 
calbindin-D28K-/-/calbindin-D9K-/-mice fed a Ca2+ -deficient diet as compared to 
calbindin-D28K-/- or wild-type mice, and calbindin-D28K-/-/calbindin-D9K-/-mice died after 4 
weeks on a Ca2+ -deficient diet. Taken together, these results indicate that deletion of 
calbindin-D28K or calbindin-D9K alone does not affect body Ca2+ homeostasis, but that 
double deletion of calbindin-D9K and calbindin-D28K has a significant effect on Ca2+ 
processing under Ca2+-deficient conditions. However, these data cannot exclude the 
possibility that other molecular mechanisms could compensate for the deficiency of 
calbindin or that downstream reabsorptive segments balance an impaired Ca2+ 
transport capacity of DCT lacking calbindin.
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IS TRPV6 IN INTESTINE THE MIRROR IMAGE OF TRPV5 IN KIDNEY?
TRPV6, discovered as a counterpart of renal TRPV5, is located in the luminal brush 
border of intestinal epithelial cells. Within the gastrointestinal tract, TRPV6 is primarily 
expressed in the duodenum and constitutes the postulated rate-limiting entry step of 
active intestinal Ca2+ absorption. Bianco et al. generated TRPV6 knockout (TRPV6-/-) 
mice to investigate the role of TRPV6 in intestinal Ca2+ absorption in vivo (19). 
Corresponding to the distribution of TRPV6 in wild-type littermates, the knockout mice 
exhibited marked Ca2+ disturbance, including a 60% reduction in intestinal Ca2+ 
absorption, hypercalciuria and decreased bone mineral density (BMD) despite 
elevated levels of serum PTH and 1,25(OH)2D3. Under Ca2+-deficit conditions, 
TRPV6-/- mice developed hypocalcemia without a further increase of serum PTH and 
vitamin D. Interestingly, some TRPV6-/- mice displayed alopecia, dermatitis and 
reduced fertility, indicating that TRPV6 plays an important role in intestinal Ca2+ 
absorption and in other tissues not directly involved in the Ca2+ homeostasis. However, 
the applied TRPV6 knockout targeting strategy affected not only the TRPV6 gene, but 
also the neighboring Ephrin type-B receptor 6 (EphB6) gene that might have 
contributed to the observed phenotype. Thus, the characterization of TRPV6-/- mice 
should be carefully interpreted.
Similar to TRPV5-/-/calbindin-D28K-/- mice, TRPV6-/-/calbindin-D9K-/- mice have serum 
Ca2+ levels similar to those of wild-type, calbindin-D9K-/- and TRPV6-/- mice. Using 
everted gut sac assay, there was a 4.1-, 2.9-, 3.9, and 2.1-fold increase in Ca2+ 
transport in the duodenum of wild-type, TRPV6-/-, calbindin-D9K-/- and 
TRPV6-/-/calbindin-D9K-/- mice fed the low Ca2+ (0.02%) diet, respectively, compared 
with mice under high dietary Ca2+ (1%) conditions. Furthermore, active Ca2+ transport 
stimulated by 1,25(OH)2D3 administration was observed in calbindin-D9K-/-, TRPV6-/- 
and TRPV6-/-/calbindin-D9K-/- mice, indicating active intestinal Ca2+ transport occurs in
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the absence of TRPV6 and/or calbindin-D9k. These data challenge the dogma that 
TRPV6 and calbindin-D9k are essential for vitamin D-induced active intestinal Ca2+ 
transport.
CT-STIMULATED RENAL CA2+ REABSORPTION OCCURS INDEPENDENT OF 
TRPV5
CT is known to affect renal Ca2+ handling. However, it remains unclear how CT affects 
Ca2+ transport in the distal convolutions. The study presented in Chapter 3 
investigated the contribution of TRPV5 to renal Ca2+ handling in response to CT. We 
showed that administration of CT for 16 hrs resulted in a prominent reduction of 
urinary Ca2+ excretion, whereas did not affect the renal abundance of TRPV5 in 
wild-type mice. In addition, TRPV5-/- mice responded to CT treatment for 16 or 40 hrs 
in a similar manner to wild-type mice. Given the data obtained in these models, it is 
likely that the effect of CT on renal Ca2+ transport occurs independently of TRPV5.
A single bolus injection of CT significantly reduced the urinary excretion of Ca2+ in 
wild-type mice. This decrease was associated with a reduction in the urinary Na+ and 
K+ excretion, leaving the urinary Na+/K+ ratio unchanged. These data are consistent 
with the previously reported effects of CT on stimulating TAL and DCT transport of 
NaCl and K+ (20-23). Earlier studies in the TAL of mice and rats have demonstrated 
that CT activates NaCl transport only in the cortical TAL (20, 23). This segment of the 
TAL is also thought to drive paracellular Ca2+ reabsorption in these species. Although 
never delineated in detail, CT is likely to activate a cAMP cascade leading to 
increased Na+-K+-2Cl- cotransporter (NKCC2)-mediated transport, perhaps via 
increased membrane trafficking and potentially phosphorylation. Currently, it remains 
unknown which transporter CT stimulates in the DCT (21). One option may be the 
thiazide-sensitive NCC transporter that resides there.
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Although CT does not affect TRPV5-mediated Ca2+ reabsorption, it is clear that CT 
strongly stimulates renal Ca2+ reabsorption. This is likely to occur primarily through 
changes in Ca2+ transport within the TAL. It should be stated that although the effects 
of CT on renal Ca2+ transport are present in TRPV5+/+ as well as in TRPV5-/- mice, and 
that TRPV5 expression is unaltered after CT administration, does not fully exclude an 
effect upon TRPV5. Alternatively, a lack of stimulation of CT on TRPV5 in TRPV5-/- 
mice, may be masked due to the pronounced effect of CT in the TAL.
ESTROGEN: A NEWLY IDENTIFIED CALCIOTROPIC HORMONE INVOLVED IN 
THE TRANSCRIPTIONAL REGULATION OF TRPV5
Our understanding of the calciotropic hormones has evolved over the last years. Our 
previous studies have demonstrated stimulatory effects of the classical calciotropic 
hormones, vitamin D and PTH, on active transepithelial Ca2+ reabsorption. In vitro and 
in vivo experiments show that 1,25(OH)2D3 and PTH stimulates Ca2+ (re)absorption in 
the distal part of the nephron (24, 25). The mechanism of action is mediated by an 
upregulation of mRNAs encoding TRPV5, the calbindins, and NCX1, which translates 
into increased Ca2+ (re)absorption. Although it is well known that estrogen deficiency 
leads to a negative Ca2+ balance and bone loss in postmenopausal women, the 
underlying mechanism by which estrogen might affect renal Ca2+ handling is still 
poorly understood. Recently, estrogen has been recognized as a calciotropic 
hormone involved in the regulation of renal Ca2+ reabsorption (10). Supplementation 
with 17p-estradiol to ovariectomized (OVX) rats normalized the renal mRNA levels of 
TRPV5, calbindin-D28K, NCX1, and PMCA1b and increased the protein abundance of 
TRPV5. Furthermore, estrogen increases renal expression of TRPV5 in a 
1,25(OH)2D3-independent manner (10). This was confirmed in 25-hydroxyvitamin 
D3-1a-hydroxylase-knockout mice where 17p-estradiol replacement therapy
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enhanced renal expression of TRPV5, leading to the normalization of serum Ca2+ 
levels. By altering transcriptional expression of TRPV5, the rate-limiting step in 
transcellular Ca2+ transport, estrogen might positively regulate Ca2+ reabsorption and 
homeostasis.
GENDER DIFFERENCES IN CA2+ HOMEOSTASIS
Sex hormones play a key role in the regulation of skeletal growth and maturation. 
Similar to estrogen deficient postmenopausal women, long-term male sex hormone 
androgen deficiency resulted in a negative Ca2+ balance and osteoporosis among 
elderly men. A number of in vitro and in vivo studies suggested that the effect of 
androgen on Ca2+ homeostasis is mainly ascribed to its anabolic and anti-resorptive 
effects on the bone remodeling (26, 27). Interestingly, recent studies demonstrated a 
gender difference in the molecular mechanisms involved in the inhibition of 
osteoclastogenesis and bone resorption (28). Furthermore, it is well known that 
urolithiasis is a male-predominant disorder with a male-to-female ratio of 
approximately 2:1 to 3:1 (29, 30) and several studies have reported gender 
differences in the urinary Ca2+ excretion, showing a greater urinary Ca2+ loss in males 
than in females (31, 32). In addition, estrogens have been shown to increase the renal 
reabsorption of Ca2+, which is in good agreement with the observed gender 
differences (10). Presently, it remains unclear whether androgens play an opposing 
role to estrogens in modulating renal Ca2+ reabsorption. The androgen receptor (AR) 
is expressed in renal epithelial cells (33), and a growing body of evidence points to 
gender differences in various functional characteristics of mammalian kidneys (33); 
for example, a higher glomerular filtration rate in the male rat kidney (possibly due to 
higher renal plasma flow and lower vascular resistance).
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ANDROGEN: A NOVEL CALCIOTROPIC HORMONE ATTENUATES RENAL 
TRPV5 EXPRESSION
The study in Chapter 4 uncovered the molecular mechanisms of renal Ca2+ handling 
by the male sex hormone. We observed a larger urinary Ca2+ excretion in male mice 
than in females which is consistent with previous clinical studies evaluating sex 
differences in humans (31). In addition, orchidectomy (ORX) induced hypocalciuria in 
male mice, thus resembling a female-like phenotype on renal Ca2+ reabsorption. 
Moreover, testosterone supplementation of ORX (ORX+T) mice caused a 
normalization of their urinary Ca2+ excretion, accompanying a decreased expression 
of renal TRPV5 and calbindin-D28K. Notably, we studied the effects of androgen 
deficiency in male mice within the time frame only of 2 weeks, to avoid the possible 
interference of Ca2+ released from bone. Conversely, previous studies evaluating the 
effect of estrogen on renal Ca2+ handling, demonstrated that this hormone exerts a 
direct effect on renal Ca2+ reabsorption via up-regulation of TRPV5 and calbindin-D28K 
in female mice (10). Thus, both testosterone and estrogen have opposing regulatory 
properties in terms of renal transcriptional expression of Ca2+ transporters. 
Furthermore, we substantiated our in vivo data by experiments in primary cultures of 
renal connecting tubule (CNT) / cortical collecting duct cells (CCD) and incubation 
with the non-aromatizable androgen DHT for 24 h resulted in a marked inhibition of 
the net apical-to basolateral (transcellular) transport of Ca2+. Our previous and present 
studies clearly demonstrated that TRPV5 expression is regulated at transcriptional 
level by sex steroids (estrogen and androgen) and gonads concert with kidney, 
intestine and bone involved in the regulation of body Ca2+ homeostasis (Figure 1).
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Figure 1. Major organs and key calciotropic hormones in Ca2+ homeostasis
The concerted interplay of intestinal uptake, reabsorption in kidney, and bone (de)mineralization 
establishes the maintenance of a normal Ca2+ balance. The Ca2+ sensing receptor (CaSR), presents in 
the parathyroid cells and C-cells of the thyroid glands, senses blood Ca2+ levels and triggers the secretion 
of the calciotropic hormones parathyroid hormone (PTH) and calcitonin (CT). PTH stimulates the 
conversion of 25(OH)D3 to 1,25(OH)2D3, the active form of vitamin D. CT counteracts the Ca2+-releasing 
effects of PTH. Ovarian-produced estrogen may stimulate, whereas testis-produced androgen may inhibit 
Ca2+ reabsorption.
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ROLE OF CALCIOTROPIC HORMONES IN ANDROGEN-DEPENDENT 
REGULATION OF TRPV5
As described in Chapter 4, no difference in serum 1,25(OH)2D3 and PTH 
concentrations was detected between sham-operated, ORX, and ORX+T mice, 
suggesting that the up-regulation of TRPV5 in ORX mice is not mediated by these 
calciotropic hormones. Conversely, androgens have previously been suggested to 
affect Ca2+ homeostasis by altering the regulation of calciotropic hormones. Some 
discrepancy has been reported. In a study by Nyomba et al. (34), the serum 
concentration of 1,25(OH)2D3 was shown to decrease after ORX in male rats, while 
testosterone replacement therapy restored serum 1,25(OH)2D3 to normal levels. In 
agreement with our data, a study by Hope et al.(35), reported that ORX performed in 
male rats could not be associated with any changes in active 1,25(OH)2D3 levels. 
Possible explanations for these discrepancies are currently unclear and may not 
exclude a contribution of 1,25(OH)2D3 to overall Ca2+ handling by androgens.
GENDER DIFFERENCES IN THE REGULATION OF RENAL TRANSPORTERS
In Chapter 4, we found that both testosterone and estrogen have opposing regulatory 
properties in terms of renal transcriptional expression of Ca2+ transporters. Similar sex 
differences have been found for the regulation of the thiazide-sensitive 
sodium-chloride cotransporter (NCC) that is expressed in DCT. Chen et al. (36) 
demonstrated that the density of NCC (quantified by [3H]metolazone binding) was 
two-fold higher in female compared to male rats. Furthermore, ORX resulted in an 
increase in metolazone binding sites in males, whereas ovariectomy decreased the 
binding density in females (36). In addition, gender differences in mineral/solutes 
secretion have been found in the regulation of several renal transporters including 
Oat1, Oat2, Oat3, Oat5, Oct2, Urat1, Oatp1a1, Oatp3a1, Oat-K, NKCC2 and Sglt1
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(37). However, the detailed molecular mechanism of gender differences in regulation 
of aforementioned renal transporters is not completely understood.
ROLE OF AR IN ANDROGEN-MEDIATED DECREASE OF TRPV5 EXPRESSION
In general, the binding of androgens to the AR results in a conformational change and 
dimerization of the AR (38, 39). The AR dimer interacts with androgen-response 
elements (AREs) and subsequent recruitment of transcription factors into the nucleus 
leads to regulation of specific gene transcription. In Chapter 4, we showed that the AR 
is present in TRPV5-expressing cells, which is in line with previous results 
demonstrating the presence of the AR in the distal part of the nephron (40). It is 
presently unclear whether the activated AR is directly or indirectly involved in the 
androgen-induced decrease in the expression of the investigated Ca2+ transporters 
and hence a higher urinary Ca2+ excretion. We investigated this by expressing a 5 kb 
fragment (-5,000 to +1) of the mouse TRPV5 promoter coupled to the luciferase gene 
in androgen-responsive human prostate adenocarcinoma (LnCAP) cells. However, 
we were not able to observe any effect of DHT on luciferase activity in these cells. 
Currently, it remains unclear how large the promoter fragment should be to 
adequately drive TRPV5 transcription in response to androgens. In addition, 
transcriptional regulators that could be necessary for the androgen-mediated 
inhibition may be absent in this cell system.
TRANSCRIPTIONAL REGULATION OF TRPV5 GENE
It has been well established that the transcriptional expression of TRPV5 is 
up-regulated by 1,25(OH)2D3, PTH and estrogen, and down-regulated by androgen. 
These classical and novel calciotropic hormones form complexes with their 
corresponding nuclear receptors and subsequently these complexes initiate TRPV5
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transcription by binding to the nuclear receptors-response elements in the promoter 
regions of TRPV5. Analyses of first 5-kb fragment upstream of the transcriptional start 
site of mouse TRPV5 via the Promoter Inspector database (http://www.genomatix.de) 
revealed two androgen response elements (AREs), two estrogen response elements 
(EREs), two glucorticoid response element (GRE) and five RXR/VDR (retinoic acid 
receptor/vitamin D receptor) binding sites. In addition, there are five activator protein 1 
(AP-1) and four GC-rich stimulatory protein (Sp-1) binding sites within the promoter 
sequence of TRPV5. The 5'-flanking region sequence of TRPV5 promoter with 
predicted transcription receptor binding sites is summarized in Figure 2. Both AP-1 
and Sp-1 have been shown to participate in the processes of sex hormones mediated 
genes transcription (41, 42). Further detailed promoter analysis by using luciferase 
reporter assay is necessary to elucidate the molecular mechanisms responsible for 
the regulation of TRPV5 transcription.
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Figure 2. Genomic structure and promoter sequence of mouse TRPV5 gene
(A) Schematic diagram of the genomic structure of TRPV5. Filled boxes represent coding sequences 
and open boxes represent untranslated regions. The exons are numbered 1-15. The start codon (ATG) 
and stop codon (TGA) are indicated. (B) Analyses of first 5-kb fragment upstream of the transcriptional 
start site (+1) of mouse TRPV5. Transcription factor binding sites are predicted by the Promoter 
Inspector database (http://www.genomatix.de). The putative binding sites for ERE, ARE and AP-1 are 
underlined. The predicted GRE, RXR/VDR and Sp-1 binding sites are marked in solid-, dashed- and 
dot-line box, respectively. ERE, estrogen response element; ARE, androgen response element; GRE, 
glucocorticoid response element; RXR/VDR, retinoic acid receptor/vitamin D receptor; AP-1, activator 
protein 1; Sp-1, GC-rich stimulatory protein.
TRPV5 POLYMORPHISM AND UROLITHIASIS
Although it is evident that TRPV5 plays a crucial role in renal Ca2+ disorders, the 
majority of reported studies are performed in mice. Until now there is no direct 
evidence obtained from humans. According to our in vivo observations obtained in 
mice, we deduced that TRPV5 might involve in the pathogenesis of urolithiasis, which 
is a major socio-economic problem in human and one of the common causes for 
chronic renal insufficiency. Renkema et al. investigated 20 subjects displaying renal 
hypercalciuria and screened the TRPV5 coding region and intron-exon boundaries for 
gene mutations (43). Genotying of TRPV5 in patients with renal hypercalciuria 
revealed three non-synonymous and five synonymous polymorphisms. The detected 
synonymous polymorphisms were L205L, Y222Y, Y278Y, T281T and T344T. The 
non-synonymous gene polymorphisms identified were A8V, R154H and A561T. They 
further investigated the functional properties of these three non-synonymous gene 
polymorphisms by electrophysiological analysis. However, electrophysiological 
characterization of the TRPV5 mutants did not reveal significant functional changes 
compared to wild-type TRPV5 channel recordings. Although these data do not support 
a primary role of TRPV5 in renal hypercalciuria, TRPV5 can not be precluded as a
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candidate gene in hypercalciuria. Large scale genetic study is necessary to confirm 
the role of TRPV5 in patients with renal hypercalciuria.
Conversely, Suzuki et al. analyzed 170 patients with renal Ca2+ stone formation and 
found that the frequency of an ancestral TRPV6 haplotype consisting of three 
non-synonymous gene polymorphisms (C157R, M378V and M681T) was significantly 
higher in Ca2+ stone former than stone-free subjects (44). They further expressed 
these missense TRPV6 mutants in Xenopus laevis oocytes and found a significant 
45Ca2+ uptake, indicating an enhanced Ca2+ entry through gain-of-function mutations 
of TRPV6. Taken together, these data suggest that TRP5 or TRPV6 channels possibly 
contribute to kidney stone formation and the potential of these channels in therapeutic 
and preventive settings for urolithiasis.
PREVALENCE OF HETEROZYGOUS NCC MUTATIONS IN CHINESE CHILDREN
There are few studies that address the prevalence of heterozygous NCC mutations in 
a large general population (50-52). In Western countries, the prevalence of 
heterozygous mutations has been estimated at approximately 1% in the Swedish and 
Italian populations based on phenotypic expression (51). However, carrier prevalence 
in 3125 unrelated subjects of Framingham Heart Study was approximately 0.5% (53). 
In Asia, the overall frequency of 9 heterozygous NCC mutations was 2% in 1852 
Japanese subjects (52, 54). Using Restriction Fragment Length Polymorphism 
analysis (RFLP), our previous study showed that heterozygous carrier for 12 
previously-identified NCC mutations in 100 unrelated healthy Chinese adults was 
approximately 3% (50). In Chapter 6, we estimated the allele frequency o f 1 5  
heterozygous NCC mutations in 500 Chinese children was also approximately 3%. A 
recent study in China also found a 3% prevalence of heterozygous NCC mutations for 
10 NCC mutations in 50 unrelated healthy subjects (55). The discrepancy of
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prevalence of heterozygous carriers between Western and Asian countries may be 
related to screening methods with the entire NCC gene or selected NCC for analysis 
and pathogenicity of selected NCC mutations. If the pre-selected 15 NCC mutations in 
our study were all pathogenic, the expected prevalence of patients with autosomal 
recessive GS should be at least 2.1 per 10,000 children (2.9/100 * 2.9/100 * 1/4). Our 
results suggest that GS is not rare in the Chinese population while being more 
common than in Western countries.
THE NATURE AND POSITION OF THE NCC MUTATIONS
The NCC mutations in GS are located throughout the entire coding sequence of the 
NCC protein (56, 57, 50). Although more than 100 NCC mutations have been 
identified in patients with GS, only some of these published NCC mutations have 
been proven to be functional defects. Bindels’ group reported 14 NCC mutations with 
functional defects by determining metolazone-sensitive Na+ uptake and subcellular 
localization in Xenopus laevis oocytes expressing mutant hNCC (58, 59). Three 
distinct types were classified as defective protein processing (G316V, R339C, G439S, 
T649R, G741R), defective protein insertion (R145C, L215P, F536L, N611S, R955Q, 
G980R, C985Y) and defective intrinsic activity (S555L, A588V). Notably, most of the 
reported NCC mutations associated with defective trafficking of NCC to the apical 
membrane have been shown to restrict within the carboxyl terminus. The study in 
Chapter 6 demonstrated that four out of the seven (57%) heterozygous NCC 
mutations are located within the cytoplasmic carboxyl terminus and R928C (0.9%) 
and R959frameshift (1.0%) were the two most common heterozygous NCC mutations 
among Chinese children.
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ASSOCIATION BETWEEN HETEROZYGOUS NCC MUTATIONS AND BLOOD 
PRESSURE
NCC activity in the DCT has been implicated in the regulation of blood pressure. In 
patients with pseudohypoaldosteronism type II, enhanced NaCl reabsorption in DCT 
resulting from WNK1/4 mutations contributes to secondary hypervolaemia and 
hypertension (60). Conversely, diminished renal NaCl reabsorption due to NCC 
mutations in GS causes renal salt wasting and relative hypovolaemia leading to low or 
normal blood pressure (61, 62). It has been proposed that heterozygous NCC carriers 
may also have impaired renal salt reabsorption and increased susceptibility to 
diuretics. A previous study in a large Amish family having GS demonstrated that 
heterozygous children, but not adults, had significantly lower blood pressure 
accompanied by higher urinary Na+ excretion than their non-affected relatives (61). 
Why this phenomenon was seen only in children remains elusive. However, an 
additional intra-familial study in Sweden found that NCC-heterozygous subjects had 
significantly lower blood pressures but did not have higher urinary Na+ excretions 
compared to controls (62). A new study by Ji et al. showed that the inactivating NCC 
carrier was associated with a significant reduction in blood pressure and a reduced 
risk of hypertension in a Western population (53). Conversely, the NCC heterozygous 
children in our study and NCC heterozygous adults in a Japanese study did not have 
a relative hypotension (63). This discrepancy may be explained by racial differences, 
genetic background or variable salt intakes in these studies. Recently, we generated 
NCC knock-in mice carrying a R959frameshift mutation and found that heterozygous 
mice displayed normal blood pressure as compared to wild-type littermates 
(unpublished data, The NCC S707X knock-in mice as an ideal animal model of GS by 
Yang et al.), which was consistent with our clinical observation.
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CONCLUSION AND FUTURE DIRECTIONS
Maintenance of Ca2+ balance in the human body is essential for numerous 
fundamental physiological processes. Previous research has documented the 
importance of TRPV5 and the regulation of renal Ca2+ reabsorption by calciotropic 
hormones. The investigations described in this thesis, which characterized TRPV5 
and calbindin-D28K double gene ablation mice, support the role of TRPV5 as a 
"gatekeeper” of transcellular Ca2+ transport in the distal part of the nephron. Moreover, 
we have clearly demonstrated that TRPV5 expression is actively regulated at the 
transcriptional level by classical (1,25(OH)2D3 and PTH) and novel (estrogen and 
androgen) calciotropic hormones and that the gonads may interact with the kidney, 
intestine, and bone to maintain Ca2+ homeostasis. In numerous kidney diseases, 
disturbance of these calciotropic hormones leads to Ca2+ imbalance, so targeting 
these calciotropic hormone-activated signal cascades is a possible therapeutic 
strategy for treatment of renal Ca2+ disorders. Further studies are needed to 
determine the molecular mechanisms that underlie the regulation of TRPV5 by 
calciotropic hormones. In particular, identification of interacting transcriptional 
activators and repressors, potential ligand-nuclear receptor complex binding sites, 
and downstream signals that participate in the transcription of TRPV5 gene will 
provide important insights into the mechanisms of Ca2+ handling in the distal part of 
the nephron. Such studies may also lead to the development of new therapies for 
treatment of renal Ca2+ disorders. CT, a classical calciotropic hormone, augments the 
renal reabsorptive capacity for Ca2+. This increase is likely to occur independently of 
TRPV5. Repeated administration of CT leads to a loss of its hypocalciuric effect, 
which makes it problematic for the treatment of hypercalcemia. We suggest a 
re-evaluation of the timing or necessity for CT as adjunctive therapy for hypercalcemia 
in clinical practice. Patients with GS due to NCC mutations present with hypocalciuria,
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renal salt wasting, and slightly low or normal blood pressure. Based on RFLP analysis 
of 15 NCC mutations, we demonstrated a relatively high prevalence of heterozygous 
NCC mutations in Chinese children. R928C and R959frameshifts were the two most 
common heterozygous NCC mutations. The association of heterozygous NCC 
mutations, blood pressure, and glucose intolerance remains largely unknown due to 
the limited number of cases. However, the generation of knock-in mice carrying NCC 
mutations could further elucidate the physiological role of NCC in the regulation of 
blood pressure and glucose metabolism. A prospective, longitudinal clinical study 
could also determine the role of insulin resistance, glucose metabolism, and the 
development of diabetes in patients with GS.
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SUMMARY
There is a sequence of processes in the distal convoluted tubules (DCT) and the 
connecting tubules (CNT) of the kidney that are critical for active Ca2+ reabsorption. At 
the cellular level, transcellular reabsorption is mediated by Ca2+ entry across the 
apical membrane through a specialized epithelial Ca2+ channel, TRPV5. There is 
intracellular buffering of Ca2+ and facilitated diffusion of Ca2+ that is bound to 
Ca2+-binding proteins (calbindin-D28K or calbindin-D9K). Ca2+ extrusion across the 
basolateral membrane occurs by a Na+/Ca2+ exchanger (NCX1) and a plasma 
membrane Ca2+-ATPase (PMCA1b). Identification of the epithelial Ca2+ channel 
TRPV5 and the generation of TRPV5 knockout (TRPV5"7") mice have significantly 
contributed to our understanding of the molecular mechanism of active renal Ca2+ 
reabsorption. TRPV5-/" mice display profound renal Ca2+ wasting due to impaired 
active reabsorption in the DCT and CNT, and this is accompanied by elevated plasma
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) levels, compensatory intestinal Ca2+ 
hyperabsorption, and reduced bone thickness. There is, however, only subtle Ca2+ 
wasting in calbindin-D28K gene ablated mice, calling into question its physiological 
importance in transepithelial Ca2+ transport. Chapter 2 reports the results of 
experiments with single and double knockout mice of TRPV5 and calbindin-D28K 
(TRPV5-/", calbindin-D28K'/_ and TRPV5'/'/calbindin-D28K'/') that were fed different Ca2+ 
diets (0.02% and 2% w/w). These studies provide insight into the in vivo role of 
TRPV5 and calbindin-D28K in the maintenance of Ca2+ balance. Urine analysis 
indicated that TRPV5-/-/calbindin-D28K-/- mice on both diets were hypercalciuric 
compared to wild-type mice. Ca2+ excretion by TRPV5'/'/calbindin-D28K'/' mice was not 
significantly different from that of TRPV5-/" mice, whereas calbindin-D28K'/_ mice had no 
hypercalciuria. The similarity between TRPV5'/'/calbindin-D28K'/' mice and TRPV5-/" 
mice was also supported by a similar increase in renal calbindin-D9K expression, a
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similar increase in intestinal Ca2+ hyperabsorption due to up-regulation of 
calbindin-D9K, and similar TRPV6 expression in the duodenum of both mutants. 
Intestinal Ca2+ absorption and expression of calbindin-D9K and TRPV6, and serum 
parameters of calbindin-D28K-/- mice were not different from wild-type mice. Collectively, 
these results point to the significance of TRPV5 as the rate-limiting step in active Ca2+ 
reabsorption, in contrast to calbindin-D28K, which may be compensated by 
calbindin-D9K.
In the kidney, expression of TRPV5 is mainly regulated by well-known calciotropic 
hormones, PTH and 1,25(OH)2D3. Several previous reports have described the effect 
of CT (a hypocalcemic calciotropic hormone) on renal Ca2+ handling. However, the 
mechanism of CT on Ca2+ transport in the DCT is still not clear. As described in 
Chapter 3, when C57BL/6 mice were given a single bolus injection of CT, there was a 
significant reduction in the urinary excretion of Ca2+, Na+, and K+. There were no 
apparent changes in the renal expression of TRPV5, calbindin-D28K, or TRPV6 in 
CT-treated and control mice. We studied TRPV5-/- mice to determine whether TRPV5 
activity is needed for the CT-induced increase in Ca2+ reabsorption. Knockout mice 
(TRPV5-/-) and wild-type controls (TRPV5+/+) were given three bolus injections of CT 
over 40 h and urine was collected at 16 h and at 40 h. Overnight urinary Ca2+ 
excretion (16 h) was reduced in TRPV5-/- and TRPV5+/+ mice after the first a bolus 
injection of CT, but the subsequent 40 h urinary excretion of Ca2+ (collected after the 
third bolus injection) showed no effect of CT on renal Ca2+ handling in either group. 
Three bolus injections of CT did not alter the intrarenal protein abundance of TRPV5 
or calbindin-D28K so CT-stimulated renal Ca2+ reabsorption appears to occur 
independently of TRPV5.
Although estrogen is not usually considered a calciotropic hormone, recent studies 
demonstrated TRPV5 is upregulated by estrogen in a 1,25(OH)2D3 independent
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pathway. Nevertheless, the effect of androgen on active Ca2+ reabsorption in the 
distal part of the nephron remains unexplored. Previous studies have reported sex 
differences in the renal handling of Ca2+ and the experiments described in Chapter 4 
showed that male mice have a higher urinary Ca2+ excretion and reduced renal 
expression of Ca2+ transporters. In addition, bilaterally orchidectomized (ORX) mice 
excreted less Ca2+ in their urine than sham-operated controls. ORX-induced 
hypocalciuria was normalized after testosterone replacement. Consistent with these 
results, we also found that androgen deficiency resulted in an increase of mRNA and 
protein levels of renal TRPV5 and calbindin-D28K, and that these were suppressed by 
testosterone treatment. There were no significant differences in serum estrogen, PTH, 
or 1,25(OH)2D3 levels between controls, ORX mice, and testosterone-supplemented 
ORX mice. Moreover, it has also been reported that androgens directly affect renal 
Ca2+ reabsorption, as primary cells of rabbit CNT and cortical collecting ducts (CCD) 
incubated with selective non-aromatizable androgen dihydrotestosterone these 
primary cultures showed a reduced transcellular Ca2+ transport. Taken together, we 
conclude that sex differences in renal Ca2+ handling are at least partly mediated by the 
inhibitory actions of androgens on TRPV5-mediated active renal Ca2+ transport.
There is increasing evidence that TRPV5 plays a role in acquired and inherited renal 
Ca2+ disorders. For example, Gitelman syndrome (GS), which is caused by 
homozygous or compound heterozygous mutations in the thiazide-sensitive Na+-Cl- 
cotransporter (NCC), usually manifests with hypocalciuria. The role of TRPV5 in the 
development of hypocalciuria in GS has been well documented by studies that 
characterized the effect of thiazides on urinary Ca2+ excretion in TRPV5-/- mice. The 
Ca2+-sparing effect of thiazides can be elicited in both wild-type and TRPV5-/- mice 
and Na+ repletion prevented the hypocalciuria indicate that thiazide affects Ca2+ 
reabsorption indirectly via contraction of extracellular volume, independent of
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TRPV5-mediated active Ca2+ reabsorption in the DCT. These results suggest that 
hypovolemia-enhanced proximal Ca2+ reabsorption may be the cause of hypocalciuria 
in GS patients. GS usually manifests in children, and NCC activity in DCT is closely 
linked to reduced blood pressure and urinary Ca2+ excretion. Previous studies 
reported that GS is more common in Chinese population than in Western countries, 
but the prevalence of heterozygous NCC mutations and their association with reduced 
blood pressure in Chinese children has not yet been studied. Chapter 5 describes 
restriction fragment length polymorphism (RFLP) analysis of 15 NCC mutations in 500 
Chinese children. The results indicated that the overall incidence of positive 
heterozygous NCC mutations was approximately 2.9%. There were no significant 
differences in systolic and diastolic blood pressure of children with heterozygous NCC 
mutations and non-affected controls, but NCC-heterozygous children had slightly 
higher fasting plasma glucose concentration. The relatively high prevalence of 
heterozygous NCC mutations in Chinese children suggests that GS is relatively 
common in this population.
The findings of this thesis reinforce that TRPV5 is instrumental for active Ca2+ 
reabsorption and contributes to a better understanding of the physiological 
importance of TRPV5 in the regulation of renal Ca2+ handling by both classical 
(1,25(OH)2D3 and PTH) and novel (estrogen and androgen) calciotropic hormones. 
We found that CT strongly stimulates renal Ca2+ reabsorption, but that this increase 
occurs independently of TRPV5. Targeting calciotropic hormone-activated signal 
cascades may be a new therapeutic strategy for treatment of renal Ca2+ disorders. 
Further studies are needed to identify the detailed molecular mechanisms that 
underlie the regulation of TRPV5 by calciotropic hormones.
206
Samenvatting
SAMENVATTING
Een reeks processen in het distale convoluut (DCT) en de verzamelbuis (CNT) van 
de nier is cruciaal voor de actieve resorptie van calcium. De eerste stap van het 
transcellulaire resorptieproces is de opname van calcium door een epitheliaal 
calciumkanaal, TRPV5, gelegen op het apicale membraan. Vervolgens wordt calcium 
in de cel gebufferd met behulp van calciumbindende eiwitten (calbindine-D28K of 
calbindine-D9K) en vindt gefaciliteerde diffusie plaats. Ten slotte wordt calcium aan de 
basolaterale zijde naar buiten getransporteerd door een natrium/calciumwisselaar 
(NCX1) en een calcium-ATPase (PMCA1b).
De identificatie van het epitheliale calciumkanaal TRPV5 en de ontwikkeling van 
TRPV5- knockout-muizen (TRPV5"7") hebben aanzienlijk bijgedragen aan het begrip 
van het moleculaire mechanisme dat zich bij de actieve resorptie van calcium in de 
nier voordoet. TRPV5-/'-muizen verliezen een grote hoeveelheid calcium door een 
lagere actieve resorptie in het DCT en de CNT. Bovendien hebben zij een verhoogde 
concentratie van 1,25-dihydroxyvitamine D3 (1,25(OH)2D3) in het bloed, 
hyperabsorptie in de darm ter compensatie van het calciumverlies, en een 
verminderde botdikte. In muizen die het calbindine-D28K-gen missen is het 
calciumverlies echter zeer beperkt. Hierdoor staat de fysiologische betekenis van 
calbindine-D28K bij het transepitheliale calciumtransport ter discussie. Met het oog 
hierop zijn in vivo experimenten uitgevoerd die inzicht verschaffen in de rol van 
TRPV5 en calbindine-D28K bij de calciumhuishouding.
In hoofdstuk 2 worden de resultaten besproken van de experimenten met 
muismodellen waarbij TRPV5, calbindine-D28K of beide uitgeschakeld zijn (TRPV5-/", 
calbindine-D28K-/' and TRPV5'/'/calbindine-D28K'/'). De knockout-muizen krijgen twee 
verschillende calciumdiëten (0,02% en 2% w/w). De analyse van urine wijst uit dat 
TRPV5'/'/calbindine-D28K'/'-muizen met beide diëten hypocalciurie vertonen ten
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opzicht van de wildtype muizen. Tussen TRPV5-/-/calbindin-D28K-/--muizen en 
TRPV5-/--muizen zijn geen significante verschillen in calciumexcretie gevonden. 
Bovendien hebben beide muismodellen een verhoogde calbindine-D9K-expressie in 
de nier, daardoor een verhoogde hyperabsorptie van calcium in de darm, en een 
vergelijkbare expressie van TRPV6 in de twaalfvingerige darm. Bij calbindine-D28K-/-- 
muizen komt geen hypocalciurie voor. Daarnaast vertonen zij geen verschillen met 
wildtype muizen wat betreft de calciumabsorptie en de expressie van TRPV6 en 
calbindine-D9K in de darm. Ook verschillen de serumwaarden niet tussen beide 
muismodellen. Uit al deze resultaten blijkt dat bij calciumresorptie TRPV5 de 
beperkende factor is, in tegenstelling tot calbindine-D28K, dat mogelijkerwijs 
gecompenseerd wordt door calbindine-D9K.
In de nier wordt de expressie van TRPV5 voornamelijk gereguleerd door 
1,25(OH)2D3 en het parathyroïdhormoon (PTH), twee bekende calciotrope hormonen. 
Alhoewel oestrogeen voorheen niet beschouwd werd als een calciotroop hormoon, 
stimuleert het volgens recent onderzoek de expressie van TRPV5 door middel van 
een 1,25(OH)2D3-onafhankelijk mechanisme. De effecten van een ander calciotroop 
hormoon, calcitonine (CT), en van het geslachtshormoon androgeen op de actieve 
calciumresorptie in het distale gedeelte van de nefron zijn onbekend. Om meer 
informatie over de invloed van deze twee hormonen te verkrijgen, zijn experimenten 
uitgevoerd die in de hoofdstukken 3 en 4 aan de orde komen.
In hoofdstuk 3 wordt beschreven dat C57BL/6-muizen na een CT-injectie een 
significant verminderde uitscheiding van calcium, natrium en kalium vertonen. In de 
nieren zijn echter geen veranderingen in de expressie van TRPV5, calbindine-D28K of 
TRPV6 meetbaar. Om te achterhalen of de activiteit van TRPV5 nodig is voor de 
toename van calciumresorptie door CT, zijn ook TRPV5-/--muizen onderzocht. Aan 
knockout-muizen (TRPV5-/-) en wildtype muizen (TRPV5+/+, ter controle) zijn drie CT-
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injecties toegediend gedurende een periode van 40 uur. Na 16 uur en na 40 uur is er 
urine opgevangen. In het eerste monster (opgevangen na één CT-injectie) blijkt de 
uitscheiding van calcium bij beide muismodellen afgenomen te zijn. In het tweede 
monster (opgevangen na drie injecties) is echter bij geen van beide muismodellen 
een effect van CT op de calciumhuishouding van de nier waarneembaar. Aangezien 
de drie CT-injecties de aanwezigheid van TRPV5 of calbindine-D28K in de nier niet 
beïnvloeden, lijken de effecten van CT op de resorptie van calcium zich onafhankelijk 
van TRPV5 voor te doen.
Eerdere studies hebben uitgewezen dat er verschillen in de calciumhuishouding in de 
nier zijn tussen mannen en vrouwen. De rol van androgenen blijft echter onduidelijk. 
De experimenten in hoofdstuk 4 tonen aan dat bij mannelijke muizen meer calcium 
wordt uitgescheiden en minder calciumtransporteiwitten in de nier tot expressie 
worden gebracht. Muizen die een bilaterale orchidectomie (ORX) hebben ondergaan, 
vertonen bovendien een lagere calciumexcretie in de urine dan de controlegroep. 
Daarnaast blijkt de toediening van testosteron de ORX-gerelateerde hypocalciurie te 
compenseren. Er is aangetoond dat androgeendeficiëntie leidt tot een toename van 
mRNA- en eiwitconcentraties van TRPV5 en calbindine-D28K in de nier. Ook deze 
veranderingen worden tenietgedaan door de behandeling met testosteron. In de 
serumwaarden van oestrogeen, PTH, 1,25(OH)2D3 zijn geen significante verschillen 
gevonden tussen ORX-muizen, ORX-muizen met testosterontoediening en de 
controlegroep. In eerdere studies is ook bericht dat androgenen direct de 
calciumresorptie in de nier beïnvloeden: het transcellulaire calciumtransport neemt af 
in primaire cellen van de CNT (konijn) en de corticale verzamelbuis (CCD), 
geïncubeerd met androgeen dihydrotestosteron (DHT). Dit leidt tot de conclusie dat 
verschillen in de calciumhuishouding van de nier tussen mannen en vrouwen in ieder
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geval deels veroorzaakt worden door het remmende effect van androgenen op actief 
calciumtransport door TRPV5.
In toenemende mate is er bewijs dat TRPV5 een rol speelt bij zowel aangeboren als 
verworven calciumgerelateerde aandoeningen in de nier. Het syndroom van 
Gitelman (GS), veroorzaakt door homozygote en samengesteld heterozygote 
mutaties in de thiazidegevoelige natriumchloridecotransporteur (NCC), gaat 
bijvoorbeeld vaak gepaard met hypocalciurie. De rol van TRPV5 bij de ontwikkeling 
van deze hypocalciurie is uitvoerig gedocumenteerd in studies waarbij de effecten 
van thiazides op calciumexcretie in de urine bij TRPV5-/--muizen gemeten werd. 
Deze studies hebben uitgewezen dat thiazide indirect de resorptie van calcium 
beïnvloedt door middel van volumecontractie, onafhankelijk van het actieve 
resorptieproces door TRPV5 in het DCT: het calciumsparende effect van thiazides 
kan namelijk worden opgewekt bij zowel wildtype als TRPV5-/--muizen. Daarnaast 
kan natriumdepletie de hypocalciurie voorkomen. Deze resultaten suggereren dat 
hypovolemie-gerelateerde proximale calciumresorptie de oorzaak is van de 
hypocalciurie bij GS-patiënten. GS manifesteert zich doorgaans bij kinderen. De 
activiteit van NCC in het DCT is gekoppeld aan een lage bloeddruk en 
calciumexcretie in de urine. Eerder onderzoek wijst uit dat GS meer voorkomt onder 
de Chinese bevolking dan in het Westen, maar het verband tussen de prevalentie 
van heterozygote NCC-mutaties en lage bloeddruk bij Chinese kinderen is nog niet 
onderzocht.
In hoofdstuk 5 wordt de RFLP-analyse (analyse van restrictiefragmentlengte- 
polymorfismen) van vijftien NCC-mutaties bij 500 Chinese kinderen beschreven. De 
resultaten wijzen uit dat positieve heterozygote NCC-mutaties bij circa 2,9% van de 
gevallen voorkomen. Tussen kinderen met heterozygote NCC-mutaties en de 
controlegroep zijn geen significante verschillen gevonden in de systolische en
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diastolische bloeddruk. NCC-heterozygote kinderen hebben echter wel een hogere 
nuchtere bloedsuikerspiegel. De hoge prevalentie van heterozygote NCC-mutaties 
suggereert dat GS relatief vaak voorkomt bij Chinese kinderen.
De resultaten van dit proefschrift bekrachtigen de cruciale rol van TRPV5 bij de 
actieve resorptie van calcium. Daarnaast dragen ze bij aan een beter begrip van de 
fysiologische betekenis van TRPV5 bij de regulatie van de calciumhuishouding in de 
nier door zowel klassieke (1,25(OH)2D3 en PTH) als nieuwe (oestrogeen en 
androgeen) calciotrope hormonen. Zo is gebleken dat het calciotrope hormoon CT de 
calciumresorptie in de nier aanzienlijk doet toenemen, maar dat deze toename 
onafhankelijk van TRPV5 plaatsvindt. De signaaltransductieroutes, die door 
calciotrope hormonen geactiveerd worden, zijn daarom een mogelijk 
aanknopingspunt voor de ontwikkeling van behandelmethoden bij een verstoorde 
calciumhuishouding in de nieren. Nader onderzoek is vereist om de exacte 
moleculaire mechanismen te bepalen die ten grondslag liggen aan de regulatie van 
TRPV5 door calciotrope hormonen.
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List of abbreviations
LIST OF ABBREVIATIONS
1,24(OH)2Ü2 1a,24-dihydroxyvitamin D2
1,25(OH)2Ü3 1,25-dihydroxy-vitamin D3
1a(OH)Ü2 1a-hydroxyvitamin D2
1a-OHase 25-hydroxyvitamin-D3-1a-hydroxylase
1a-OHase-/- 1a-OHase knockout mice
ADH antidiuretic hormone
AQP5 aquaporin 5
AP-1 activator protein 1
AR androgen receptor
ARE androgen responsive element
ATL ascending thin limb of Henle’s loop
BAPTA 1,2- bis (2-aminophenoxy) ethane-N,N,N*,N*-tetraacetic acid
BK bradykinin
BMD bone mineral density
[Ca2+]e extracellular Ca2+ concentration
[Ca2+]i intracellular Ca2+ concentration
cAMP cyclic adenosine monophosphate
CaSR Ca2+-sensing receptor
CaT2 calcium transporter 2
CCD cortical collecting duct
CD collecting duct
cDNA complementary DNA
CGRP calcitonin gene-related peptide
CNS central nervous system
CNT connecting tubule
COOH carboxyl
CRF chronic renal failure
cRNA Complementary or copy RNA
CSs control subjects
CT calcitonin
CTR calcitonin receptor
DAG diacylglycerol
DCT distal convoluted tubule
DHT dihydrotestosterone
DM diabetes mellitus
DTL descending thin limb of Henle’s loop
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List of abbreviations
E2
ECaCI
ECFV
Endo-F
ER
ERa
ERß
ERE
FGF23
FGFR
FKBP
FSGS
Gs
GLUT4
GRE
GS
GST
GTPase
HCTZ
HEK
HSH
KKS
NCC
NCX1
NKCC2
NH2
ORX
OVX
PCT
PHAII
PKA
PKC
PKD
PLC
PM
PMCAlb
PRE
PST
estradiol
epithelial Ca2+ channel 1
extracellular fluid volume
N-glycosidase F
endoplasmic reticulum
estrogen receptor-alpha
estrogen receptor-beta
estrogen responsive element
fibroblast growth factor 23
fibroblast growth factor receptor
FK506-binding protein
focal segmental glomerulosclerosis
stimulatory G protein
glucose transporter 4
glucocorticoid responsive element
gitelman syndrome
glutathione S-transferase
guanosine triphosphatase
hydrochlorothiazide
human embryonic kidney
hypomagnesemia with secondary hypocalcemia
kallikrein-kinin system
Na+-Cl- cotransporter
Na+-Ca2+ exchanger
sodium-potassium-chloride Na+-K+-Cl- cotransporter 
amino
orchidectomy
ovariectomy
proximal convoluted tubule 
pseudohypoaldosteronism type II 
protein kinase A 
protein kinase C 
polycystic kidney disease 
phospholipase C 
plasma membrane 
plasma membrane Ca2+-ATPase 
progesterone responsive element 
proximal straight tubule
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PT proximal tubule
PTH parathyroid hormone
PTHR parathyroid hormone receptor
RAMP receptor activity modifying protein
RXR retinoid X receptor
SHPT secondary hyperparathyroidism
siRNA small interference RNA
Sp-1 GC-rich stimulatory protein
STZ streptozotocin
T testosterone
TAL thick ascending limb of Henle’s loop
TM transmembrane
TK tissue kallikrein
TRP transient receptor potential channel
TRPA TRP ankyrin
TRPC TRP canonical
TRPM TRP melastatin
TRPV TRP vanilloid
TRPV4-/- TRPV4 knockout mice
TRPV5-/- TRPV5 knockout mice
TRPV6-/- TRPV6 knockout mice
TRPV5-/-/1a-OHase-/- TRPV5/1a-OHase double knockout mice
TRPP TRP polycystin
TRPML TRP mucolipin
TRPN TRP NOMP, no mechanopotential
VDDRI vitamin D-dependent rickets type I
VDDRII vitamin D-dependent rickets type II
VDR vitamin D receptor
VDR-/- VDR knockout mice
VDRE vitamin D responsive element
WNK With-No-Lysine [K]
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